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3Abstract
The bacterial and archaeal Asp/Glu racemase enzyme superfamily contains a variety
of catalytic functions that have great potential for use in industrial biocatalysis.
Members of this superfamily include aspartate racemases (AspRs), glutamate
racemases (GluRs), hydantoin racemases (HydRs), arylmalonate decarboxylases
(AMDs) and maleate cis-trans isomerases (MIs). Despite their catalytic diversity, all
characterised members share the same protein fold, catalytic cysteine residues and
reaction intermediate. Attempts to exploit this evolutionary flexibility for new processes
have had limited success so far, showing that the employed mechanisms are not yet
fully understood. For example, the well-characterised Bordetella bronchiseptica AMD
(BbAMD) enantiospecifically decarboxylates a range of arylmalonates was but is not
able to decarboxylate alkylmalonates despite considerable efforts made by site
directed mutagenesis.
In this work an investigation of the sequence diversity of the superfamily was
undertaken and a range of BbAMD sequence homologues was tested for both aryl-
and alkylmalonate decarboxylation (Chapter 3). However, none of the homologues
exhibited decarboxylation activity. Targeted mutation of active site residues in an
attempt to introduce decarboxylase activity was also unsuccessful. In an alternative
approach to identify new alkylmalonate decarboxylating enzymes, a range of bacterial
strains capable of processing alkylmalonates was isolated using selective enrichment
from soil samples (Appendix D).
The only characterised superfamily enzymes without a described three dimensional
protein structure are MIs. In order to illuminate the distinct mechanism of MIs, the
activity of the superfamily member Nocardia farcinica MI (NfMI) was characterised
(Chapter 4) and its structure was determined by X-ray crystallography (Chapter 5). A
potent inhibitor and substrate analogue bromomaleate was found. Mutagenesis of the
active site cysteine dyad confirmed its catalytic role and Cys76 was found to be more
important than Cys194. The data support a mechanism initiated by nucleophilic attack
by Cys76 on the double bond of maleate. Although alternative mechanisms cannot be
excluded at present, these findings indicate that the mechanistic chemistry in the
superfamily is more adaptable than previously thought.
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For Family and Friends
Thesis made easy
A PhD thesis is a book of over a hundred pages that only very few
people are ever going to read - if at all. Someone apparently put a
sentence in the middle of his thesis stating he would pay a pint to
anyone who would reach that part. The examiners apparently never
claimed their prize.
The purpose of this book is firstly to check whether the author is worthy of progressing
to the next level of his scientific career and secondly to be added to long bookshelves
of different theses conservation institutions: the library, the supervisor and the family.
To prevent my thesis from being immediately lost in the eternal past of irrelevant
human history, I wrote this uncommon introduction. I hope it will prevent the family
copy from being used as a uniquely ornamental addition to their household.
Part I
is a reaction to my partner's question: "What is actually a
molecule?" ...!? This question comes after several years in
a relationship with a fanatic scientist and after four years of
chemistry lessons in her pre-university formation! Part I will
reintroduce the molecule to all others who were sleeping
during their chemistry lessons too.
Part II
is there to convince you that enzymes are more than
digestion. After reading it, you should be humbled every
time you hear of enzymes as they support every single
piece of your body.
Part III
is about how enzymes can be used for chemical industry
- the ultimate aim of this thesis. (You should always aim
high!) There will also be references to the different parts of
my thesis.
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I. A World of Molecules
What are things around us made of? A Greek called Leucippus was asking himself this
question 2500 years ago. If we divide things in smaller and smaller parts, could we go
on forever or would we reach a limit that cannot be passed? Leucippus decided that
there must be a moment when we cannot divide things further when we reach the "un-
dividables" (a-tomos). These smallest possible undividable things would have all the
properties of the substances they form.
Leucippus idea was very close to
what others have shown much
later to be true. We know today
that things are indeed made of
tiny particles. Atoms, however,
are not as undividable as their
name suggests. They break into
even smaller particles when
collided at the speed of light. The
things that contain the properties
of the substances, however, are
arrangements of bound atoms
also known as molecules. All
things around us are made of
molecules, except metals and
minerals.
If we want to understand a
substance (and chemists want
that!) we have to understand the
qualities of the molecules the
substance is composed of. We
have to understand the shape of
the molecule, its weight and
electrical charge.
Molecules like to stick to each
other. That's why water stays in
Two molecules. Water is one of the smallest
molecules, made of only three atoms. Naproxen
is a painkiller that is made of thirty atoms.
Chemists represent molecules as letters and
numbers: Carbon (C), hydrogen (H) and oxygen
(O). To indicate the bonds between atoms lines
are drawn or to indicate the size and shape of the
molecule atoms are drawn as balls.
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drops without the molecules going in all directions. When molecules are cooled down
they stick to each other even more and form solid crystals like ice. When they are
heated up they lose contact and fly away from each other like vapour.
When two molecules bump into each other they may exchange some atoms. This is
called a chemical reaction. By reacting they give themselves new identities and start to
be a completely different substance. For example, when six oxygen molecules (O2)
come together with one grape sugar molecule (C6H12O6) they will react. The result is a
process called burning, which results in six water molecules (H2O) and six carbon
dioxide molecules (CO2) being formed and energy released. This only happens if the
molecules are bumping into each other fast enough (by heating) or when enzymes are
used.
II. Enzymes – Machines of Life
When a tree grows, it has to convert small and simple molecules such as carbon
dioxide and water into very large and complex molecules that make its sugars (the
basis for wood) and lots of other molecules such as the green colour in the leaves.
When in turn, we eat the tree's fruit, we are breaking down all these large molecules
again into small and simple molecules to recover the energy that keeps us alive.
All these hundreds of thousands of reactions in the tree, as well as in our body, are
done by enzymes. Without the enzymes we would be petrified (dead) in an instant. Our
dead bodies wouldn't even decay as the microorganisms degrading the bodies would
also be petrified instantly without enzymes.
Enzymes digest our food (large and complex molecules) in the mouth, stomach and
gut, they make our muscles contract, our eyes see, our brain think and our body heat.
These are chemical reactions where molecules are broken apart, flipped around and
stuck together by enzymes. An enzyme can carry out a reaction very efficiently and
without the need of intense heat.
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An enzyme is a molecule itself (an extremely large and complex one). It contains a
cavity where the molecule, which needs to be altered, fits in perfectly. Thanks to the
perfect fit, the enzyme can push the atoms of the molecule around easily and thereby
change the molecule. This is a bit like a key that fits perfectly into its lock, making it
easy to open the door. Without the correct key it is hard to open a locked door. To
understand how enzymes change molecules we need to know the precise shape of the
enzyme and their cavity.
III. Using Enzymes in Industry
People have used enzymes for thousands of years already. Beer brewers use both the
starch and the enzymes from barley grains. The enzymes break down starch in the
grains when soaked in water. The released sugars are then broken down further by
many other enzymes in yeasts to produce alcohol. Cheese is also made with the use of
An enzyme reaction. By chewing a bit of bread for a long time we can feel some
sweetness developing slowly. The reason for this is an enzyme in our saliva that cuts
the long starch chains from bread, cereals and potatoes into its sugar molecule
elements. The enzyme is able to cut fast and precisely because starch fits perfectly
into the cavity. In the cavity, starch is optimally positioned for the enzyme to attack
from the right angle. Our gut can only absorb the small sugars but not the large starch.
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enzymes, from calf stomach (rennet). The enzymes break down the milk proteins so
they stick together and form a flan like texture.
Today, enzymes are also used in washing powders. They break proteins, fats and
sugars that are part of the dirt on clothes. Genetic engineering, and thus this thesis,
would not have been possible without enzymes. They can cut long DNA molecules in
half, stick them together or assemble small molecules to produce a copy of the whole
DNA molecule.
Traditional industrial chemistry is very crude compared to the chemistry of life
performed by enzymes. Traditionally molecules often have to be dissolved in toxic
solvents made from oil, heated to high temperatures to make them react and the result
is not very pure. Only recently chemists have started to appreciate enzymes as they
are useful for the production of drugs, pesticides, biofuels or new materials. It's not
always easy because enzymes were "invented" to support life rather than industry.
Producing a drug with an enzyme. In traditional chemical reactions the carbon
dioxides of the precursor are removed at random. The two molecules produced this way
are hard to separate chemically as they are mirror images with exactly the same weight,
colour and melting point. Nevertheless they have totally different biological effects: one
is toxic and the other is a drug. The carbon dioxide cutting enzyme has no problem
removing the correct carbon dioxide precisely from one side, thus producing pure
naproxen painkiller.
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My thesis was sponsored by the chemical company BASF who wanted me to look at a
carbon dioxide cutting enzyme (see image above). They wanted me to change the
enzyme so it would cut the carbon dioxide from different molecules instead.
There I went and checked lots of enzymes I was convinced would cut carbon dioxide
(Chapter 3). Unfortunately, they didn't! I had to learn what most PhD students have to
learn: coping with frustration. So I changed my approach and looked for completely
unknown enzymes in soil bacteria. There are so many different bacteria in the world
that there must be one having the enzyme I want (Appendix D). Luckily, there was one!
But I found something that interested me even more. One of the enzymes tested for
carbon dioxide cutting was instead a maleate switching enzyme. This is interesting
because I can learn why the enzyme switches maleate rather than cuts carbon dioxide
despite the very similar shape. I therefore first studied its activity in detail (Chapter 4)
and then I determined its precise shape (Chapter 5). I don't completely understand the
enzyme yet, but that's science: work in progress. And I love it!
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Chapter 1
General Introduction
1.1 Enzymes in Industrial Biocatalysis
The production of biologically active compounds, such as pharmaceuticals and
agrochemicals, is highly complex. The processes require specific alterations of mostly
large molecules, which in addition have to be supplied in high purity. Economic
considerations drive the search for fast and inexpensive production of these
compounds.
Enzymes are increasingly accepted as an elegant way of meeting the needs of the
chemical industry as they are highly chemo-, regio- and enantioselective. Non-
enzymatic reactions and chemical catalysis are typically much less selective and
therefore require more sophisticated purification processes and chemical
protection/deprotection steps. In addition, enzymes are generally more efficient than
traditional catalysts, can be combined to perform multiple reactions in one container
and are sometimes capable of catalysing reactions that do not have an alternative
production pathway in organic chemistry (1,2).
A positive side effect of the utilisation of enzymes is that they represent a step in the
path of sustainable development in the chemical industry as they do not require toxic
heavy metals or organic solvents and can work efficiently at low temperatures (1-3).
Enzymes are already used in many industrial applications, especially in the
pharmaceutical industry, where in 2000 about 80% of the drug targets in the pipeline
were chiral. The production of amino acids, carboxylic acids and alcohols make a large
portion of the industrial applications (4).
Amino acids for example are synthesised in large quantities for human and animal
nutrition. In 2000 amino acids were sold for about 3.5 billion Euros worldwide. L-
aspartate is one of the most produced amino acids. It can be produced from fumarate
and ammonia using aspartate ammonia lyase (Fig. 1.1, EC 4.3.1.1). In a further
transformation, L-aspartate can be converted into L-alanine using the L-aspartate β-
decarboxylase (EC 4.1.1.12). (Fig. 1.2) (4).
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Figure 1.1. Industrial biocatalytic production of L-aspartate.
Figure 1.2. Industrial biocatalytic production of L-alanine.
Another, more general, way for the production of amino acids is the production from
hydantoins in the “hydantoinase process”. The chemical production of racemic 5-
substituted hydantoins is relatively easy. Enantiospecific hydantoin hydrolases (EC
3.5.2.2/X) can be used to open the ring and produce the corresponding carbamoyl.
Enantiospecific carbamoyl hydrolases (EC 3.5.1.77/87) further transform them into the
corresponding amino acids releasing ammonia and carbon dioxide. A hydantoin
racemase (EC 5.1.99.5) can be used to achieve complete conversion. This is a well
established process for D-phenylglycine and D-hydroxyphenylglycine used for the
production of β-lactam antibiotics (Fig. 1.3) (4).
Carboxylic acids are also important products of the chemical industry. The acidification
and stabilisation of fruit juices, for example, is most often achieved by the addition of
the diacid L-malate. The enantioselective addition of water to fumarate is used in the
production of L-malate performed with fumarate hydratase (EC 4.2.1.2, Fig. 1.4) (4).
Most chemical methods for the production of chiral products produce racemates or
mixtures with low enantiomeric excess. The product purification is expensive, laborious
and time consuming. Using an enantioselective biocatalyst with a lower catalytic
efficiency for one product, significant improvements can be achieved. By stopping the
reaction at the maximum enantiomeric excess, kinetic resolution can be achieved.
Racemic alcohols are typically acylated in this way, yielding nearly 50% of the desired
ester (Fig. 1.5) (5).
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Figure 1.3. Industrial biocatalytic production of D-phenylglycine.
Figure 1.4. Industrial biocatalytic production of L-malate.
Figure 1.5. Kinetic resolution. S, P: substrate and product in opposite
enantiomeric forms.
Although the product purity is increased, the maximum yield for a kinetic resolution
process is still as low as 50%, resulting in economic and environmental costs. A
number of processes have been developed to overcome this limitation and achieve
close to 100% yields with nearly 100% enantiomeric excess. Dynamic kinetic resolution
allows the replenishment of the depleted substrate enantiomer through the inclusion of
substrate racemisation, which finally channels all the substrate through the faster
transformation route (Fig. 1.6, left) (5). The hydantoinase process, mentioned above, is
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a typical dynamic kinetic resolution that is applied industrially. Deracemisation of a
racemic product is another method. In this process, the addition of an enantiospecific
enzyme converts the undesired product enantiomer into a symmetric intermediate. The
intermediate is then immediately non-specifically converted back to the product, which
allows the correct product enantiomer to be accumulated. A well known example is the
enantiospecific oxidation of a D-amino acid to the corresponding imine. The
symmetrical imine is then reduced non-specifically with a chemocatalyst, leading to
enrichment in L-amino acid. (Fig. 1.6, middle) (6). If enantiospecific enzymes are
available to convert symmetrical pro-chiral substrates, full desymmetrisation can be
achieved (Fig. 1.6, right) (7). The industrial production of L-aspartate or L-malate from
fumarate by aspartate ammonia lyase and fumarate hydratase, mentioned above, are
typical desymmetrisations.
Figure 1.6. Methods to produce pure enantiomers. Dynamic kinetic resolution
(left), deracemisation (middle) and desymmetrisation (right). S, P, I: Substrate,
product and intermediate with opposite enantiomer if available.
Arylmalonate decarboxylase (AMD) is a prime example of an enzyme achieving
desymmetrisation. Decarboxylation is a thermodynamically highly favourable reaction
with a yield of nearly 100%. AMD decarboxylates disubstituted aryl- and
alkenylmalonates to give apparent 100% enantiomeric excess (Fig. 1.7). It is a
potentially useful biocatalyst and has therefore sparked a lot of interest. In particular,
the 2-arylpropionates are used for the production of ferroelectric liquid crystals,
pyrethroids used as insecticides and non-steroidal anti-inflammatory drugs such as
flurbiprofen (3,8-13).
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Figure 1.7. Quantitative enantiospecific conversion of 2-methyl-2-
phenylmalonate to (R)-2-phenylpropionate.
1.2 Enzymatic Decarboxylation
Carboxylations and decarboxylations are crucial processes for life. The biosphere
largely depends on the fixation of carbon dioxide from the atmosphere by ribulose
bisphosphate carboxylase, present in the chloroplasts of plants and algae. The organic
molecules formed by photosynthesis are in turn degraded by many heterotrophic
organisms through decarboxylation, mainly in the citric acid cycle. Decarboxylations
are thermodynamically favourable in physiological conditions, also due to an increase
in entropy through the release of carbon dioxide. Therefore carboxylations can drive
other unfavourable reactions such as the synthesis of NADH or fatty acids (14).
In contrast to the above, carboxylates are typically very recalcitrant to decarboxylation.
This is particularly the case for monocarboxylates such as fatty acids. The carbanion
formed by the electron transfer from the oxyanion to the α-carbon is very unstable and
needs to be stabilised effectively in order to drive the reaction (Fig. 1.8). The
dicarboxylate malonate can be decarboxylated at relatively low temperatures (135 °C)
due to the delocalisation of the negative charge between the remaining carbonyl
oxygen and the α-carbon, forming an enol (15).
Figure 1.8. Formation of carbanion after decarboxylation.
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To stabilise the negatively charged carbanion intermediate, many decarboxylases rely
on cofactors such as PLP, ThDP, phosphopantetheine and biotin (Fig. 1.9) (16).
However, some decarboxylases are capable of stabilising the intermediate without
cofactors. Consequently, the catalytic burden must be carried solely by the enzyme,
the substrate or both.
Figure 1.9. Cofactors employed by decarboxylases. The catalytic portions of
the cofactors are highlighted in red.
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1.2.1 PLP-Dependent Decarboxylation
The cofactor PLP is recruited by enzymes for many reactions involving amino acids.
The condensation of the amine with the aldehyde forms a Schiff base. Both the
protonated imine nitrogen and the pyridine ring act as efficient electron sinks. The
pyridine ring is able to do this with the series of conjugated double bonds allowing the
removal of the α-carboxyl of the amino acid. (Fig. 1.10) (16).
Figure 1.10. Stabilisation through Schiff base formation between ornithine
and PLP.
A number of amino acid decarboxylases use that mechanism, including the ornithine
decarboxylase (OrnD, EC 4.1.1.17). OrnD produces the diamine putrescine from the
amino acid ornithine. The decarboxylation is the first step in the production of
polyamines necessary for cell growth and differentiation. OrnD is therefore a target for
antibiotics against parasites such a Trypanosoma brucei, the agent of sleeping
sickness (17).
There are two folds for OrnD, the α/β-fold for prokaryotes and the α/β-barrel-fold for
eukaryotes. Eukaryotic OrnD is closely related to arginine decarboxylases (EC
4.1.1.19) and diaminopimelate decarboxylase (EC 4.1.1.20), which are all distantly
related to alanine racemases (EC 5.1.1.1) (18). OrnD is found as a homodimer in
solution where the active site is built by the N-terminus of one monomer and the C-
terminus the another. Some crucial amino acids have been identified for the reaction
mechanism of OrnD (numbering as in T. brucei). Lys69 forms a Schiff base with PLP
when no substrate is bound. Glu274 stabilises the positive charge on the pyridine
nitrogen and Arg277 binds the negatively charged phosphate. Lys69 is also thought to
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be responsible for protonation of the intermediate that proceeds through inversion of
configuration (Fig. 1.11). In prokaryotic OrnD the configuration is retained (17,19,20).
Figure 1.11. Binding of PLP to the active site of OrnD.
Upon substrate binding, first a gem-diamine is formed and then Lys69 is released
through Schiff base formation with the substrate. The reaction is reversed for product
release, which was found to be the rate limiting step through stop flow kinetics
experiments. After decarboxylation, the formed quinonoid intermediate stabilises the
negative charge before the substrate α-carbon is protonated. All reaction steps,
including the non substrate-bound, are tautomers between the charged form having a
protonated imine nitrogen and a deprotonated pyrimidine hydroxyl and their uncharged
forms (21).
Aspartate β-decarboxylase (AspβD, EC 4.1.1.12) is another type of PLP-dependent
decarboxylase. This enzyme is widely used in industrial biocatalysis for the production
of alanine. AspβD is related to the aspartate transaminase (EC 2.6.1.1) and also uses
a similar mechanism. Instead of removing the α-carboxyl it removes the proton at the
same position. In Pseudomonas dacunhae this is done by Lys315. After the
deprotonation β-decarboxylation can occur. In the case of P. dacunhae AspβD the
same Lys315 protonates the quinonoid at the carbonyl carbon of PLP. After the
decarboxylation at the β-carbon, the negative charge goes to the double bond with the
α-carbon and the imine nitrogen is neutralised. An as yet uncharacterised acid
protonates the methylene, inverting the stereochemistry. The reaction is then reversed
with Lys315 deprotonating the carbonyl and subsequently reprotonating the α-carbon
retaining the configuration (Fig. 1.12) (22,23).
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Figure 1.12. PLP and β-decarboxylation of aspartate.
1.2.2 Pyruvoyl-Dependent Decarboxylation
Pyruvoyl cofactor functions in an analogous way to PLP. It forms a Schiff base between
its carbonyl and the amino group of the amino acid and stabilises the α-decarboxylation
by acting as an electron sink with a series of conjugated double bonds (Fig. 1.13) (24).
Figure 1.13. Pyruvoyl stabilisation of the carbanion.
Pyruvoyl is typically used by aspartate α-decarboxylase (AspD, EC 4.1.1.11). AspD is a
prokaryotic enzyme involved in the production of β-alanine necessary for the formation
of phosphopantetheine, a cofactor used for carboxyl transfer (see below). As animals
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do not have AspD, it is a good target for antibiotics. Recently, it was proposed as a
biocatalyst for the industrial production of nitrogen containing compounds from organic
waste material, where the aspartate to β-alanine is a central step in the pathway (25).
Pyruvoyl is a special cofactor as it is formed by an auto-catalytic process, creating and
modifying an internal N-terminus. In Helicobacter pylori the amide bond between Gly24
and Ser25 is broken transforming Ser25 to a dehydroalanine, which in turn is
deaminated. The formed ketone is the catalytic ketone in pyruvoyl cofactor effectively
attached to Ile26 (26).
1.2.3 ThDP-Dependent Decarboxylation
The thiazolium C2 carbanion is the active centre of ThDP. The generally unstable
carbanion is stabilised by several factors. One factor is the positive charge on the
neighbouring tetravalent nitrogen that stabilises the ylid form electrostatically. Another
factor is that, when bound to enzymes, ThDP adopts a "V" conformation, not found in
free ThDP, that orientates the amine at position 2 of the pyrimidine ring so it is closest
to the thiazolium C2 carbon. Furthermore, the aminopyrimidine tautomerises to form an
iminopyrimidine, the thiazolium C2 carbon is deprotonated by the imine (Fig. 1.14).
This equilibrium is not leaning to the right, but favoured enough to allow reactions to
occur at reasonable rates (16,27).
Figure 1.14. Stabilisation of the active carbanion form of ThDP.
Pyruvate decarboxylase from Saccharomyces cerevisiae (PD, EC 4.1.1.1) is a typical
example of a ThDP-dependent decarboxylase. Although mechanistically very similar,
PD is not to be confused with the E1 subunit of the pyruvate dehydrogenase best
described in Escherichia coli (EC 1.2.4.1) that also relies on ThDP. PD is the first
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enzyme in the ethanol production pathway. In PD, the thiazolium carbanion conducts a
nucleophilic attack on central carbonyl carbon of pyruvate that is concomitantly
protonated. The negative charge left on the decarboxylated intermediate is stabilised in
the ThDP thiazolium through the formation of an ylid and through resonance between
the carbanion form and the enamine form. The stabilised carbanion is finally protonated
and released as acetaldehyde (Fig. 1.15) (16,27).
Figure 1.15. Decarboxylation by ThDP through enamine stabilisation.
PD forms a dimer of dimers with two active sites on the tight interfaces of each dimer.
The diphosphate moiety of ThDP is bound to PD through the intermediate of a bound
Mg2+ ion. Ile415 maintains the ThDP in the "V" conformation through its position
between the pyrimidine ring and the tetrazolium ring (28). It was shown, mainly by
mutagenesis experiments, that most of the catalysis is performed by the cofactor rather
than by the protein. No proton transfer was found to be rate limiting and no particular
residue was indispensable for catalysis. The role of the protein is mainly to position the
reaction partners involved. This involves binding the cofactors and substrate as well as
maintaining ThDP in the "V" form. There is a heavy strain imposed onto ThDP by the
enzyme. The release of that strain is thought to be the main driving force for the
decarboxylation rather than electrostatic repulsion by negatively charged residues. It is
also thought that the active site provides an environment with a lower dielectric
constant favouring the formation of ylid and thus dramatically decreasing the pKa of the
C2 proton on the thiazolium by 9 to 10 units (27).
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1.2.4 Phosphopantetheine- and Biotin-Dependent
Decarboxylation
Phosphopantetheine is a cofactor that forms a thioester with malonate. The formation
of an ester effectively removes the negative charge on the carboxylate making it easier
to stabilise the negative charge left after the decarboxylation. Thioesters can also
accommodate the negative charge better than esters (Fig 1.16) (29).
Figure 1.16. Decarboxylation of malonyl thioester. Stabilisation by resonance.
Phosphopantetheine in cells is either linked to a phosphoadenyl to form free CoA or as
a prosthetic group via a serine to an acyl carrier protein (ACP). In some prokaryotes
the ACPs have a dephosphorylated form of CoA linked via a phosphoribosyl to a serine
(Fig 1.9). The thioesters of these phosphopantetheine derived cofactors can readily
exchange bound acyl groups and therefore act as acyl carriers. In addition, their
elongated form helps to function as flexible linkers presenting the substrates to different
enzyme subunits or domains. This is well known for eukaryotic fatty acid syntheses
where the phosphopantetheinyl group receives malonyl that subsequently elongates an
acyl by two carbons with concomitant decarboxylation. The elongated chain is then
reduced in three steps and translocated, which all happens while the group is bound to
the phosphopantetheinyl group (14,30).
Biotin is a carrier of activated carbon dioxide. It is a prosthetic group that is linked to a
lysine of a protein via an amide bond. As for phosphopantetheine, this makes it a long
flexible linker that is able to transport carbon dioxide to different active sites. The
carbon dioxide is covalently attached to the amino group of an amide that can be
decarboxylated easily as the negative charge is well delocalised and neutralised
through protonation of the nitrogen (14).
Malonate is both an energy source and an inhibitor of the citric acid cycle. A number of
prokaryotes have evolved a malonate decarboxylase that converts malonate to
acetate. They use a phosphoribosyl linked CoA prosthetic group as carrier of the bound
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malonyl. The enzyme consists of many subunits. In one group of organisms
(Malonomonas rubra) the enzyme is membrane bound and biotin dependent (EC
4.1.1.88) whereas in the other group the enzyme is soluble and does not require biotin
(EC 4.1.1.89). The soluble proteins can be found in either the periplasm (Acinetobacter
calcoaceticus) or the cytoplasm (Pseudomonas ovalis). In biotin dependent malonate
decarboxylases the decarboxylation on ACP occurs via biotin that conserves the
energy in order to drive a Na+ pump (EC 4.3.99.2, Fig. 1.17) (31-33).
Figure 1.17. Decarboxylation of malonate.
In all cases the first step is a transacylation that releases the acetyl and binds malonyl
via the thioester. The decarboxylation of malonyl occurs with retention of the
stereochemistry as shown with isotope labelling and substrate analysis with NMR. The
malonyl thioester decarboxylation resembles the decarboxylation observed in
eukaryotes in respect to retention of configuration and type of cofactor (34,35).
1.2.5 Cofactor-Independent Acetoacetate Decarboxylase
Schiff bases are not only formed with cofactors such as PLP. They are also formed in
cofactor-independent proteins through the condensation of lysines with carbonyl
groups in ketones or aldehydes. This arrangement equally allows the stabilisation of
the negative charge formed by decarboxylation as the positively charged Schiff base
acts as an electron sink (Fig. 1.18) (16).
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Figure 1.18. Decarboxylation of acetoacetate by Schiff base formation.
Acetoacetate decarboxylase (AAD, EC 4.1.1.4) is an enzyme used by solventogenic
bacteria such as Chromobacterium violaceum. The conversion of acetoacetate into
carbon dioxide and acetone is important in the anaerobic metabolism. The fold of AAD
has not been found in other enzymes (PDB: 3bh3). Its central part consists of a β-cone
that is exposed to the solvent on the wider end and contains the active site at the
narrow end. The substrate is therefore effectively channelled to the active site. The
protein forms a dodecamer thought to be involved in maintaining the stability towards
low pH and high solvent as well as effectively concentrating the products of the
reaction to one localisation (36).
AAD was long seen as the classical example for the microenvironment effect in the
active site changing the pKa by neighbouring residues. In AAD the catalytic Lys116 was
shown to have a pKa of 6 being 4.5 units below the expected pKa of lysine. Using an
optical reporter group Lys115 was found to electrostatically perturb the Lys116 so that
it was mainly in the deprotonated state (37,38). The recently solved structure of AAD
showed, however, that Lys115 could not be the cause of the pKa change but that the
hydrophobic environment of Lys116 was the cause for charge destabilisation. The
observed effect on the reporter group was most probably caused by the neighbouring
Arg29 that is involved in binding the carboxylate. Another charged residue, Glu76, is
destabilising the negative charge on the carboxylate and the position is maintained by
electrostatic repulsion of Glu61 (Fig. 1.18) (36).
1.2.6 Cofactor-Independent Phenolic Acid Decarboxylase
The uncatalysed decarboxylation of p-coumarate occurs at 150 °C in a non-
stereospecific manner. Whereas, the pyrolytic decarboxylation of [8D]-p-coumarate
yields both cis- and trans-[8D]-hydroxystyrene, the phenolic acid decarboxylase (PAD)
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from Klebsiella oxytoca specifically produces the trans form, thus retaining the
stereochemistry. PAD does not accept the cis isomer of p-coumaric acid. Substrates of
PAD include ferulate and caffeate, whereas m-coumarate is not accepted, suggesting
the requirement of a 4-hydroxyl substituent on the aromatic ring. The mechanism of
decarboxylation is therefore thought to occur via a p-quinone methide intermediate with
the substrate acting as its own electron sink (Fig. 1.19, (39,40).
Figure 1.19. Decarboxylation of p-coumaric acid by PAD
The structure of Bacillus subtilis PAD has recently been solved and released but no
accompanying publication exists. The structure forms a dimer of two orthogonal β-
sheets that form the active site between the sheets. The structure contains two ethane
diols in the active site that span approximately the length of p-coumarate. There are
many aromatic residues around the active site and its mouth that are candidates for
binding the aromatic moiety of the substrate of which Tyr31 is the best positioned. A
series of other residues could be involved in protonation and deprotonation of the
substrate such as Tyr11 and Tyr13 on one end and Arg41, Glu64 and Thr68 on the
other end (PDB: 2p8g, K194Y mutant) (41).
PAD is of economic interest as it is involved in the degradation of cinnamic acids to 4-
hydroxyethyl phenols that are components of bad odours in wine (40). The cofactor-
independence of PAD also makes it a useful biocatalyst for the production of a range of
4-hydroxystyrenes.
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1.2.7 Cofactor-Independent Vanillate Decarboxylase
Vanillate decarboxylase (VD) from Nocardia sp. NRRL 5646 was described as a
cofactor-independent decarboxylase producing guaiacol. It was found to specifically
incorporate solvent deuterium into position 1 of the aromatic ring but not into the
hydroxyl. VD is specific for 4-hydroxylated benzoates including vanillate, 4-
hydroxybenzoate, protocatechuate, syringate. Substrates having the hydroxyl group in
a different position such as isovanillate, 2- or 3-hydroxylbenzoate were not substrates.
Neither was 4-aminobenzoate or the substrates for PAD p-coumarate and ferulate. By
analogy to PAD the mechanism is thought to occur via a quinonoid intermediate (Fig
1.20) (42).
Figure 1.20. Possible mechanism for decarboxylation of vanillate.
VD is a 23 kDa protein found to be dimeric in solution, but no structural data is
available for it. It was found to be inhibited by thiol reagents. A 21 residue long N-
terminal sequence fragment is identical to superoxide dismutatse (EC 1.15.1.1)
sequence from Nocardia asteroides except for the first residue. The substrate
specificity, however, matches with 4-hydroxybenzoate decarboxylase (EC 4.1.1.16)
that was reported to depend on metal ions (42-45).
1.2.8 Cofactor-Independent Arylmalonate Decarboxylase
Arylmalonate decarboxylase (AMD, EC 4.1.1.76) is another cofactor-independent
decarboxylase. It typically converts 2-methyl-2-phenylmalonate (MPM) into (R)-2-
phenylpropionate ((R)-PP) in a stereospecific manner. As it belongs to the Asp/Glu
racemase superfamily, it will be described further in the following section.
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1.3 Asp/Glu Racemase Enzyme Superfamily
New enzyme activities evolve from old protein folds resulting in the formation of diverse
enzyme families. This may occur through the retention of substrate specificities, protein
architecture or mechanistic property. The latter leads to mechanistically diverse
superfamilies with low sequence identities. A reaction step or the stabilisation mode of
an intermediate is conserved while substrate and product change significantly. The first
identified superfamily was the enolase superfamily that conserved the α-proton
abstraction of a carboxylate. In 2001 twelve distinct reactions of the enolase
superfamily were known, including mandelate racemase, muconate lactonising enzyme
and enolase. Other superfamilies have since been identified such as the crotonase, the
thiyl radical and the amidohyrolase/phosphotriesterase superfamilies (46).
Based on sequence identities the versatile Asp/Glu racemase enzyme superfamily
comprising glutamate racemase (GluR, EC 5.1.1.3), aspartate racemase (AspR, EC
5.1.1.13), hydantoin racemase (HydR, EC 5.1.99.5), maleate cis-trans isomerase (MI,
EC 5.2.1.1) and arylmalonate decarboxylase (AMD, EC 4.1.1.76) activities was defined
with an average overall sequence identity of 22% (Fig. 1.21, Pfam: PF01177) (47). This
superfamily contains over 1500 known homologous sequences.
The conserved fold of the superfamily is composed of two pseudo-symmetrical
domains most probably arising from an ancestral gene duplication. The active site cleft
is located between the domains and is buried under two covering loops. Most
superfamily members contain two opposed catalytic cysteines, one on each domain
(Fig. 1.22). The superfamily is thought to share a catalytic enediolate reaction
intermediate (48).
The enzymes of the Asp/Glu racemase superfamily have sparked interest in the
chemical industry because they are small proteins mainly from bacterial or archaeal
origin and are therefore relatively easy to handle. The main advantage of the
superfamily members is their independence from cofactors (49-52).
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Figure 1.21. Alignment of selected Asp/Glu racemase superfamily members.
Sequences of all selected homologues (black, see Chapter 3, Table 3.1), all
experimentally confirmed activities and all known structures were aligned using
ClustalW2. Four highly conserved stretches from the active site (see Appendix C)
were used to calculate a ClustalW2 guide tree based on sequence identity (for
details see Chapter 2). UniProt accession codes are indicated followed by the
initials of the species, the activity and PDB identifiers in square brackets.
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Figure 1.22. Structure of the Asp/Glu racemase superfamily members. The
secondary structure is shown for α-helices (red) and β-sheets (blue). Top left:
EfGluR with bound D-glutamate (light blue) and two cysteines (PDB: 2vvt). Top
right: BbAMD with bound PO4 (magenta) and one cysteine (PDB: 3dg9). Bottom:
Stereoview of the typical Rossmann fold domain of the superfamily corresponding
to domain 2 in EfGluR including one cysteine on the loop following the third β-
strand.
1.3.1 Glutamate Racemase
The best characterised enzyme in the Asp/Glu racemase superfamily is GluR that
catalyses the racemisation of both L- and D-glutamate (Fig 1.23). The enzyme
provides D-glutamate necessary for the peptidoglycan cell wall synthesis and is
therefore thought to be an interesting target for antibiotics. GluR activity was
discovered in lactic acid bacteria as early as 1952 when it was also shown that α-
50
ketoglutarate was not transformed into glutamate and was, therefore, not an
intermediate of the racemisation (53).
Figure 1.23. Glutamate racemase activity.
Over the years there was some confusion over the cofactor requirement of GluR (54-
57). In other amino acid racemases such as alanine, serine and arginine racemases,
PLP was found to act as a cofactor forming a Schiff base between the aldehyde and
the substrate amine. Later studies on heterologously expressed Lactobacillus
fermentum GluR (LfGluR, UniProt: Q03469) showed that the typical optical absorption
peak for a Schiff base of the covalently attached PLP does not exist and that adding
PLP was not necessary for activity. A Pyruvoyl group observed in some
decarboxylases and reductases could not be detected by acid or base hydrolysis or
specific inhibition by sodium borohydride, hydroxylamine or phenylhydrazine. The
requirement of metal cofactors was excluded as the presence of EDTA did not have an
effect on the activity of GluR. It was thus concluded that GluR is a cofactor-
independent racemase (47).
The mechanism of GluR was studied extensively with isotope labelling. After incubating
[18O]glutamate with enzyme in water, no loss of 18O from could be observed by MS,
indicating that there was no acyl intermediate formation during the reaction. Incubating
the unlabelled glutamate with enzyme in [2H]water and following the reaction with 1H-
NMR showed that the peak corresponding to the C2 hydrogen disappeared. This
demonstrated that racemisation occurs via general acid/base catalysis involving
deprotonation and reprotonation at the C2 position. By comparing the kcat of GluR when
incubated with pure enantiomers of [2-2H]glutamate or [2-1H]glutamate, a primary
kinetic isotope effect could be observed indicating that deprotonation rather than
substrate binding was the rate limiting step. Furthermore, GluR was incubated with
either pure D-glutamate or L-glutamate in [2H]water and the product was analysed by
chiral GC/MS. During the initial reactions [2H] was only incorporated into the product
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but not into the substrate showing that the GluR operates with a two-base rather than
with a one-base mechanism. Oversaturation could not be observed for GluR indicating
that the interconversion of one enzyme species to the other species with opposite
cysteines protonated was not rate limiting (Fig. 1.24) (58).
Figure 1.24. Mechanism of GluR. Deprotonation and reprotonation of D-
glutamate proceeding through an enediolate intermediate (59).
GluR was found to be stabilised by thiols, inactivated by thiol alkylating agents and two
cysteine residues were conserved in all homologues to LfGluR. Mutating the two
conserved cysteines to alanines or serines abolished or significantly reduced the
activity of the enzyme, indicating that they are indeed the catalytic bases involved in
the deprotonation and reprotonation. A series of observations allowed the identification
of which of the cysteines deprotonates L-glutamate and which deprotonates D-
glutamate. The single cysteine to alanine mutants led to the stereospecific
deprotonation of threo-3-chloroglutamate and the single cysteine to serine mutants led
to the deprotonation of N-hydroxyglutamate. Moreover, it was shown that the kcat/KM
isotope effect was reversed depending on which cysteine was mutated, indicating that
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the activating energy barrier for the serines was higher when they were involved in
deprotonation (47,60,61).
A series of structures of GluRs has been determined to date. The first structure from
the thermophile Aquifex pyrophilus (ApGluR, PDB: 1b73, 1b74) had the weak inhibitor
D-glutamine bound (Ki = 50 mM) (62) whereas the second structure from B. subtilis
(BsGluR, PDB: 1zuw) (63) had D-glutamate bound in the active site. Both structures
contained the catalytic cysteines in positions flanking the substrate with correct
distances. However, the orientation of D-glutamine in ApGluR was upside down
exposing C5 to the thiols of the cysteines instead of C2. In addition, the domain 2 of
ApGluR was moved by maximally 13 Å largely exposing the bound D-glutamine to the
solvent. This probably arises from the fact that ApGluR was soaked in D-glutamine in
contrast to the co-crystallisation of BsGluR with D-glutamate. ApGluR seems to
resemble the empty form of GluR and BsGluR the substrate-bound form (Fig. 1.25,
1.26) (63).
Figure 1.25. Residues involved in binding of D-glutamate in BsGluR. The
dotted lines indicate hydrogen bonds that are thought to form at different stages
during the reaction.
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Figure 1.26. Overlay of GluR structures. Stereoview of BsGluR (light blue) and
ApGluR (light red) overlaid on domain 1 (left halves of the proteins). D-glutamate
and catalytic cysteines of BsGluR (blue) and D-glutamine and catalytic cysteines of
ApGluR (red) are shown as stick model.
The findings presented above give a cofactor-independent mechanism for GluR but do
not explain how the reaction can be catalysed against the odds of a high pKa of both
the C2 proton and the thiol of the cysteines as well as the low stability of carbanion
intermediate with an adjacent negatively charged carboxylate. It was suggested that
the cysteines do not have to be deprotonated for activity but that other bases would
assist in the deprotonation once the substrate has been bound. Mutations of a
conserved aspartate and histidine to asparagine in GluR were found to have
significantly lower kcat with an unchanged KM (64). The residues Asp10 and His187
were adjacent to the catalytic Cys74 and Cys185 respectively (63). In a molecular
dynamics approach using D-glutamate in BsGluR this scenario was simulated coming
to the conclusion that a deprotonating cascade starting from Asp10 to Cys74, over to
C2 of D-Glu and finally to His187 represents a probable pathway (Fig. 1.27). This
mechanism would act in a concerted way, going through a single high energy peak, but
highly asynchronic as both cysteines are fully protonated in the intermediate stage. It
was found that the ammonium group was assisting the reaction by stabilising the
deprotonated residue at each stage of the reaction (65). In another molecular dynamic
approach based on BsGluR and D-Glu, the behaviour of the unstable carbanion
intermediate was simulated in the active site. The conclusion was that the negative
charge is destabilised by a range of interactions involving three waters and Ser11,
Asn75, Thr76, Thr186 and His187 (66). This is supported by the observation of a
dioxyanion hole in the homologous BbAMD where the residues equivalent of Asn75,
Thr76, Thr186 and a water form six hydrogen bonds with a ligand modelled on the
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basis of a benzylphosphonate (67). The dipoles of the N-termini of helices 3 and 8
could provide additional stabilisation of the deprotonated cysteines (63).
Figure 1.27. Catalytic cascade in BsGluR.
Proline racemase (EC 5.1.1.4) is another well studied cofactor-independent racemase.
Interestingly, it employs almost the same mechanism to GluR but adopts a completely
different fold. Proline racemase is related to the diaminopimelate epimerase (EC
5.1.1.7). As in GluR, these enzymes recruit a cysteine dyad that deprotonates and
reprotonates the bound substrate. In the structure of proline racemase the same
aspartate and histidine residues were found adjacent to the catalytic cysteines. It has,
therefore, been hypothesised that they would assist in the deprotonation and
reprotonation of the cysteine residues (68). However, in a recent molecular dynamics
simulation study it was argued that they were tightly bound to the enzyme framework
and could not move towards the cysteines. Therefore, the cysteines would have to be
deprotonated by water or the substrate rather than by neighbouring residues.
Stabilisation of the intermediate in these enzymes would be made by dioxyanion hole
formed by three hydrogen bond donors per carboxylate oxygen, equivalent to the
proposition made for AMDs (48,68).
1.3.2 Aspartate Racemase
Discoveries of AspR activities were always closely linked to GluR activities. The activity
was discovered in lactic acid bacteria and subsequently shown to be an activity of a
different enzyme than GluR (Fig. 1.28) (54,56). The enzyme was later purified from
Streptococcus faecalis and the first AspR gene sequence was cloned from
Enterococcus faecium (69,70). To date there are three solved structures available from
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two genes, both originating from Pyrococcus horikoshii OT3 (PhAspR). One structure
from the PhAspR C82A mutant has citrate bound in its active site showing similar
binding of one carboxyl group to D-Glu in GluRs (UniProt: O58403, PDB: 2dx7) (71).
Figure 1.28. Aspartate racemase activity.
The sequence alignment, the protein fold conservation and the substrate similarity
clearly indicate that AspR is a member of the superfamily. By analogy the mechanism
is thought to be the same as for GluR with deprotonation by one cysteine thiol,
stabilisation of the intermediate by hydrogen bonds and reprotonation by the opposite
cysteine thiol. An alternative mechanism was also proposed where the same cysteine
would deprotonate both aspartate enantiomers, which in turn would be reprotonated by
the same cysteine (72).
1.3.3 Hydantoin Racemase
The first HydR activity was discovered in Pseudomonas sp. NS671 and found to be on
an operon including a hydantoin hydrolase and a carbamoyl hydrolase involved in the
degradation of hydantoins into amino acids (Fig. 1.29) (49). This sequence of reactions
is also used industrially to produce enantiopure D- and L-amino acids (see first
section). Several HydR sequences from various bacterial strains and one structure of
P. horikoshii OT3 have been determined (UniProt: O58781, PDB: 2eq5). Both the
sequence homology and the fold indicate that HydRs are also members of the
superfamily.
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Figure 1.29. Hydantoin racemase activity. R = methyl, ethyl, isopropyl, isobutyl,
benzyl, methylthioethyl, phenyl, hydroxyphenyl, 3-methyl-indol.
It was shown that 2H from the solvent is incorporated specifically at the 5-position
confirming the conservation of the deprotonation/deprotonation mechanism found in
GluR. By analogy to GluR it was assumed that the intermediate is an enol (73).
Through single mutations of the catalytic cysteines to alanine the activity of HydR was
completely abolished. Single mutations to serines left some residual activity (100 to
500-fold reduced). As in GluRs, the serines in HydRs have reduced but detectable
deprotonation capacity compared to cysteines (74). Binding studies using calorimetry
and fluorescence showed that the alanine mutants were able to bind only one of the
two enantiomers of the hydantoins suggesting that the proton rather than the side chain
of the substrate is determining the binding specificity (75).
1.3.4 Arylmalonate Decarboxylase
A new cofactor-independent decarboxylase was discovered through selective
enrichments of soil cultures growing on PM as their sole carbon source. AMD from B.
bronchiseptica KU 1201 (BbAMD) was specifically and completely decarboxylating
MPM yielding pure (R)-PP (Fig. 1.30, e.e. > 99%, conversion > 99%) (51,76). The
physiological role of AMD was not identified but it was thought to be implicated in the
catabolism of special nutrients.
Figure 1.30. Typical reaction of BbAMD.
The enzyme was purified from bacterial cell extract and found to be a monomeric 25
kDa protein with an isoelectric point of 4.7. It had a pH optimum of 8.5 and stable
between pH 6.5 and 8.5. It was found to be stable up to 30 °C but inactivated rapidly at
50 °C and could be stored for months at 4 °C. The enzyme was found to be
independent of cofactors such as ATP, ADP, CoA or metal ions. BbAMD was
effectively inactivated by thiol reagents such as iodoacetate and by Pb2+, Sn2+, Hg2+,
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Hg+ and Ag2+ metal ions. It was therefore concluded that cysteines are the active site
residues (51).
The gene of BbAMD was identified using a genomic fragment library cloned into E. coli
cells that were selected for alkalinisation of the medium using the pH indicator BTB
changing its colour from yellow to blue. The gene was sequenced and found to be 720
bp long (UniProt Q05115). BbAMD was later found to be member of the Asp/Glu
racemase superfamily (77-79). Three more sequences of clearly active AMD have
been discovered by additional soil culture enrichment and genome mining (48,80,81).
Apart from the achiral substrate PM and the pro-chiral substrate MPM a vast range of
other malonates was tested on BbAMD. One substituent had to be an aryl or an alkenyl
electron withdrawing group. The other substituent had to be a small hydrogen, methyl,
hydroxyl, amine, fluorine or chlorine. The best substrate is PM that yielded achiral PA,
whereas interesting and good substrates were MPM, 2-methyl-2-napthylmalonate, 2-
methyl-2-thienylmalonate. It was found that even rather large and complex electron
withdrawing groups could be accepted as it was possible to produce flurbiprofen from a
dicarboxylic precursor with BbAMD (Fig. 1.31). The more electron withdrawing the
group was, however, the more active was the enzyme. The aromatic moiety or the
double bond had to be connected directly to the α-carbon as any longer linker
abolished any activity. The small groups did not have any electrostatic requirements
but had to be small and even 2-ethyl-2-phenylmalonate was not converted by the
enzyme. The small substituent was more active the smaller it was (51,67,76,79,82-87).
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Figure 1.31. BbAMD activity and selection of representative substrates.
The affiliation of BbAMD to the Asp/Glu racemase superfamily was confirmed when the
structure was solved and showed that the typical two pseudosymmetric domain
structure was retained. As was already seen in sequence alignments, BbAMD only had
one catalytic cysteine (Cys188) on domain 2 whereas the other catalytic cysteine on
domain 1 is replaced by a glycine (Gly74). There are currently five structural
coordinates published in the structure database (PDB: 3dg9, 3ip8, 2vlb, 3eis, 3dtv).
Two of them have a phosphate or a benzylphosphonate bound in the active site that
represents a model for the decarboxylated intermediate bound in the active site. Both
structures are high resolution structures and show the enzyme in a closed form,
assumed to be the substrate-bound form. In this form two loops, one from each
domain, cover the ligand in the active site completely. The other three structures are
lower resolution and show different molecules with different conformations especially in
these covering loops probably indicating the flexibility of the unliganded open form (Fig.
1.32) (48,67,88-90).
The benzylphosphonate bound high resolution structure shows distinct pockets for the
ligands. The phosphate moiety is bound with two of its oxygen atoms to six hydrogen
bonding partners by the hydroxyls of residues Thr75, Ser76 and Tyr126 as well as the
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backbone amides of residues Thr75, Ser76 and Gly189. This structure was called the
dioxyanion hole. The benzyl moiety is bound in a large aryl binding pocket formed by
hydrophobic residues and backbones of Pro14, Val43, Val156, Met159, Gly189 and
Gly190. A small binding pocket is formed by Leu40, Val43 and Tyr48, most probably
for binding the small substituent and the leaving carboxyl (Fig. 1.32) (67).
Figure 1.32. Structure of BbAMD. Top: Stereoview of the open, non-liganded
structure (light red, PDB: 2vlb) is superposed to the closed, phosphate bound form
(light blue, PDB: 3dg9). Bottom: Stereoview of the active site with bound
benzylphosphonate (purple, PDB:3ip8). Six hydrogen bonds (dashed lines) are
formed between the active site and the phosphate moiety of benzylphosphonate.
A series of mutagenesis experiments has been produced to confirm the catalytic
residue and the stereochemistry of the decarboxylation by BbAMD. The C188S mutant
was nearly 600 times less active than wild type and all other cysteine to serine
mutations had much smaller effects on the activity. Interestingly, the double mutant
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G74C/C188S, although even less active than C188S, showed inversion of the
enantioselectivity yielding (S)-PP instead of the (R)-PP, which was also confirmed for
other pro-chiral substrates of BbAMD. Furthermore, the G74C mutant not only lost the
stereoselectivity of MPM decarboxylation but was able to racemise (R)- and (S)-PP, the
products of the decarboxylation, although at very low rates. The rates of the
enantiospecificity-reversed mutant could be slightly improved 10-fold by the S36N
mutation found through a random mutagenesis approach. The improvement had to
come from a distant structural effect as Ser36 is located at the solvent exposed part of
BbAMD (77,91-95).
The stereospecificity of the decarboxylation and the protonation was determined by
decarboxylating MPM carboxyls labelled with 13C or 18O on either the pro-R or the pro-
S carboxyl. NMR was used to analyse 13C and MS was used to analyse 18O. Both
cases confirmed that the pro-R carboxyl was removed specifically. The product in all
cases was (R)-PP, indicating an inversion mechanism contrasting with the malonate
decarboxylases described in the previous section. The S36N/G74C/C188S mutant was
also decarboxylating the pro-R carboxyl but showed retention of configuration. The
decarboxylation in H218O solvent did not show incorporation of 18O into the product as
shown by MS. This suggested a mechanism with no thioester intermediate (48,91,96).
In analogy to the related racemases the mechanism is thought to occur through a
planar enediolate intermediate that is stereospecifically protonated by a Cys188 from
the si-face. The doubly negatively charged enediolate intermediate has to be stabilised
by the six hydrogen bonds offered by the dioxyanion hole (Thr75, Ser76, Tyr126 and
Gly189). The pro-R carboxyl is bound and destabilised in a hydrophobic pocket made
of Leu40, Val43 and Tyr48. By analogy to the racemases the decarboxylation and
protonation probably happen in a concerted and asynchronous manner without a clear
transition state. This mechanism was further confirmed by the inhibition by 2-
bromophenylacetate and benzylphosphonate (Fig. 1.33) (48,67,91).
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Figure 1.33. Mechanism of BbAMD with MPM. The retained carboxyl is bound
in the dioxyanion hole with up to six hydrogen bonds acting as an electron sink
(dotted lines). The leaving carboxyl is destabilised in the hydrophobic small
carboxyl binding pocket (small grey arc). The aryl group is bound in the
hydrophobic large aryl binding pocket (large grey arc). Cys188 protonates carbon
C2.
The mechanism of AMD could also be exploited to achieve a cascading aldol reaction.
BbAMD is able to catalyse the decarboxylation 2-(2-oxoethyl)phenylmalonate and the
subsequently formed enediolate intermediate is able to undergo a cascading aldol
reaction to form a 2-hydroxy-2,3-dihydro-1-indenecarboxylate (Fig. 1.34) (86).
Figure 1.34. Cascading aldol reaction triggered by BbAMD.
1.3.5 Maleate cis-trans Isomerase
Maleate isomerase (MI) was discovered in bacteria growing on nicotinic acid. It was
involved in the last step of degradation of nicotinic acid after ring cleavage producing a
cis double bonded compound. The last compound being maleate was isomerised into
its trans form fumarate that was fed into the citric acid cycle (Fig. 1.35) (97). Since
then, a series of MIs from other organisms have been discovered, purified and
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characterised (98-102). Only three MI genes have so far been characterised
(52,103,104). Sequence alignments and the presence of two conserved cysteine
residues clearly indicate that MIs are Asp/Glu racemase superfamily members.
Figure 1.35. Maleate cis-trans isomerase reaction.
MIs represent a peculiarity in the Asp/Glu racemase superfamily as they require a
fundamentally different reaction mechanism to the simple stereospecific
deprotonation/reprotonation. The mechanism must proceed through an intermediate
that is able to rotate around the reduced double bond. This requires both another
function for the catalytic cysteines as well as flexibility in the active site. Although no
protein structure of a MI has been determined to date, the importance of the catalytic
cysteine dyad as in the racemases has been confirmed. Direct evidence was given by
the inactivation through mutation to alanines (104). Indirect evidence was given by the
sensitivity of the enzymes to thiol reagents and heavy metals (100,101). Also the
absence of cofactor requirement has been confirmed for MIs (52,101). The enzyme
was found to be completely specific for maleate (98,100,101). Despite this restriction,
MIs could be useful to industry as fumarate is widely applied in industry for the
production of L-aspartate or L-malate (see section above, (105-107).
Maleate and fumarate differ only by their double bond configuration (Fig. 1.35). They
are both planar as a result of conjugation between their two carbonyl groups and the
central double bond. The difference in configuration has major effects on the properties
of the compounds. Maleic acid (cis configuration) forms an intramolecular hydrogen
bond that fumaric acid (trans configuration) does not. Therefore maleic acid is more
soluble and more acidic than fumaric acid. Fumarate is also more stable than maleate;
however, the rotation around the double bond requires a large activation energy
resulting in maleate being relatively stable in physiological conditions. The
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isomerisation only occurs at temperatures above 200 °C or through irradiation with UV-
light. The cis-trans isomerisation can be catalysed by reducing the double bond to a
single bond allowing free rotation. This has been achieved with metals, radical addition
and nucleophilic attack by thiols and acids (105,108-110).
Some cis-trans isomerases involve double bond migration such as linolenate
isomerase (EC 5.2.1.5). MI operates through a mechanism without double bond
migration as do maleylacetoacetate isomerase (EC 5.2.1.2) and malylpyruvate
isomerase (EC 5.2.1.4) (110). These maleyl decarboxylases are dependent on the
coenzyme glutathione that is thought to attack double bond at the 2-carbon (111).
Analogously, the catalytic cysteines of MI are thought to act like glutathione, but
alternative mechanisms cannot be excluded (104,110).
1.4 Aims
Although many enzymes are already applied in industry, there is still a great need for
optimisation and extension of the enzymatic tool kit. Carboxylations/decarboxylations,
racemisations and isomerisations are reactions without appropriate biocatalysts that
still require development in order to become useful for particular applications (112).
Fortunately, enzymes are very flexible catalysts because of the huge number of
potential variants and because their sequences can be adapted by directed evolution
approaches. With the knowledge of their three dimensional structures more rational
approaches can also be applied (113).
The biocatalytic route to the production of chiral alkylalkanoates as chemical
intermediates is highly attractive. The decarboxylation of alkylmalonates analogous to
the arylmalonate activity of BbAMD seems be a promising approach. The present work
aimed to exploit the potential of the Asp/Glu racemase enzyme superfamily to produce
a suitable biocatalyst.
In Chapter 3 the sequence diversity of the Asp/Glu racemase enzyme superfamily was
mined in order to identify new AMDs. A range of BbAMD sequence homologues was
identified, cloned, expressed and assayed for aryl- and alkylmalonate decarboxylation
activity. As no decarboxylation activity could be observed for the tested homologues
some homologues were analysed in more depth. The presence of GluR, AspR, MI and
PP racemase activity was tested in three homologues. Site directed mutagenesis was
applied to change the active site sequence of one homologue to resemble more the
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BbAMD sequence. In an alternative approach the microbial diversity in the soil was
mined in an attempt to isolate bacterial strains capable of decarboxylating
alkylmalonates. Soil samples were selectively enriched in organisms capable of
growing on alkylmalonates. Substrate and product quantities in pure cultures were
analysed (see Appendix D).
In Chapter 4 BbAMD homologue NfMI was identified to be a MI. MIs are the most
closely related enzymes to AMDs in the Asp/Glu racemase superfamily but have a
fundamentally different activity. As not much is known about MIs the NfMI was
characterised biochemically. A range of substrate analogues were tested in order to
find a competitive inhibitor to NfMI. Also the role of the catalytic cysteines was
investigated using site directed mutagenesis. In Chapter 5 the structure of NfMI was
determined by X-ray crystallography. Based on these findings several hypotheses for a
reaction mechanism are discussed which reveal insights into the catalytic plasticity of
the Asp/Glu racemase superfamily.
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Chapter 2
General Methods
2.1 Cloning
2.1.1 Strategy
For the rapid and partially automated cloning of bacterial genes from gDNA samples
the ligation independent cloning (LIC) approach was chosen. LIC uses simple
annealing of complementary single strand overhangs of the insert and plasmid, directly
followed by the transformation; circumventing an inefficient ligation process and the
design of restriction sites.
For the production of long overhangs, the exonuclease proofreading activity of the DNA
polymerase was used adding only one type of dNTP to the reaction mix. The
exonuclease removes nucleotides from the strand until it reaches a specific nucleotide
in the sequence where the polymerase activity predominates. The length of the
overhangs was previously determined through the design of the cloning site and is
matched by the complementary sequence of specific PCR primer overhangs (114).
The plasmid used was pET-YSBLIC3C that is both a cloning and expression vector
based on IPTG inducible pET-28a(+) plasmid (Novagen, Appendix B). The vector
contains an N-terminal His-tag to facilitate purification and it is cleavable by the HRV
3C-protease to improve crystallisation if required (Fig. 2.1).
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Figure 2.1. LIC vector containing a gene of interest. Based on pET-28a(+)
plasmid with an altered cloning site containing the open reading frame (ORF)
including a 6x His-tag (His) cleavable at the HRV 3C protease site (3C). The
plasmid further contains a T7 promotor (T7P) and terminator (T7T), a Lac operator
(LacO) and repressor gene (LacI) for IPTG induction, a ribosome binding site
(RBS), a kanamycin resistance gene (KanR) and two origins of replication (ori, f1
ori).
2.1.2 Construct Preparation
Inserts were amplified using 1 U KOD Hot Start DNA Polymerase (Novagen), 1x PCR
buffer, 1 mM MgSO4, 2 mM of each dNTP, 4 μM of each forward and backward primer
(Table 2.1, Sigma Genosys), 0.5 ng μL-1 DNA and was completed to 50 μL total volume
with water. The temperature cycles were one initial melting step at 94 °C for 120 s
followed by 35 times melting at 94 °C for 30 s, annealing at 65 °C for 30 s and
elongation at 72 °C for 60 s ending with one final elongation step at 72 °C for 180 s
performed on a Px2 Thermal Cycler (Thermo Scientific, Fig. 2.2).
The pET-YSBLIC3C plasmid was cleaved with 20 U of BseR I (NEB), 1x restriction
buffer 2 and 5 μg DNA completed to 100 μL total volume with water. The mix was
incubated at 37 °C for 110 min, separated from uncleaved plasmid by agarose gel
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electrophoresis and the target band was purified using the Wizard SV Gel Clean-Up Kit
(Promega).
Single strand overhangs were produced with 0.2 pmol of the PCR product together with
2.5 mM dATP or 0.4 pmol cleaved plasmid together with 2.5 mM dTTP. Both insert and
plasmid were mixed with 2 U T4 DNA Polymerase (Novagen), 1x polymerase buffer
and 5 mM DTT, then incubated at 22 °C for 30 min and inactivated at 75 °C for 20 min.
The plasmid reaction was cleaned using the QIAquick PCR Purification Kit (QIAGEN)
whereas the insert was used without cleaning.
Annealing was performed by mixing 2 μL insert reaction and 1 μL cleaned plasmid,
incubating at room temperature for 10 min. Then 1 μL 25 mM EDTA was added and
incubated at room temperature for another 10 min. Escherichia coli NovaBlue Singles
were transformed with 2 μL of the annealing reaction.
Figure 2.2. LIC procedure. Left: PCR product of BbAMD including LIC overhangs.
Middle: Gel purification of cleaved LIC plasmid. Right: Seven clones tested for the
presence of the insert.
2.1.3 Plasmid Transformations
E. coli strains used in this study were NovaBlue Singles for cloning, BL21(DE3) for
expression of codon optimised genes, Rosetta 2(DE3) for expression of genes
containing rare codons. Rosetta 2(DE3) cells contain a pRARE2 plasmid encoding rare
E. coli tRNA genes and a chloramphenicol resistance gene.
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For the production of competent cells, aseptic technique was use throughout the
process, 100 mL LB were inoculated with a freshly grown colony of the appropriate
strain. 34 μg mL-1 chloramphenicol were added if Rosetta 2(DE3) were used. The
culture was incubated at 37 °C until an optical density at 600 nm of 0.4-0.5 was
reached. From that moment the cells were kept at 0 °C, spun down at 2,000 × g for 10
min, resuspended in 40 mL sterile 50 mM MgCl2, 20 mM CaCl2, incubated for 30 min,
spun down again and finally resuspended in 4 mL sterile 80 mM CaCl2, 20% (v/v)
glycerol. The cell suspension was then aliquoted in 50 μL portions, snap frozen in liquid
nitrogen and stored at -80 °C.
A microcentrifuge tube containing 50 μL competent cells was thawed at 0 °C and 100
ng plasmid DNA was added. The mix was incubated 5 min, heat shocked at 42 °C for 2
min and cooled down at 0 °C for 5 min. 600 μL LB was added to the suspension and
incubated at 37 °C shaking for 1 h. Then 10 μL were spread on LB-agar plates
containing 100 μg mL-1 kanamycin and in the case of Rosetta 2(DE3) cells additionally
34 μL mL-1 chloramphenicol.
2.1.4 Plasmid Purification and Verification
5 mL LB containing the appropriate antibiotic were inoculated with a freshly grown
colony, grown at 37 °C shaking at 200 rpm for 16 h and then extracted using the
QIAprep Spin Miniprep Kit (QIAGEN). The purified quantity was determined by
measuring the absorbance at 260 nm (0.1 units corresponding to 5 μg mL-1 DNA).
The presence of the insert with the correct length was verified by double digesting 100
ng plasmid DNA with 3 U of each Nco I and Nde I in 1x restriction buffer 4 and
1 mg mL-1 BSA (NEB). The constructs were sequenced by an in-house sequencing
service, using Sanger sequencing on an ABI 3130 (Applied Biosystems) with T7P and
T7T primers (Table 2.1).
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Table 2.1. List of primers.
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2.1.5 Source of DNA Samples
BbAMD was received from Dr. Krzysztof Okrasa (University of Manchester) as a codon
optimised synthetic gene in a pGA4 plasmid containing an ampicillin resistance gene
(GENEART). For the other genes, gDNA samples were acquired: Nocardia farcinica
IFM 10152 from Dr. Jun Ishikawa (Nocardia farcinica Genome Project), Rhodococcus
sp. RHA1 as a generous gift from Prof. Lindsay Eltis (UBC, Vancouver), Pyrococcus
furiosus Vc1 and Streptomyces avermitilis NRRL 8165 from ATCC (numbers 43587
and 31267 respectively), Streptomyces coelicolor A3(2) from DSMZ (number 40783,
renamed to Streptomyces violaceoruber), Sulfolobus tokodaii 7 from NBRC (number
100140), Sinorhizobium meliloti 1021 from Delphine Capela (INRA-CNRS, Castanet
Tolosan), Mesorhizobium loti from Takakazu Kaneko (Rhizobase). The pET-YSBLIC3C
plasmid was obtained from Dr. Mark Fogg (YSBL).
2.1.6 Agarose Gel Electrophoresis
Agarose gel electrophoresis was used to verify the size of DNA fragments. 1.2% (w/v)
agarose was heated to dissolve in 100 mL TAE buffer (40 mM TRIS, 20 mM acetic
acid, 50 mM sodium EDTA, pH 8.0) and 1 μL 10 mg mL-1 ethidium bromide added.
DNA samples of approximately 100 ng were were diluted in 4x DNA loading buffer
(0.25 mg mL-1 bromophenol blue, 0.25 mg mL-1 xylene cyanol, 60% (v/v) glycerol, 15
mM TRIS, pH 7.6) and run at 100 V for 30 min together with 1 kbp or 100 bp DNA size
ladders (NEB).
2.1.7 Site Directed Mutagenesis
Single amino acid mutants were produced with an adjusted QuickChange protocol
(Stratagene, http://www.stratagene.com/manuals/200518.pdf) and the primers were
designed with PrimerX (http://www.bioinformatics.org/primerx). Mutant strands were
produced using 2 U Phusion High Fidelity DNA Polymerase, 1x HF buffer (Finnzymes),
0.22 mM of each dNTP, 0.22 μM of both forward and backward primer (Table 2.1,
Sigma Genosys), 3.4 ng μL-1 original plasmid DNA and was diluted to 50 μL total
volume with water. The temperature cycles were an initial melting step at 98 °C for 30 s
followed by 16 times melting at 98 °C for 30 s, annealing at 55 °C for 60 s and
elongation at 72 °C for 370 s performed on a Px2 Thermal Cycler (Thermo Scientific).
The original DNA was digested specifically with 10 U DpnI (NEB) for 3 h at 37 °C and 2
μL were directly transformed into NovaBlue Singles (Novagen). All mutations were
checked by sequencing in both directions using the T7P and T7T primers (Table 2.1).
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2.2 Sequence Alignments
2.2.1 Determination of Sequence Identity
Pairs of sequences were aligned globally with "EMBOSS::needle" alignment tool on
EBI (http://www.ebi.ac.uk/Tools/emboss/align) to determine the sequence identity.
2.2.2 Phylogenetic Tree
A selection of Asp/Glu racemase superfamily sequences was created from all
homologues chosen for decarboxylation assays (Chapter 3), all sequences with a
known structure and all sequences with a published, experimentally determined
activity. The sequences were aligned with the ClustalW2 alignment tool (version 1.82)
on EBI allowing end gaps (http://www.ebi.ac.uk/Tools/clustalw2). For all other
parameters the default values were used (gap open penalty = 10, gap extension
penalty = 0.2, gap separation penalty = 4, matrix = Gonnet). Obvious misalignements
in the regions of the conserved cysteines were corrected by hand. The final alignment
is shown in Appendix C.
For the production of the tree, the most conserved stretches were selected that are
involved in the active site formation. They contain the positions of each of the
conserved cysteines and the conserved dioxyanion hole position (Tyr128 in BbAMD).
The streches were then extracted the corresponding guide tree was calculated with
ClustalW2 producing an unrooted tree with Phylip and neighbour joining that is based
on pairwise sequence identities (Fig. 1.21). The stretches used for the tree calculation
are shown in Appendix C.
2.3 Protein Production and Purification
2.3.1 Protein Expression
All the proteins were expressed heterologously in E. coli host strains using the lac
operator system of the pET vector induced by IPTG
(http://kirschner.med.harvard.edu/files/protocols/Novagen_petsystem.pdf, Novagen).
BL21(DE3) strain was used for BbAMD while Rosetta 2(DE3) strain (Novagen) was
used for the homologues in pET-YSBLIC3C. Colonies were grown on LB-agar plates
containing 100 μg mL-1 kanamycin and for Rosetta 2(DE3) containing an additional
34 μg mL-1 chloramphenicol. 5 mL LB starter cultures containing the same antibiotics
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were inoculated with a fresh colony and incubated at 37 °C shaking at 200 rpm for 16
h. Then 5-2,000 mL main cultures with the same medium were inoculated with 1% (v/v)
of the starter culture and incubated in the same conditions. When the optical density at
600 nm reached 0.7-0.9, 1 mM IPTG was added and the culture was incubated at 30
°C shaking for another 21 h before the cells were then spun down at 2,000 × g for 10
min.
2.3.2 Cell Lysis
The cell pastes produced containing the protein were then resuspended in 20 mM
TRIS, 150 mM NaCl pH 8.0 supplemented with 200 μM PMSF to inhibit periplasmic
proteases, 5 mM DTT to keep the protein reduced and stable, 5 μg mL-1 hen egg white
lysozyme to digest the cell walls, 5 μg mL-1 DNase I and 1 mM MgCl2 to cut the DNA in
order to reduce the viscosity of the sample. In some cases of sodium phosphate buffer
and 300 mM NaCl was used at the same pH.
The cell suspension was then sonicated using an S-4000 Sonicator (Misonix) at 70%
amplitude during for total duration of 4 min in 3 s intervals interrupted by 7 s cooling
periods at 0 °C. The lysate was then cleared of cell debris by centrifugation at 45,000 ×
g for 20 min.
2.3.3 Protein Purification
To purify the protein by its His-tag the clarified cell lysate was filtered through a 0.22
μm membrane (Millipore) and loaded with a syringe onto a 5 mL HisTrap HP nickel
column (GE Healthcare). The buffer used was 20 mM TRIS, 150 mM NaCl pH 8.0. The
protein was then washed by increasing the imidazole concentration from 0 to 50 mM
for 100 mL and eluted by increasing further from 50 to 300 mM for another 100 mL.
The fractions corresponding to the peak in absorbance measured at 280 nm were
pooled (typically around 130 mM imidazole) and concentrated to 2 mL using Amicon
Ultra15 centrifugal filters 10 kDa molecular weight cut off (Millipore). If the protein was
only needed for activity assays simple nickel affinity resin batch purification was
performed by stepwise adding of higher concentrations of imidazole and spinning down
the resin.
Gel filtration was performed to purify the protein further and remove imidazole with the
aim of crystallisation. The concentrated protein sample was injected into a HiLoad
16/60 Superdex 75 preparative grade column (GE Healthcare) and eluted with the
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same nickel column wash buffer. Again the peak fractions were pooled and
concentrated to 5-15 mg mL-1 protein concentration as determined by the Bradford
assay. Aliquots of 50 μL were snap frozen in liquid nitrogen and stored at -80 °C (Fig.
2.3).
Figure 2.3. Typical purification of BbAMD homologues. Top: Chromatogram of
a nickel affinity column purification (Ni). Bottom: Chromatogram of a gel filtration
column (GF). Absorbance (blue) and imidazole concentration (red) are shown in
chromatograms. Right: SDS-PAGE of different purification steps.
2.3.4 Protein Size and Purity Determination
The proteins were analysed by SDS-PAGE using 0.75 mm, 12% gels. Separating gel
(375 mM TRIS pH 8.8, 0.1% (w/v) SDS, 10% (w/v) acrylamide, 0.3% (w/v) N,N-
methylene-bis-acrylamide, 0.04% (v/v) TEMED, 0.1% (w/v) APS) was topped by
stacking gel (as separating but 125 mM TRIS pH 6.8, 5% (w/v) acrylamide, 0.1% (w/v)
N,N-methylene-bis-acrylamide) and immersed in running buffer (25 mM TRIS, 200 mM
glycine, 0.1% (w/v) SDS). The samples were diluted 1:4 in loading buffer (2% (w/v)
SDS, 0.15% (w/v) bromophenol blue, 62.5 mM TRIS pH 6.8, 40% (v/v) glycerol, 20%
(v/v) BME) and unfolded at 95 °C for 2 min.
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To analyse whole cell samples including insoluble protein, the pellet of 1 mL cell culture
was heated to 95 °C for 10 min in total solubilisation loading buffer (1% (w/v) SDS, 2 M
urea, 1.25 (v/v) BME, 2.5% (v/v) glycerol, 15 mM TRIS pH 6.8, 0.15 % (w/v)
bromophenol blue) (115). Gels were typically run at 200 V for 45 min and stained using
Blue Silver (0.12% (w/v) Coomassie G-250, 10% (w/v) (NH4)2SO4, 10% (v/v)
phosphoric acid, 20% (v/v) methanol) for 1 h and then destained in water for 1 h (116).
As a size marker the prestained broad range protein marker (NEB) was used.
2.3.5 Protein Quantification Assay
The Bradford protein quantification assay is an easy to use assay that can be applied
to protein mixtures as well as pure protein. A standard curve was produced using
Coomassie (Bradford) Protein Assay solution and the BSA standard (Thermo
Scientific) using 10 μL samples added to 1 mL of reagent. The absorbance at 595 nm
was measured. The approximation formula for the protein concentration in mg mL-1
“c = 2 x A - 0.25” was used, where A corresponds to the absorbance. The linearity is
maintained for absorbance values between 0.2 and 0.8.
2.3.6 Analysing Protein Monodispersity
Dynamic light scattering (DLS) was used to assay the monodispersity (i.e. non-
aggregation) of the protein solution and gain an indication of the multimerisation state
of the protein. The protein was diluted to 1 mg mL-1 in buffer and centrifuged for 10 min
at 18,000 × g to remove large particles. The solution was tested on a DynaPro particle
sizer (Wyatt Technology) at 18 °C. The samples were measured until 15 statistically
good data points were recorded (indicated by the software). The polydispersity <25%
was considered monodisperse and the corresponding molecular mass, assuming a
spherical particle, was read.
2.3.7 Analysing Secondary Structure
Circular dichroism (CD) was used to assess the folding state of the protein by checking
the existence of secondary structure elements. Protein solutions of 1 mg mL-1 were
diluted to 0.2 mg mL-1 in water to reduce buffer content and the CD spectrum was
measured between 195 nm and 260 nm on a J-810 spectropolarimeter (Jasco). The
buffer spectrum was subtracted from the spectrum of the protein in buffer. The
presence of properly folded α-helices was verified by the presence of characteristic
troughs at 208 and 222 nm.
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Chapter 3
Screening of BbAMD Homologues
for Decarboxylation of Malonates
3.1 Introduction
BbAMD was isolated from soil cultures growing on phenylmalonate as their sole carbon
source and was found to stereospecifically decarboxylate disubstituted malonates (76).
BbAMD accepts malonates containing an aryl group as one substituent and hydrogen,
methyl or fluorine as the other substituent (51,67,85). BbAMD accepts a large range of
aryl substituents including napthyl, thienyl and phenyl with various substituents on the
aromatic rings such as chloro, fluoro, methoxy and methyl groups to alkenyls (51).
Special substrates such as [2-(2-oxoethyl)phenyl]propanedionate and 2-(2-fluoro-4-
biphenyl)-2-methylmalonate were also reported to be decarboxylated by BbBMD
producing an aldol reaction cascade and the drug flurbiprofen respectively (Fig. 3.1)
(86,117).
Figure 3.1. Activity of AMD. R = H, CH3, OH, NH3. Ar = aryl, alkenyl.
By analogy to AspRs and GluRs, the mechanism of BbAMD is thought to go through an
enediolate intermediate resulting from the decarboxylation of the substrate. The
intermediate is stabilised by interactions with the active site and is then protonated by
Cys188 from the si-face of the planar intermediate as shown by deuterium labelling in
GluRs and mutation to alanine in BbAMD (58,92). Both the decarboxylation and the
protonation have been shown to be stereospecific by experiments involving isotope
labelling. The decarboxylation was shown to proceed directly through the loss of the
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pro-R carboxylate with an overall inversion of stereospecificity by 13C and 18O labelling
(48,118).
Recently the structure of BbAMD was solved and found to have the same overall fold
as the other known racemase structures (48,67,88,90). The structures have different
ligands bound in the active site: BME, phosphate and benzylphosphonate. The binding
site of phosphate and the phosphonate revealed six potential hydrogen bonding
partners, able to stabilise a doubly negatively charged enediolate intermediate. This
dioxyanion hole is formed by the hydroxyl of Thr75 and the backbone amides of both
Thr75 and Gly189 for one negative charge and for the other negative charge by the
backbone amide of Ser76 together with hydroxyls of both Ser76 and Tyr126. The
structures also revealed a large and a small binding pocket thought to be responsible
for binding the substituents of malonates. By analogy to the binding of the aromatic ring
of benzylphosphonate it is thought that the aryl group binds in the large binding pocket
whereas the small binding pocket is thought to bind both the cleaved carbon dioxide
and the small substituent if present. The overall reaction is ultimately thought to be
driven by the destabilisation of the negative charge in the leaving carboxyl group by the
hydrophobic environment and the stabilisation of the double negative charge in the
carboxyl group bound at the dioxyanion hole (48). Gaseous carbon dioxide then leaves
the solution driving the equilibrium strongly in the decarboxylation direction.
BbAMD catalyses the efficient production of chiral 2-arylpropionates from 2-methyl-2-
arylmalonate substrates. Conversely, the production of neither chiral 2-arylalkanoates
with longer aliphatic chains nor fully aliphatic chiral 2-alkylalkanoates has been
achieved yet. These chiral intermediates for chemical synthesis would be of
commercial interest to industry. The enzymatic decarboxylation of alkylmalonates
would represent an easy and efficient route to obtain the intermediates.
There is a range of BbAMD homologues available in the public sequence database
UniProt. Testing diverse potential AMDs is interesting in many ways. On one hand,
finding new AMDs would allow new patents to be filed for commercial exploitation of
the discoveries with engineering methods. On the other hand, the diversity of enzymes
might be expected to offer a range of completely new substrate specificities allowing
the exploration of the active site flexibility and gaining useful insight for future
engineering efforts.
In this chapter, ten sequence homologues of BbAMD were also tested for
decarboxylation of PM and a range of other disubstituted malonates. Mutants of an
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inactive homologue were produced to increase the resemblance to BbAMD and tested
for PM decarboxylation. Another inactive homologue was also tested for alternative
activities found in the Asp/Glu racemase superfamily.
3.2 Methods
3.2.1 Chemical Synthesis of MPM
MPM was not available commercially and therefore had to be synthesised in our
laboratory. The strategy was to start from readily available dimethylphenylmalonate,
methylate the C2 carbon and hydrolyse the methylesters.
The methylation was performed as follows: In 25 mL anhydrous ethanol 1.2 g (17.6
mmol) sodium ethoxide was dissolved at 0 °C and under nitrogen atmosphere. Then
2.73 mL (12.7 mmol) dimethyl-2-phenylmalonate was added and stirred for 20 min at
room temperature. Then 3 g (21.1 mmol) iodomethane was added and stirred for 1 h at
room temperature. After verifying the completion of the reaction by TLC, 100 mL water
was added to stop the reaction. The products were extracted with 400 mL ethyl acetate
adding some saturated NaCl solution and methanol, dried with MgSO4 and filtered. The
extract was concentrated by rotary evaporation and purified by silica gel column
chromatography with a mobile phase of ethyl acetate/petroleum ether starting with 200
mL 1:19 (v/v) and finishing with 200 mL of 1:9 (v/v). Fractions of 10 mL were collected
and analysed by TLC. The fractions containing the product were pooled and the
solvent was removed by rotary evaporation. The yield was 2.5 g (11.2 mmol, 88%)
dimethyl-MPM.
Reaction products were analysed by TLC with silica gel as the solid phase and ethyl
acetate/petroleum ether 1:9 (v/v) as the mobile phase. The plates were stained by
immersing in 1% (w/v) KMnO4 and 2% (w/v) Na2CO3, followed by a heat-drying process
to reveal the spots (Fig. 3.2, top left).
The hydrolysis was performed as follows: Diethyl-MPM was dissolved in 120 mL
ethanol and 110 mL 4M KOH was added and stirred at room temperature for 16 h. The
hydrolysis was checked by TLC. Then the product was acidified with concentrated HCl
to pH 1 and extracted with 1 L ethyl acetate adding some saturated NaCl and
methanol, dried with MgSO4 and filtered. The extract was concentrated by rotary
evaporation and crystallised by adding petroleum ether and cooling it down to 0 °C.
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Crystals were filtered with blotting paper. The yield was 0.9 g (4.6 mmol, 41%
hydrolysis, 36% overall).
3.2.2 Analysis of Synthesised MPM
The identity and purity of the product were tested by three methods: 1H-NMR, HPLC
and MS.
The NMR was conducted by an in-house service using the 500 MHz NMR
spectrometer AV500 (Bruker). 20 mg of MPM were dissolved in 750 μL of
CDCl3/acetone-D6 9:1 (v/v). A total of 8 H were expected: A singlet peak equivalent to 3
H with a chemical shift of 1.82 ppm corresponding to the three methyl H, a multiplet
peak corresponding to 5 H with a chemical shift of 7.15-7.38 ppm corresponding to the
5 phenyl H, and a broad singlet peak equivalent to 2 H with a chemical shift of 7.55-
8.75 ppm corresponding to the 2 carboxylic acid H. These peaks were all visible on the
spectrum (Fig. 3.2, top right).
The MS was performed by an in-house service as well using the ABI Qstar ESI-TOF
mass spectrometer (Applied Biosystems). 1 mM MPM in methanol was prepared and
diluted 1:100 in acetonitrile/water 1:1 (v/v). The m/z of 193.1 Da was detected
corresponding to the mass minus 1 H+ (Fig. 3.2, bottom right).
The HPLC was performed by dissolving MPM in 2-propanol at 100 mM and diluting it
1:20 in eluent and injecting 10 μL as described in HPLC method below. The run
resulted in a single and clear peak at RT of 13 min (Fig. 3.2, bottom left)
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Figure 3.2. MPM production and purification. Top left: TLC of MPM production
steps. S: Dimethyl-2-phenylmalonate. M: Methylated S = 2-methyl-dimethyl-2-
phenylmalonate. P: Purified M. H: Hydrolysed P = MPM. Top right: 1H-NMR of
MPM. The peaks correspond to carboxyl-Hs at 8.1 ppm, aromatic Hs at 7.1-7.4
ppm and methyl-Hs at 1.8 ppm. Bottom left: HPLC trace of 10 μL of 5 mM MPM.
Bottom right: MS of MPM.
3.2.3 Strategy for Malonate Decarboxylation Assays
Three methods have been described for measuring the decarboxylation activity of
disubstitued malonates: HPLC, GC and spectrophotometric detection of a pH change
(48,76). HPLC and GC offer the possibility of detecting the stereospecificity of the
reaction through chiral columns, whereas the spectrophotometric method allows a real
time recording of the reaction and the application of the method to high throughput
screening useful for directed evolution approaches.
There are various limitations to the spectrophotometric assay that uses a pH indicator
to measure a difference in absorbance. As the pH is used to quantify the turnover it
cannot be constant as it should ideally be for enzyme assays. It is also not entirely
clear how the reaction and pH change are linked and how solvation and degassing of
carbon dioxide indirectly and directly influence the pH during the reaction. In fact, two
separate increases of absorbance could be observed upon addition of the enzyme both
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not corresponding to the increase observed by HPLC. This method was therefore
explored but not applied in the present work.
The HPLC method detects aromatic groups with a high sensitivity at 210 nm and is
therefore well suited for the analysis of arylmalonates, but alkylmalonates only have the
carboxyl group that only gives a weak signal at 205 - 210 nm. For chiral separations of
the products of stereospecific decarboxylations, a normal phase column was used,
requiring prior extraction of the reaction products. For the detection of alkylmalonate
decarboxylation activities an easier non-chiral reverse phase column was used that
was insensitive to the chirality of the compounds.
To increase the sensitivity of the alkylmalonate detection, GC coupled with FID would
be a good choice, offering a sensitive and easily quantifiable signal. However, in this
case the carboxyl groups would have to be derivatised to become apolar and therefore
volatile. The method was not applied in the present work.
3.2.4 Extraction and Normal Phase HPLC Analysis
Samples were saturated with NaCl so non-dissolved residual crystals were visible in
the tube and acidified by adding 1/5 volume of 2 M HCl. 1 volume ethyl acetate was
added and the samples were vigorously shaken for 30 s. The phases were separated
by centrifuging at 18,000 × g for 1 min and the organic layer was removed and dried
with MgSO4. A 20 μL sample was added to 180 μL eluent and 10 μL were run on
normal phase CHIRALPAK IA, 250 x 4.6 mm (CHIRAL Technologies Europe) HPLC
column using n-Heptane/2-propanol/TFA 90:10:0.1% (v/v) as mobile phase at a flow
rate of 0.7 mL min-1 on a 510 Pump with 717plus Autosampler (Waters). The peaks
were detected at 210 nm using a 2487 Detector (Waters). Retention times were PM
16.7 min, PA 7.6 min, MPM 14.3 min, (R)-PP 7.6 min, (S)-PP 7.8 min, MEM 8.5 min,
MPrM 8.7 min, EBM 8.2 min and DMCHDC (4 diastereoisomers) 8.6, 9.0, 9.8, 10.0
min.
3.2.5 Whole Growing Cell Decarboxylation Assay
Escherichia coli Rosetta 2(DE3) cells were grown and induced as described earlier
(Chapter 2). During induction 1, 4, 20, 40, 400 or 1000 mM PM, pH 8 were added to
the cell culture. The culture was at 60% (alternatively 50%, 75%) of the total reaction
volume. The reaction was buffered to pH 8.0 with 20 mM TRIS or pH 6 with 20 mM
sodium citrate/sodium phosphate buffer and 150 mM NaCl were added. The mix was
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then incubated at 30 °C shaking at 200 rpm for 16 h. The products were extracted and
analysed by normal phase HPLC.
3.2.6 Whole Resting Cell Decarboxylation Assay
The proteins were expressed as described earlier but grown for 3 h at 37 °C after
induction. Then the cells were spun down and the pellet was resuspended in the
reaction mix at 0.5 g mL-1. The mix was 20 mM PM, 150 mM NaCl and 20 mM TRIS pH
8.0. The samples were incubated at 37 °C shaking at 200 rpm for 16 h. The products
were extracted and analysed by normal phase HPLC.
3.2.7 Cell Lysate Decarboxylation Assay
The proteins were expressed as described earlier and induced for 6 h at 30 °C or 3 h at
37 °C. The 16 h induction cells were spun down and the equivalent of 3.75 mL culture
volume were resuspended in water and 750 μL of 100 mM PM, pH 8.5, 500 μL 1 M
TRIS, pH 8.5 were added. The cells were lysed by adding 200 μL BugBuster
(Novagen) and the mix was incubated at 37 °C shaking for 24 h.
Alternatively, the cells from the 3 h induction were resuspended in the same volume of
20 mM TRIS, pH 8.0, 150 mM NaCl and 5 μg mL-1 hen egg white lysozyme. The cells
were sonicated using S-4000 Sonicator (Misonix) at 70% amplitude during for 4 min
total duration in 3 s intervals interrupted by 7 s cooling periods at 0 °C. The cell debris
was removed by centrifugation at 2,000 × g for 10 min and 500 μL aliquots were snap
frozen in liquid nitrogen and stored at -80 °C. 88 μL of thawed lysate was mixed with 10
μL of water and 2 μL of 1 M PM and incubated at 37 °C shaking at 200 rpm for 16 h.
The reaction products were extracted and analysed by normal phase HPLC.
3.2.8 Pure Enzyme Decarboxylation Assay
The enzymes were expressed and purified as described earlier (Chapter 2). 10 mM PM
or 15 mM PM, MPM, MEM, MPrM, EBM, DMCHDC were incubated with 1, 2, 20 or
100 μg mL-1 enzyme. Reactions were conducted with 5 mM MOPS pH 7.2 or 100 mM
TRIS pH 8.5 at room temperature for 10 min or 3.5 d. The products were extracted and
analysed by normal phase HPLC.
3.2.9 Spectrophotometric Decarboxylation Assay
The reaction mix was typically prepared with 10 mM PM, pH 7.2, 5 mM MOPS, pH 7.2
(pKa of 7.20), 15.5 μM BTB (pKa of 7.10). The enzyme concentration was typically 0.8
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μM. The increase in absorbance due to a BTB colour change was measured at 595 nm
indicating change in pH from acidic (yellow) alkaline (blue). The number of OH- ions
produced by the reaction is proportional to the change in absorbance as long as the
pKa of the buffer and the pKa of the indicator are sufficiently close (±0.1). As the buffer
hides part of the produced OH- from the indicator the ratio between the concentration of
the buffer and the indicator is used to relate the change in absorbance to the change in
concentration of substrate or product (48,119,120).
3.2.10 Homology Modelling of RseC
The RseC sequence was aligned with BbAMD (PDB: 3dg9), Ste (PDB: 2dgd), PhHydR
(PDB: 2eq5), ApGluR (PDB: 1b73) and PhAspR (PDB: 1jfl) using the ClustalW2
alignment tool on EBI allowing end gaps (http://www.ebi.ac.uk/Tools/clustalw2). It was
then manually adjusted and realigned with the T-Coffee alignment tool on EBI
(http://www.ebi.ac.uk/Tools/t-coffee). A model was calculated with the software
MODELLER (121). The resulting structure was aligned with BbAMD structure on PyMol
(DeLano Scientific).
3.3 Results
3.3.1 Cloning and Expression of BbAMD Sequence
Homologues
The protein sequence of BbAMD was used to perform a BLAST
(http://www.expasy.ch/tools/blast) search against the UniProt database in order to
identify known homologues. Ten hits were selected that were more distantly related to
BbAMD but still among the top hits (Table 3.1). Ste was included as its crystallographic
structure was available. The selection was biased towards easily available gDNA
samples and to avoid overlap with the simultaneous process performed by our
collaborator Dr. Krzysztof Okrasa from the University in Manchester (personal
communication).
All homologues were of similar size (25 - 31 kDa). Despite the relatively low sequence
identities (19 - 30% to BbAMD) the homologues contain two conserved sequences
around the positions known to contain the active site cysteines in GluR. In GluR both
cysteines are located one on each domain opposite each other. The cysteines are
conserved in most homologues with some notable exceptions. One exception is
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BbAMD, which contains a glycine at position 74 (domain 1). RseD, Sae and SceD
contain an aspartate at the position on domain 2 and Ste contains an arginine at the
position on domain 1 (Table 3.1, Appendix C). It has to be noted that although the
arginine in Ste is a large residue at a conserved position in the active site, the structure
of the protein shows that the side chain is bound in the core of the protein exposing
only the backbone part to the active site. The impact on the active site therefore
resembles the impact of a glycine.
Table 3.1. Selected homologues and properties.
All homologues were cloned from gDNA except BbAMD, which was cloned from a
codon optimised sequence provided by Dr. Krzysztof Okrasa. The sequences were
cloned using the LIC technique into the pET-YSBLIC3C vector allowing IPTG-inducible
protein expression in the heterologous host E. coli. The vector encodes an N-terminal
His-tag for convenient protein purification.
All proteins expressed well in E. coli Rosetta 2(DE3) (Fig. 3.3). With most constructs,
soluble expression could be achieved. Large insoluble fractions were obtained only
with RseC, Pfe and SceD although later nickel affinity column purification of RseC and
Pfe showed that there was a smaller soluble fraction still present, enough to produce 5
- 10 mg of pure protein for further analysis and crystallisation trials.
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Figure 3.3. Expression and purification of BbAMD homologues. SDS-PAGE of
cell culture (0), induced cell culture (I), lysate (L), purified protein (P). The gels
were graphically sized to approximately the same scale. All lanes of one
homologue are from the same gel except the purified protein.
3.3.2 Decarboxylation Assays with BbAMD
BbAMD was reported to accept a wide range of disubstituted malonates as substrates.
For the malonates to be accepted as substrates the portion accepted by the large
binding pocket has to be electron withdrawing and the portion accepted by the small
binding pocket has to be smaller than an ethyl group. The large pocket binds
substrates such as phenyl, naphthyl, thienyl and alkenyls, whereas the small pocket
accepts hydrogen, methyl, hydroxyl and amines. The best substrates contain naphthyl
or chlorophenyl substituents for the large portion and hydrogen for small portion (Fig.
3.1) (51,67).
From an industrial perspective it would be interesting to develop an AMD that accepts
alkylmalonates as substrates that have both larger substituents and no requirement for
electron withdrawing potential. A series of substrates was therefore provided by BASF
for testing with BbAMD homologues: MEM, MPrM, EBM and DMCHDC (Fig 3.4). The
substrate PM and all the products were commercially available. MPM had to be
synthesised in-house (see methods above).
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Figure 3.4. Substrates and products tested on BbAMD.
For the analysis of decarboxylation in enzyme assays a quick and easy colorimetric
method was proposed (48). However, the signal obtained from a pH indicator could not
be linked to the activity and selection. Additionally changes of colony colour on agar
plates could never be made a reliable indicator for activity. This method was therefore
abandoned in favour of a more laborious HPLC method. Substrate and products were
extracted with ethyl acetate and injected into a normal phase chiral HPLC column and
detected as absorbance at 210 nm.
BbAMD was established as a positive control, as reported earlier, using purified
enzyme together with HPLC analysis (51). The enzyme converted 10 mM of PM
completely into PA in less than 10 min. Despite the relatively high experimental error
(most of it probably due to the handling of volatile solvent during extraction) the initial
activity approximately corresponds to a kcat of 40 s-1. This is approximately nine times
lower than the published value. This is not suprising as the assay temperature for the
published value was 37 °C wheras here the temperature was only 25 °C (51).
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Figure 3.5. Activity of BbAMD on PM. 10 mM of substrate was incubated with
2 µg mL-1 (E) and without (0) purified AMD at 25 °C and pH 8.5. Compounds were
extracted with ethyl acetate and 10 μL were analysed by HPLC. Mean values are
plotted and error bars correspond to standard deviation of experiments performed
in triplicate.
3.3.3 Screening for Arylmalonate Decarboxylation in
Homologues
All homologues were tested with the whole resting cell assay for conversion of PM to
PA and analysed by HPLC. This method keeps the enzymes in their cytoplasmic
environment avoiding degradation during the extraction process. Compared to a
growing cell approach, which was also used, the resting cell approach allowed the cells
to concentrated and control reaction conditions such as temperature and buffer
composition. A positive BbAMD control was always performed to show that the
substrate and product could diffuse through the bacterial cell wall and membrane.
For all of the homologues analysed, the results remained the same. The positive
BbAMD control invariably converted all the substrate into product. The negative control
clones with the empty vector showed no conversion. The small PA peak constantly
visible on the chromatograms corresponds to substrate contamination also observed in
pure standard injections. A typical result, representative of all assays performed this
way is shown in Fig. 3.6.
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A number of variations of this assay were performed with the same result. Some
homologues were tested in growing cell assays, allowing the substrate to interact with
the enzyme at different concentrations or different post-translational modification
stages during the induction time. Almost all were tested in lysate, which allows tighter
control of the reaction conditions such as pH and high temperatures. RseC and Pfe
were also tested as purified enzymes. Purified Pfe and Ste lysate, both originating from
thermophilic organisms, have been tested at high temperatures. The applied
temperatures ranged from 50 °C to 95 °C. No decarboxylation could be observed in
these conditions either, although at approximately 80 °C a chemical background
decarboxylation appeared but never exceeded the negative control (data not shown).
A summary of the homologues tested and assays performed can be found in the
discussion of this chapter (Table 3.3).
Figure 3.6. HPLC chromatograms of a typical PM decarboxylation assay. In
this case it is a whole resting cell assay with 20 mM PM transformed by a
0.5 g mL-1 suspension of induced cells incubated overnight at 37 °C and pH 8. The
samples were extracted with ethyl acetate and 10 μL were injected into the HPLC
run. PM runs at 15.3 min, PA at 7.3 min and ethyl acetate at 5.2 min.
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3.3.4 Screening for Arylmalonate Decarboxylation in Mutants of
RseC
Given the position of the tested homologues in the phylogenetic tree of the Asp/Glu
racemase superfamily, it is rather surprising not to find any decarboxylase activity. In
particular, the residues identified as being part of the mechanism of BbAMD are
retained in RseC and Pfe as seen in the alignment of the superfamily sequences
(Appendix C) (48). In addition, the 26 and 28% overall sequence identities of RseC and
Pfe with BbAMD in the background of only 22% identity for the whole superfamily might
also suggest at least some residual AMD activity potential in these homologues. In
another study, residual activity has been identified in other similarly closely related
BbAMD homologues with similar sequences (48).
To check whether one or two crucial mutations in the active site would transform an
inactive homologue into an AMD, three dimensional models of RseC and Pfe were
produced based on the homology of the superfamily. The modelling was based on the
sequence alignment of one enzyme with each activity in the Asp/Glu racemase
superfamily including the structure of Ste (PDB: 3dg9 for BbAMD, 2dgd for Ste, 2eq5
for PhHydR, 1jfl for PhAspR and 1b73 for ApGluR).
The resulting models were aligned with the BbAMD structure. It has to be noted that
the alignments of the sequences are ambiguous on large stretches and as the models
are heavily dependent on the correct alignment they have to be considered carefully.
As expected, both models conserved the overall fold. The dioxyanion hole region was
very well conserved in these models but large discrepancies with BbAMD were found
in external loop regions as well as in the in the residues forming the small binding
pocket. The proline residues of the large binding pocket were conserved but many
other residues in RseC were pointing into that pocket introducing charge, polarity or
simply volume into the active site. The charged or polar residues are expected in
AspRs, GluRs where carboxyl groups would be bound but not in AMDs where the
aliphatic aryl group has to be bound.
Site directed mutagenesis was finally used to introduce changes into RseC. Three sites
were targeted and mutated into the corresponding residues in BbAMD according to the
alignment. The cysteine on domain 1 was changed to glycine (C87G). The threonine
and asparagine following the cysteine on domain two were mutated to glycines
(T198G/N199G) as these could sterically and electrostatically inhibit binding of the aryl
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group. Finally, the glutamate and arginine in the back of the large binding pocket were
mutated to aliphatic residues removing the charge (E29P/R46G) that could also
potentially hinder aryl group binding. As R46G is a very large change in the volume of
the residue at this position a more conservative methionine mutant was introduced
(R46M, Fig. 3.7).
All of the single and double mutants described above were tested with the whole
resting cell assay. All proteins were expressed successfully as judged by SDS-PAGE
(data not shown). However, as with the homologues none of the mutants showed any
residual activity (Fig. 3.2).
Figure 3.7. Alignment of active sites of RseC model and BbAMD structure.
The structure of BbAMD (grey, PDB: 3dg9) aligned to the modelled RseC (purple).
The carboxyl group of the intermediate of MPM decarboxylation (orange) is aligned
to the PO4. The active site is seen from the bottom.
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Table 3.2. Summary of decarboxylating activities of RseC mutants. BbAMD:
Bordetella bronchiseptica AMD. RseC: Rhodococcus sp. BbAMD homologue
containing two conserved cysteines.
3.3.5 Screening for Alkylmalonate Decarboxylation
The ultimate aim of the work on the homologues was to find enzymes active on
alkylmalonates. BbAMD and the two homologues, RseC and Pfe, were tested on the
alkylmalonate substrates MPM, MEM, MPrM, EBM and DMCHDC. Purified enzyme
preparations were used for the assay and the reactions were incubated for several
days.
As reported earlier, BbAMD was able to completely convert MPM into (R)-PP without
producing any detectable (S)-PP (76). Conversely, none of the alkylmalonate
substrates was converted by BbAMD. The two homologues RseC and Pfe converted
neither MPM nor any of the alkylmalonates (data shown for BbAMD and RseC, Fig.
3.8).
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Figure 3.8. Decarboxylation assays of malonate derivatives. 15 mM substrate
was incubated for 3.5 d at 25 °C at pH 8.5. Products were extracted with ethyl
acetate and 10 μL were analysed by HPLC. Standard was injected at 20 mM. RTs
are 7.5 min for (R)-PP, 7.8 min for (S)-PP, 14.3 min for MPM, 8.5 min for MEM, 8.7
min for MPrM, 8.2 min for EBM, 5.3 min for ethyl acetate, 7.2 min for an unknown
contaminant. The four diastereoisomers of DMCHDC all separated and had RTs of
8.6 min, 9.0 min, 9.9 min, 10.0 min.
3.3.6 Alternative Activities of Pfe
Since Pfe did not convert any of the aryl- or alkylmalonates tested, a series of assays
was performed to try to determine its activity. The sequence annotation provided by the
UniProt database produced by an automated bioinformatics approach indicated that
Pfe was a maleate cis-trans isomerase. This was tested using the spectrophotometric
approach measuring conversion of maleate to fumarate at 290 nm (see Chapter 4 for
method). The enzyme was incubated with 20 mM maleate, 2 mM DTT and 1 mM BME.
The thiols are able to isomerase the double bond chemically at a low rate but the
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enzyme is expected to convert the substrate at a much higher rate (100). Nevertheless,
no activity could be observed above background in this assay (Fig. 3.9, top left). The
assays were also performed for 16h and at 50 and 95 °C without any increase in
absorbance above the negative control background (data not shown).
It was shown that it is possible to introduce (R/S)-PP racemase activity into BbAMD by
introducing a single mutation G76C (79). Although this enzyme has a very low
racemase activity it exemplifies the mechanistic flexibility of the superfamily. The
capability Pfe to racemise PP was tested with 15 mM of either (R)- or (S)-PP. After 24
h of incubation with the enzyme, the samples were tested using chiral HPLC. Also in
this case no trace of the respective opposite enantiomer could be detected in the
assays (Fig. 3.9, top right). No racemisation could be observed in RseC either (data not
shown).
As Pfe is a member of the Asp/Glu racemase superfamily, its activity towards L-
apartate and L-glutamate was tested using CD. Reactions with 10 mM of the amino
acids were followed directly for some time and then incubated over night. The CD of a
racemate is 0 mdeg and the observed signal is expected to disappear upon
racemisation of the amino acids. No such disappearance could be observed directly or
over night. In contrary, there was a small increase in the CD after 5 min of incubation,
which was correlated to an increase of the sensitivity of the detector and is thus
indicating a change in absorbance. Also after the overnight incubation only a small
increase of the same magnitude could be observed, which cannot be explained at
present (Fig. 3.9, bottom). The same assay was performed overnight at 95 °C resulting
in no detectable racemisation (data not shown). BbAMD and RseC were also tested in
overnight incubations with the identical negative result (data not shown).
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Figure 3.9. Assays for alternative activities of Pfe. Top left: Spectrophotometric
assay of maleate cis-trans isomerase activity. Purified Pfe was incubated with 20
mM maleate at 25 °C at pH 8.5. Top right: HPLC assay of PP racemase activity.
Purified Pfe was incubated with 15 mM (R)-PP or (S)-PP for 24 h at 25 °C at pH
8.5. RTs are 7.3 min for (R)-PP, 7.6 min for (S)-PP and 5.3 min for ethyl acetate.
Bottom: CD assay for Asp/Glu racemase activity. Purified Pfe was incubated with
10 mM L-amino acid at 25 °C at pH 8.0 including 200 μM DTT. CD and high
tension (sensitivity, roughly inversely proportional to absorbance) were measured
continuously (bottom left) and after an overnight incubation (single experiment,
bottom right).
3.3.7 Crystallisation Trials with Pfe
In order to understand the significance of the sequence similarities and to explain the
absence of any know Asp/Glu racemase activity in Pfe, structural data are required.
Crystallisation trials with purified Pfe were performed with the aim of resolving its
structure by X-ray crystallography. Pfe was a good candidate as proteins from
thermophiles are generally more stable due to their compact fold resulting in a higher
probability for it to crystallise. Crystallisation screens and optimisation were performed
as described later (see methods of Chapter 5).
Crystals were obtained from Pfe; however, the best ones were still highly amorphous
probably, resulting from multiple crystals (Fig. 3.10). The conditions used were: 5 mM
of each of NaH2PO4, Na2HPO4, KH2PO4 and K2HPO4 with 100 mM BIS-TRIS Propane
and pH 6.5, 20% (w/v) PEG 1500. Seeding into conditions containing less precipitant
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(15% (w/v) PEG 1500 resulted in more structured plates according to the visual aspect
(Fig. 3.10). None of the crystals diffracted on the in-house X-ray facility.
Figure 3.10. Crystals of Pfe. Initial Crystals in 20% PEG 1500 (left) were used
for seeding in 15% PEG 1500 to produce new crystals (right).
3.4 Discussion
It was possible to clone and express all ten homologues of BbAMD in E. coli with a
least a fraction as soluble proteins. Despite the automated annotation of most of the
homologues as hypothetical AMDs or hypothetical decarboxylases and despite the
close clustering of the homologues together with the known decarboxylases, no
decarboxylation activity could be detected in any of them (Table 3.3).
Table 3.3. Summary of decarboxylating activities of homologues.
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It is generally difficult to conclude that an enzyme is not active towards a substrate as
there are many variables that have to be considered. On the other hand a lot of
arguments support this conclusion. The positive control of BbAMD was always included
and was consistently active in all tested conditions. The proteins have all been tested in
whole cell (as well as other) conditions where they can be expected to be properly
folded and in physiological conditions (apart from their concentration). In addition, the
enzymes were of prokaryotic origin (mostly from soil bacteria) where they are generally
not posttranslationally modified. Eukaryotic proteins are often activated or inactivated
by modifications such as glycosylation, phophorylation or lipoylations. The absence of
the requirement for posttranslational modifications makes it more likely that the BbAMD
homologues are in the active form when overexpressed in E. coli. None of the
described enzymes in the Asp/Glu racemase superfamily is known to need cofactors or
any special conditions to be active, apart from requiring being in a reduced state, which
is normally the case in the cytoplasm. Also higher temperatures for the enzymes
cloned from thermophilic species did not result in decarboxylation activity. It is therefore
reasonable to conclude that the homologues are not AMDs.
This result seems to contradict findings that other homologues with similar sequence
identities and even the ApGluR would have residual PM decarboxylation activities (48).
This could be explained by different reaction conditions or higher concentrations of
enzyme. It has to be noted, however, that attempts to replicate the published assay
have failed. Both the initial and the late signal measured could not be correlated to the
result obtained from HPLC and no solid explanation was available for these signals (for
further details see methods).
The attempts to engineer decarboxylase activity in the RseC mutant by simply mutating
key residues to match those found in BbAMD failed. Even though the correct folding of
the proteins would have to be tested, it is another indication that the activity of the
homologues is more different from AMD than the automated annotation suggests.
The homologues do not seem to have any of the other activities found within the
superfamily. This suggests that the branches containing the homologues in the
phylogenetic tree have different activities from AMDs and MIs that have yet to be
determined. Although, it has to be noted that the data obtained from Pfe are preliminary
and difficult to establish for a thermophile species. It further has to be noted that Pfe
was not tested for HydR activity.
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Considering the phylogenetic data (Figure 1.21, Table 3.1) it is possible that there are
two different activities corresponding to the homologues with two catalytic cysteines
and the ones with a catalytic cysteine and an aspartate. To find the unknown activities
of the homologues is a very difficult task that exceeds the scope of this work. Even if
structural information of Pfe were available it would not necessarily help to find the
activity. For example Ste has a known structure exhibiting an unknown function. The
physiological role of AMDs is not known either. There are ectoine utilisation proteins
(EutA) in the same superfamily which might suggest that some homologues are used in
the catabolism of ectoine (122).
Most of the source organisms of the homologues have been sequenced, which allows
the surrounding genetic environment to be analysed. If they lie on an operon with
known genes one can speculate as to their natural role. The rhizobial homologues Sme
and Mle both lie on an operon with many potential amino acid transporters, a potential
threonine dehydratase and a potential ornithine deaminase. These homologues could
therefore be involved in the catabolism of amino acids. For the other homologues no
clear function can be found for the operon that contains them. It is interesting, however,
that all three homologues with the potentially catalytic Asp on domain 2 (RseD, SceD,
Sae) are just downstream of their two cysteine paralogue. In addition, as HydRs and
MIs are both enzymes involved in the catabolism of natural compounds, a similar role
is likely for AMDs and the unknown homologue activities. Another possibility is that
these enzymes do not have a biochemical role but are merely products of
pseudogenes ready to be recruited for new enzymatic tasks. However, this is unlikely
as prokaryotes do not tend to maintain pseudogenes.
BbAMD was successfully confirmed to be an arylmalonate decarboxylase. Its preferred
substrate is PM but it also readily accepts MPM and various other arylmalonates as
well as alkenylmalonates (51,67). Alkylmalonates, however, were not accepted by
BbAMD as was confirmed by experiments conducted by Dr. Krzyszof Okrasa (personal
communication). The nature of the substituents on carbon C2 of the malonates is,
therefore, crucial for the activity. It is not surprising that the homologues tested
unsuccessfully with arylmalonates are not active against alkylmalonates either. This
further supports the hypothesis that the electron withdrawing capability of the substrate
is essential for the stabilisation of the enediolate intermediate formed by the
decarboxylation (67). It would be interesting to know whether other electron
withdrawing groups, such as carboxyl or halo groups, would have similar effects.
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Chapter 4
Biochemical Characterisation of
NfMI
4.1 Introduction
Maleate is a metabolic intermediate appearing in the breakdown of nicotinic acid by
certain bacteria, such as Pseudomonas fluorescence N-9. It forms after oxidative ring
breakage of 2,5-dihydroxypyridine and subsequent deamidation of maleamate. Maleate
cis-trans isomerase converts maleate into fumarate, which in turn is used in the general
metabolism of the cell (Fig. 4.1). The responsible enzymes are induced when nicotinic
acid is supplied as the sole substrate for bacterial growth (97).
Figure 4.1. Activity of NfMI.
A range of maleate isomerases has been purified from various other bacterial genera
such as Arthrobacter, Bacillus, Alcaligenes and Serratia and characterised
biochemically (98-102). Only three characterised maleate isomerases genes have
been sequenced to date including maleate isomerases from Alcaligenes faeacalis MI,
Bacillus stearothermophilus and Serratia marcescens (52,103,104).
All described maleate isomerases are specific to maleate as substrate. Various other
similar compounds have been tested unsuccessfully on maleate isomerases including
maleamide, 2,3-dimethylmaleate, cis-3-chloroacrylate, citraconate, chloro- and
bromomaleate as well as various of their trans forms. Fumarate can be a substrate but,
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due to the thermodynamic equilibrium of the isomerisation maleate, was only ever
detected at amounts lower than 0.2% when the sensitivity of the methods permitted
(52,98,100,101).
Most of the maleate isomerases discovered were not dependent on any cofactors.
Nevertheless the activity was in some cases reported to be dependent on activation by
thiol compounds such as glutathione, cysteine, thioglycerol, DTT or BME. This was
concluded as dialysis was inactivating the enzymes and the addition of thiols restored
the activity (99,100). Heavy metal ions such as Hg2+ and Cu2+ and oxidising reagents
such H2O2, p-chloromercuribenzoate and NaIO4 were inhibitors (99,101,103). No
competitive inhibitor has been identified so far.
Cysteines were identified to be catalytic residues by mutational studies on B.
stearothermophilus maleate isomerase. Loss of activity occurred after replacement of
cysteines 80 and 198 with serines (103). The activating thiols are thus thought to act
through the reduction of the cysteines in the active site. However, until today no three
dimensional structure of a maleate isomerase has been published; all structural
knowledge originates from superfamily homologues.
All identified maleate isomerases are 25 to 30 kDa proteins. They have pH optima of
8.0 to 8.5 and are active in the range from pH 6.5 to 9.5. B. stearothermophilus
maleate isomerase has been reported to be stable up to a temperature of 55 °C (104).
Kinetic constants of Alcaligenesa faecalis maleate isomerase are KM of 40 μM and kcat
of 37 s-1. Compared to other members of the Asp/Glu racemase superfamily this is a
rather high activity.
Understanding the biochemical characteristics and eventually the reaction mechanism
of NfMI will allow us to understand how the superfamily recruites its fold to perform
greatly divergent reactions. This will lead to a better understanding of all superfamily
members allowing targeted engineering approaches of the substrate specificities in
order to obtain industrially useful activities.
In this chapter the identification of NfMI as a maleate cis-trans isomerase will be
presented and its biochemical properties will be characterised. Work on the newly
discovered competitive inhibitor bromomaleate as well as work on active site mutants
will also be presented.
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4.2 Methods
4.2.1 Cloning and Protein Purification of NfMI
For cloning and protein expression of wild type and mutant NfMIs as well as for
purification of NfMI wild type, see Chapter 2.
Mutants of NfMI were purified in parallel batch purification using Ni-affinity resin. Cell
cultures of 50 mL containing overexpressed NfMI mutant proteins were spun down,
resuspended in 2.5 mL BugBuster (Novagen) containing 200 µM PMSF, 5 µg mL-1
DNase I, 5 µg mL-1 hen egg white lysozyme, 1 mM MgCl2 and 5 mM DTT, and
incubated for 15 min at 4 °C shaking. The lysates were diluted with 15 mL buffer
(Chapter 2) and added to 1 mL of His-select resin (Sigma). The resin samples with
bound protein were washed in three consecutive steps with 15 mL buffer containing 0,
10, 20 mM imidazole and finally eluted with 15 mL 50 mM imidazole. Imidazole was
removed by concentrating the sample to 500 µL and diluting in 15 mL buffer without
imidazole four times; diluting first with 5 mM DTT, then without reducing agent and
finally with 5 mM TCEP. After the final concentration step, the protein sample
concentrations were adjusted to 0.1 mg mL-1 as determined by the Bradford assay
(Chapter 2), the purity analysed by SDS-PAGE (Fig. 4.2) and snap frozen in liquid
nitrogen.
Figure 4.2. Expression and purification of NfMI mutants. SDS-PAGE of lysate
(L) and purified protein (P).
4.2.2 Spectrophotometric Maleate Isomerasation Assay
Unless indicated otherwise, all reactions were performed as follows. 10 mM maleic acid
was incubated with 20 μg mL-1 purified enzyme at room temperature (~25 °C) without
100
shaking. Assays were buffered in 50 mM HEPES at pH 7.5 adjusted with sodium
hydroxide and water was added to 1 mL. Reactions were started by the addition of
enzyme and stopped, if necessary, by adding 50 μL of concentrated hydrochloric acid.
The formation of fumarate was followed at 290 nm on a Cary 50 UV-Vis
spectrophotometer (Varian). Despite a similar shape of the absorbance spectrum
fumarate has a higher extinction coefficient than maleate (Fig. 4.3) (97,100). Unless
indicated differently assays were performed in triplicate.
Figure 4.3. Absorbance spectra of maleate (M) and fumarate (F). Spectra were
recorded in 50 μM HEPES pH 7.5.
4.2.3 HPLC Maleate Isomerisation Assay
Unless indicated otherwise, all reactions were performed as follows: 30 μM maleic acid
was incubated with 140 ng mL-1 purified NfMI at 30 °C for 10 min without shaking.
Assays were buffered in 50 mM HEPES at pH 7.5, adjusted with sodium hydroxide and
final reaction volumes of 1 mL were attained by adding water. Reactions were started
by the addition of enzyme and stopped by adding 50 μL of concentrated hydrochloric
acid. 50 μL methanol were also added to match the solvent content required for HPLC
analysis (52). For long term storage samples were kept at -80 °C until analysis. Unless
indicated otherwise, assays were performed in triplicate.
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10 μL of the samples were injected using a 717plus Autosampler (Waters) into a
reverse phase Onyx Monolithic C18, 100 x 4.8 mm column (Phenomenex) and run with
a solvent mixture of 25 mM KH2PO4 pH 2.5 / methanol 95:5% at a flowrate of
1 mL min-1 on a 510 pump (Waters). The compounds were detected by absorbance on
a 2487 detector (Waters). Expected RTs were maleate 2.1 min, fumarate 2.6 min (Fig.
4.4), bromomaleic acid 3.0 (contaminating peaks at 2.1 and 2.6 min), citraconate 3.4
min, maleamine 1.8 min (small contaminating peaks 2.0, 2.4 and 2.6 min).
Figure 4.4. HPLC chromatograms of maleate and fumarate. 10 μL of 1 mM
samples were injected into a 100 mm monolithic C18 column. As eluent 5%
methanol at 1 mL min-1 flow rate was used. The samples were detected optically at
210 nm wavelength.
4.2.4 Determination of Kinetic Constants and Inhibition
Constants
HPLC maleate isomerase assays were performed for the determination of kinetic
constants. In this assay the following enzyme concentrations were used: wild type NfMI
14 ng mL-1, mutant NfMI 140 ng mL-1 for high activity mutants and 4 μg mL-1 for low
activity mutants. Seven different substrate concentrations (five for inhibition and mutant
activity studies) were evenly distributed between 1 and 200 μM. Samples from the
same reaction were taken at 5 min and at 10 min and the difference of conversion was
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taken as an approximation of initial rates. The conversion rates were below 10%. The
experiment was performed in triplicate for wild type NfMI and single experiments were
performed for each mutant NfMI. The rate between the two points was plotted and a
simple rectangular hyperbola (y = kcat · x / (KM + x) was fitted using the regression
function of SigmaPlot 10.0 (Systat Software). The values were averaged over three
(only one for the mutants) experiments. The Ki was determined as Ki = ci / (KMi / KM - 1),
where “ci“ is the concentration of the inhibitor, KMi the KM at that inhibitor concentration.
The average Ki of four different inhibitor concentrations was averaged. For single each
single hyperbolic curve the standard errors were calculated with SigmaPlot 10.0 (Systat
Software).
4.2.5 GC/HPLC Enoate Reductase
Two enoate reductases were used, provided as Escherichia coli cell extracts by
researchers at BASF (Ludwigshafen). The enoate reductase, OYE2 from
Saccharomyces cerevisiae (Old Yellow Enzyme 2, EC 1.6.99.1, UniProt: Q03558), is
NADPH dependent as is its homologue YqjM from Bacillus subtilis (EC 1.6.99.1,
uniprot: P54550).
The partially purified FactorX, thought to be a cis-trans isomerase, was also provided
by BASF. FactorX is one of three activities on methyl-pentenal isolated from Candida
rugosa (BASF Lu905) crude extract. One alcohol dehydrogenation activity produces
methylpentenol and a enoate reduction activity produces methylpentenal. When the
enoate reductase activity is purified, the incubation yields an excess of (S)-methyl-
pentanal. By replacing FactorX into the purfied sample an excess of (R)-methyl-
pentanal is produced. Although there is no direct evidence, FactorX is hypothesised to
be a methyl-pentenal cis-trans isomerase. Homologues present in UniProt (Q5AHZ9
from Candida albicans and Q6C6X4 from Yarrowia lipolytica) determined by peptide
fragment sequencing were cloned and expressed in E. coli but did not show any
activity (personal communication by Andreas Schädler, BASF).
Assays were either performed with cis/trans citral or with maleate derivatives (maleate,
fumarate, citraconate, mesaconate, dimethylcitraconate). All reactions were carried out
in 100 mM KH2PO4 buffer at pH 7, 1 mM of both NAD and NADP were added. Cofactor
regeneration was achieved by adding 100 mM glucose and a 1:4 dilution of glucose
dehydrogenase from cell extract (BASF Lu11589). Volumes were completed with PBS.
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Overexpressed OYE2 and YqjM were added from E. coli crude extract to 0.1 mg total
protein. FactorX was either added as a semi-purified protein solution to 2.2 mg mL-1 or
1.5 mg mL-1 separated from enoate reductase and alcohol dehydrogenase activities by
two purification steps or added as crude extract to 5 mg mL-1 total protein (BASF
Lu905) containing these two activities. Semi-purified enzyme was used for assays
containing citral and crude extract was used for the maleate assays. NfMI was added
to 0.015 mg from purified enzyme at 15 mg mL-1 in 20 mM TRIS, 150 mM NaCl, 5 mM
DTT, pH 8.0.
Cis/trans-Citral was added as a 10% (w/v) solution in DMSO to a final concentration of
15.8 mM whereas maleate, fumarate, citraconate, mesaconate or dimethylcitraconate
were added as 100 mM solutions (pH adjusted to 5-7) to 10 mM. The reactions were
started by the addition of substrate and stopped either by adding 250 μL chloroform (for
GC analysis) or 50 μL of concentrated HCl (for HPLC analysis). All assays were
performed at 30 °C shaking at 1,400 rpm for 0 up to 70 h. For GC analysis the
chloroform reactions were performed at 25 °C for 10 min at 1,400 rpm and then
centrifuged at 18,000 × g for 3 min. The chloroform extract was dried using molecular
sieve 4 Å for another 10 min. For HPLC analysis the reactions were only centrifuged at
18,000 × g.
The consumption of cis/trans citral and the formation of citral derivatives during enoate
reductase assays were analysed by GC. 1 uL of chloroform extract was injected into a
30 m BGM-174, 0.25 mm ID, 0.25 µm FD column on GC 02 (BASF) and eluted with He
at a flow rate of 1 mL min-1. The compounds were analysed by FID and normalised by
the total peak area. Expected RTs were (S)-citronellal (32.4 min), (R)-citronellal (33.4
min), nerol (36.0 min), (S)-citronellol (37.0 min), (R)-citronellol (37.2 min), geraniol
(41.0 min), cis-citral (45.2 min), trans-citral (50.0 min).
The interconversion of maleate and fumarate, citraconate and mesaconate as well as
the consumption of dimethylcitraconate during the enoate reductase assays were
analysed by HPLC. 1 uL of acidified sample was injected into a reverse phase Aqua
C18 100 x 4.6 mm column (Phenomenex) on LC 05 (BASF) and the compounds were
detected by absorbance at 210 nm and the identity of the peaks was verified with the
absorbance spectrum. Different methods were used for the different compounds (RTs
in brackets): Method CMF-A.M (BASF) for maleate (1.93 min), fumarate (2.34 min),
method CMF2-A.M (BASF) for citraconate (2.32 min), mesaconate (2.81 min) and
method DICSMS-A.M (BASF) for dimethylcitraconate (2.82 min).
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Succinate produced in enoate reductase assays was analysed by HPLC. 5 uL of
acidified sample was injected into an Aminex HPX-87H column on LC 09 (BASF) with
the Z9-CMF30.M method (BASF) and compounds were detected by refractive index.
Expected RTs were succinate (15.2 min), fumarate (19.6 min) and maleate (15.5 min,
signal hidden by lactic acid).
4.2.6 MS of Enzyme-Ligand Adducts
The buffer of NfMI was replaced by dilution in 20 mM ammonium acetate (pH 11) and
subsequent concentration with Amicon Ultra 15 centrifuge filters with 10 kDa molecular
weight cut off (Millipore, USA). 10 mM of the potential adduct was added to the solution
and analysed on a ABI Qstar ESI-TOF mass spectrometer (Applied Biosystems, USA).
4.3 Results
4.3.1 Activity Assays
The conversion of maleate to fumarate can be measured in a number of different ways.
In the literature two spectrophotometric methods have been described. First, a direct
and easy method is to exploit the higher extinction coefficient of fumarate compared to
maleate at wavelengths around 290 nm (97). Unfortunately, the difference in
absorbance is below the detection limit at low concentrations of substrate (< 10 μM).
For high concentrations above 0.1 mM the direct spectrophotometric method
represents an easy way to follow the reaction in real time and to quickly determine end
points (see methods for absorbance spectra).
A second method has been suggested where an excess of fumarate hydratase
(fumarase, EC 4.2.1.2) is used to specifically hydrate the double bond of fumarate and
measure the disappearance of total double bond concentration at 240 nm (99). This
method was not used in the present work as the slight difference of the extinction
coefficients of maleate and fumarate would interfere and the substrate would have to
be below 1 mM not to saturate the signal.
A third and new spectrophotometric method would be to use an excess of fumarate
hydratase in combination with an excess of L-malate dehydrogenase (EC 1.1.1.37).
The reaction could be followed by the formation of NADH, the cofactor of L-malate
dehydrogenase, at 340 nm. As NADH has a strong chromophore this is potentially a
highly sensitive method; however, the activity of the purchased recombinant enzyme
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from E. coli (Fluka) in this direction was too low at the pH used in this assay.
Consequently, the method was not used this project.
To be able to measure below 10 μM and to avoid interference of other chromophores,
reverse phase HPLC on a C18 column was used to measure end points of reactions as
already described (52). The signal was linear and could be accurately measured
between 1 μM and 1 mM (see methods for chromatograms).
4.3.2 Activity of NfMI
As NfMI sequence consistently clustered with the three other known maleate
isomerase sequences in phylogenetic analyses, having sequence identities between
44 and 28%, it was tested for activity with 10 mM maleate using the spectrophotometric
assay at 290 nm. A small increase in absorbance could be observed in cell lysate
corresponding to the formation of fumarate. The same lysate was used as for the
arylmalonate decarboxylation assays described in Chapter 3.
The assay was repeated using purified NfMI (see Chapter 3) and the formation of
fumarate was followed over time. The fumarate formation rate was constant for 15 min,
then slowed down to reach full completion of the reaction after 20 min resulting in a
typical enzyme reaction curve. To confirm the enzymatic origin of the activity, boiled
enzyme was used in the same assay. As expected, no maleate formation was
observed in this case. Furthermore, as in the literature maleate isomerase from P.
fluorescens was reported to require thiols as activators (100) a mix of DTT and BME
was added to the reaction. As suggested for other MIs, thiols did not increase the
activity of NfMI. (Fig. 4.5).
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Figure 4.5. Reaction time course of NfMI. Spectrophotometric assay using
20 μg mL-1 purified NfMI and 10 mM maleate at room temperature and pH 8.5.
4.3.3 Effect of pH on NfMI Activity
To determine the pH optimum of NfMI the amount of fumarate produced from 10 mM
maleate after 20 min was measured in three different buffers with pH ranging from 4 to
10 and activity was measured using the spectrophotometric assay at 290 nm. The
maximal activity was observed at pH 7.5 being approximately 1 pH point lower than
those measured for other known maleate isomerases (52,100,101). At pH 4.5 and 11.0
the activity was almost completely abolished (Fig. 4.6). As a consequence in further
experiments the activity was measured at pH 7.5 using HEPES, which has an optimal
pKa.
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Figure 4.6. Dependence of NfMI activity on pH. Spectrophotometric assay using
20 μg mL-1 purified NfMI with 10 mM maleate using various buffers. The reaction
was performed for 20 min at 37 °C. All experiments were performed in triplicate
and the error bars represent standard deviation.
4.3.4 Effect of Temperature and Redox State on NfMI Activity
For further characterisation of NfMI the temperature optimum was determined using the
same spectrophotometric end point assay as for pH optimum determination. The
enzyme was incubated with 10 mM maleate for 20 min at temperatures ranging from
20 to 60 °C at pH 8.5. Under these conditions the pH optimum was between 35 and 40
°C. At 20 and 50 °C almost no activity was left (Fig. 4.7).
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Figure 4.7. Dependence of NfMI activity on temperature. Spectrophotometric
assay using 20 μg mL-1 purified NfMI with 10 mM maleate at pH 8.5. Enzyme
stability was not considered. All experiments were performed in triplicate and the
error bars represent standard deviation.
As the temperature optimum depends on protein stability and as protein denaturation is
a process that is also subject to kinetics, the temperature optimum only applies under
precise conditions. For this reason it is also important to know the stability of the
enzyme with respect to the temperature. The optimal temperature would then be the
highest temperature at which the enzyme is stable over the reaction period.
To the determine the enzyme stability NfMI was preincubated for 1 h in the reaction
buffer at various temperatures and then assayed with 10 mM maleate at 25 °C for 30
min. The activity was determined using the spectrophotometric assay measuring end
points. The data show that the enzyme is stable up to approximately 30 °C and almost
completely inactivated at 55 °C under these conditions (Fig. 4.8). Further experiments
were therefore performed at 30 °C.
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Figure 4.8. Temperature stability of NfMI. Purified NfMI at 20 μg mL-1 was
preincubated 1 h in buffer at pH 7.5. The reaction was then started by adding 10
mM maleate and run for 30 min at 25 °C. The samples were analysed
spectrophotometrically. All experiments were performed in triplicate and the error
bars represent standard deviation.
As mentioned above, the activity of other maleate isomerases was dependent on thiol
activators whereas NfMI is not. It was also reported that maleate isomerases are
sensitive to inactivation by oxidation (100,103). Whether thiols act as oxidation
protectors was tested in two ways.
The first way was testing whether the temperature instability is due to thermal
denaturation of the enzyme or due to increased oxidation at higher temperature. The
enzyme was preincubated in the reaction mix for 1 h at various temperatures and
subsequently assayed with 10 mM maleate for 30 min. 10 mM DTT was added before
the preincubation or before the assay or before the analysis. As DTT interferes with the
spectrophotometric assay the end points were analysed with the HPLC.
At 95 °C preincubation, where the enzyme is completely inactivated, there is a non-
enzymatic chemical conversion of maleate to fumarate if DTT was present. After
accounting for this background, the activity was higher if DTT was present during the
reaction. If DTT was already added during the preincubation, the activity was even
higher (Fig. 4.9).
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Figure 4.9. Effect of the redox state on temperature stability of NfMI. Purified
NfMI at 140 ng mL-1 was preincubated 1 h in buffer at pH 7.5 at various
temperatures. The incubations were performed by adding 10 mM DTT at different
stages and under normal atmosphere. The reaction was started by adding 10 mM
maleate and incubated for 30 min at 30 °C. The turnover was measured by HPLC.
Single experiments were performed.
The second test of the oxidation protection on thiols was combined with a long term
stability assay. Aliquots of concentrated enzyme were incubated with 5 mM DTT in
enzyme storage buffer at 4 °C for several days. After incubation reaction mix was
added, containing 1 mM maleate and incubated at 30 °C for 10 min. The samples were
analysed by HPLC
In both conditions the enzyme lost activity over the course of less than a month.
However, the activity of the samples without DTT dropped rapidly below 50% of the
initial activity after 1 d and was almost completely inactivated after 14 d. In contrast, the
samples containing DTT were more active and dropped below 50% of the initial activity
only after 14 d and were inactive after 21 d (Fig. 4.10).
111
Figure 4.10. Long term stability of NfMI depending on redox state. Purified
NfMI at 7 μg mL-1 was incubated at 4 °C for several days with and without 10 mM
DTT under normal atmosphere. The reaction was then started by adding the
reaction mix containing 1 mM maleate diluting NfMI to 140 ng mL-1 and run for 10
min at 30 °C. The turnover was analysed by HPLC. All experiments were
performed in triplicate and the error bars represent standard deviation.
4.3.5 Kinetics and Inhibition of NfMI Activity
The Michaelis-Menten kinetic parameters were determined taking the difference of
conversion between 5 and 10 min as an approximation of the initial rate and fitting a
square hyperbola onto the data. The assay was performed at 30 °C and analysed by
HPLC. KM was 10 ± 2 μM and kcat was 6 ± 1 s-1. The initial rate was maximal at
approximately 100 μM and slightly lower at 200 μM (data not shown but also visible in
Fig. 4.13 and 4.17). This is indicative of substrate inhibition that hitherto was not
quantified. As a result kcat is underestimated.
To find competitive inhibitors of NfMI a range of compounds resembling the substrate
was identified. These include the product (fumarate), substrate analogues with
substituents on the double bond (bromomaleate, citraconate), cyclic non-isomerisable
compounds (cyclopentanedione, benzoquinone) and modified carboxylic acids
(maleamide, dimethylmaleate) as well as general small carboxylic acids (malonate,
succinate, D/L-malate, citrate, formate, acetate) and acidic amino acids (L-aspartate, L-
glutamate) (Fig 4.11).
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NfMI was incubated with 30 μM maleate well above KM but close enough to ensure
high sensitivity of the assay. The inhibitor was added at 1 μM without DTT and at 60
μM with 5 mM DTT. The conversion was analysed by HPLC.
Most of the compounds tested did not inhibit the activity of NfMI. Only bromomaleate
and benzoquinone reduced the conversion rate. When DTT was present, the inhibition
of benzoquinone disappeared despite the higher concentration, which is indicative of
oxidative inhibition. Of the tested compounds only bromomaleate inhibited NfMI activity
when the concentration was increased (Fig. 4.12).
Figure 4.11. Compounds tested for NfMI inhibition.
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Figure 4.12. Assay of substrate analogues as potential inhibitors of NfMI.
Purified NfMI at 140 ng mL-1 and 30 μM maleate were tested with 1 μM (top) and
60 μM (bottom) of each compound respectively. The 1 μM experiments were
performed without DTT whereas the 60 μM experiments contained 5 mM DTT.
Substrate analogues with a substituted double bond are shown in red, cyclic
compounds in green, ones with derivatised carboxyl groups in purple, general
carboxylates in yellow and amino acids in turquoise. NA, not available.
To test whether bromomaleate inhibition was competitive, kinetic parameters were
determined for different bromomaleate concentrations. These could be used to
calculate the inhibition constant Ki. With increasing concentration of inhibitor the KM
increased as well whereas the kcat remained approximately stable at the same level,
which is in accordance with competitive inhibition resulting in a Ki of 0.9 ± 0.3 μM (Fig.
4.13, Table 4.1).
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To test whether the substrate or the inhibitor bind covalently, MS analysis was
performed at pH 11 in the presence of both maleate and bromomaleate. At this pH the
enzyme is not active and both cysteines are expected to be deprotonated. A potential
nucleophilic attack of one cysteine on the substrate could still occur; however, no
covalent adduct was found.
Figure 4.13. Kinetics of bromomaleate inhibition. Purified NfMI at 14 ng mL-1
was assayed with different maleate and bromomaleate concentrations for 10 min
at 30 °C. The samples were analysed by HPLC. Simple rectangular hyperbola
were (y = kcat · x / (KM + x)) fitted to determine the inhibition constant (see table
4.1).
Table 4.1. Determination of the Ki of bromomaleate. Data see Fig. 4.13. The Ki
was determined using the following equation: Ki = ci / (KMi / KM -1). Standard errors
and mean of standard errors are indicated.
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4.3.6 Alternative Substrates
To extend the range of known substrates from the single one known to date, various
compounds were screened for activity. For that purpose, all tested inhibitors containing
an isomerisable double bond (fumarate, bromomaleate, citraconate, maleamide and
dimethylmaleate) were incubated at 1 mM at 1h (Fig 4.14). The samples were analysed
by HPLC checking the traces for consumption of the substrate.
None of the reactions showed detectable activity towards any alternative substrate.
The maleate control was completely converted into fumarate. A chemical background
reaction due to DTT could also be detected. The reverse reaction with fumarate could
not be detected as the maleate contamination in the used fumarate sample was higher
than the expected amount at the thermodynamic equilibrium. Using the peak areas of
the maleate and the fumarate conversion in the presence of the enzyme, the
equilibrium constant was determined to be 480. Dimethlylmaleate did not elute within
the analysed elution time (Fig. 4.15).
Furthermore, in an attempt to combine NfMI with enonate reductases (OYE2, YqjM) to
change the reaction specificity (see below), it was also incubated with either 16 mM
cis/trans citral, 10 mM mesaconate or dimethylcitraconate (Fig. 4.14). None of these
substrates was transformed by NfMI. Equally in no case did the enoate reductase
produce a different product pattern when incubated in combination with NfMI (Fig. 4.18
and Fig 4.19).
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Figure 4.14. Substrates and products used with NfMI and enoate reductases.
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Figure 4.15. Assay of potential alternative substrates of NfMI. Purified NfMI at
2.8 µg mL-1 and 1 mM substrate were incubated for 1 h at 30 °C together with 5
mM DTT. The samples were analysed by HPLC. The peak at 1.5 min corresponds
to HEPES and the peak at 4.6 min corresponds to DTT. Of the three
bromomaleate peaks only the one at 3.0 min corresponds to the initial compound.
4.3.7 Active Site Mutants
The cysteine residues in MIs aligning with the catalytic cysteines in racemases of the
superfamily were confirmed by serine mutations to be the catalytic residues in a
previous study (104). This was expected to be the case for NfMI; however, in an
alignment of NfMI with the sequence of the other maleate isomerases there is Cys193
adjacent to the suspected catalytic Cys194, resulting in some uncertainty about the
correct attribution of the role of these residues.
To clarify the situation about the correct active site cysteine, the mutants C193A and
C194A were produced and tested with 1 mM maleate and the kinetic parameters
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determined. The activity of C193A remained largely wild type. Only a slight decrease in
kcat accompanied by a three-fold decrease in KM can be observed in C193A whereas
C194A suffers an almost total loss of activity resulting in a 1000-fold reduction in kcat
accompanied by a two-fold decrease in KM (Fig. 4.16, Fig. 4.17 and Table 4.2). This
confirms the result of the alignment with Cys194 as the catalytic residue (Appendix C).
Cysteine to serine mutants were used to differentiate between their role as a potential
nucleophile and their role as a potential hydrogen bonding partner. Serine generally is
a suitable replacement for cysteines if hydrogen bonding is required as it is
approximately isosteric but a lot less likely to be a nucleophile as hydroxyl pKa is much
higher than the hydroxyl pKa of the cysteine thiol. For this reason the mutants C76S,
C193S/C194A and C193A/C194S were made and tested with 1 mM maleate and for
the determination of kinetic parameters.
The mutants C76S and C193A/C194S resulted in the complete elimination of
detectable activity. The mutant C193S/C194A showed very low residual activity of the
same magnitude as C194A (1000-fold reduction in kcat and a two-fold decrease in KM
compared to wt, Fig. 4.16, Fig. 4.17 and Table 4.2).
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Figure 4.16. NfMI mutants activity assay. HPLC chromatograms of purified NfMI
mutant enzymes incubated with 1 mM maleate for 6 min at 140 ng mL-1 (top) or
18 h at 9 µg mL-1 (bottom) at 30 °C without DTT. Maleate at RT of 2.15, fumarate
at RT of 2.55. The peak at RT of 2.40 corresponds to TCEP.
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Figure 4.17. Kinetic parameter determination of NfMI mutants. Purified NfMI
mutant enzymes assayed at different maleate concentrations for 5 min at
140 ng mL-1 (top) or 60 min at 4 µg mL-1 (bottom) at 30 °C without DTT. Samples
were analysed by HPLC. The signals of C76S and CC193AS were too low to be
analysed. Simple rectangular hyperbola were (y = kcat · x / (KM + x)) fitted to
determine the kinetic parameters (see Table 4.2).
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Table 4.2. Steady state kinetic parameters of NfMI mutants. Data in Figure
4.14. Standard errors are indicated.
4.3.8 Biotransformation in Combination with Enoate
Reductases
In an attempt to extend the industrial usefulness of NfMI, combined reactions were
conducted with enoate reductases from the old yellow enzyme family (OYE2 and YqjM)
in collaboration with scientists at BASF (Ludwigsafen). By isomerising the substrate of
enoate reductases, the stereospecificity of the reaction is expected to change.
Additionally, another potential cis-trans isomerase identified in yeast (C. rugosa) cell
extract (Lu905). FactorX was found to change the product specificity of enoate
reductase reactions. As changes in product stereospecificity of enoate reductases
resulting from the substrate double bond configuration have been observed, it was
assumed that FactorX is a cis-trans isomerase.
The enoate reductases were added as cell extracts from overexpressions in E. coli
whereas FactorX was a sample of partially purified cell extract. All combinations of
isomerases with reductases were assayed with either 16 mM cis/trans citral or 10 mM
of the other substrates at 30 °C. The purity and the amount of enzyme as well as the
incubation time varied from experiment to experiment.
In the absence of isomerases, OYE2 specifically reduced citral into (R)-citronellal and
preferred the trans over the cis configuration, which corresponds to prior knowledge of
this reaction (personal communication by Daniela Burkhardt from BASF). Of the
remaining substrates, OYE2 only transformed maleate and dimethylcitraconate. In the
case of maleate, as expected, some succinate was produced and surprisingly also
some fumarate. YqjM mainly produced geraniol plus small amounts of nerol and (S)-
citronellal hence the sample contained more alcohol dehydrogenase activity than
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enoate reductase activity. YqjM like OYE2 transformed maleate into succinate and
fumarate and converted dimethylcitraconate. Unlike OYE2, YqjM also had low activity
with fumarate, converting it into succinate. The disappearance of citraconate observed
in the presence of YqjM yet not in the presence of NfMI and YqjM is highly anomalous
and should be considered as an experimental error until confirmed by repetition (Fig
4.18 and Fig. 4.19).
NfMI did not have an effect on the activity of either of the two reductases, except in the
case of maleate, which is in accordance with previous experiments, where maleate
was the sole substrate. When NfMI was added to the OYE2 maleate reactions the
depletion of maleate (and fumarate) is slower. When added to the YqjM maleate
reactions, the depletion of maleate and fumarate is not noticeably affected (Fig 4.18
and Fig. 4.19).
The analysis of FactorX is very complex as it was used as different preparations,
initially in a partially purified form (FactorX) and when the sample ran out as C. rugosa
total cell extract (Lu905). It can therefore only be properly analysed within a single
experiment. In its freshest and semi-purified form with citral as substrate it produced
mainly (R)-citronellol and a small amount of nerol and slightly preferred trans over cis-
citral, which is indicative of alcohol dehydrogenase activity but not isomerase activity.
When combined with OYE2, surprisingly, the main product is (S)-citronellol, not
produced by any of the single enzyme controls. Also the appearance of geraniol at
lower quantity is a new observation whereas the other products are produced in similar
quantities as with both enzymes individually (Fig. 4.18 top). When older FactorX was
used in lower quantity but longer incubation time, the result was strikingly different.
Instead of (R)-citronellol, the main compound now was geraniol with nerol produced at
a similar level. The combination of YqjM besides the combination of the individual
enzymes only produces a small amount of (S)-citronellol (Fig. 4.18 bottom).
Whole cell extract containing Factor X (Lu905) was used with the remaining substrates.
Lu905 was highly active on fumarate as well as citraconate and showed some activity
on all the other compounds. The combination with the reductases did not result in any
difference in depletion of substrate. Because of high amounts of lactate present in the
samples, hiding the succinate signals, the latter could not be detected. These results
are not very informative, given that we know Lu905 contains enoate reductase activity
(personal communication by Andreas Schädler from BASF).
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Figure 4.18. Citral assay with NfMI and enoate reductases. 16 mM cis/trans-
citral was incubated with a combination of an isomerase (15 µg mL-1 NfMI or
partially purified FactorX, 2.2 mg mL-1 with OYE2 or 1.5 mg mL-1 with YqjM) and an
enoate reductase (OYE2 or YqjM, both 0.1 mg mL-1 total protein) at 30 °C for 6 h
(top) or 16 h (bottom). The samples were analysed by GC.
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Figure 4.19. Maleate analogues assay with NfMI and enoate reductases. 10
mM of maleate (top left), fumarate (top right), citraconate (middle left), mesaconate
(middle right), dimethylcitraconate (bottom) respectively were incubated with a
combination of an isomerase (15 µg mL-1 NfMI or 5 mg mL-1 total protein Lu905)
and an enoate reductase (OYE2 or YqjM, both 0.1 mg mL-1 total protein) for 16 h
at 30 °C. The samples were analysed by HPLC. The presence of succinate in
maleate and fumarate samples was determined by another HPLC method. + =
succinate detected. - = succinate not detected. ? = succinate peak hidden under a
large lactate peak.
4.4 Discussion
4.4.1 Conditions for Activity and Stability
As predicted by phylogenetic analysis of sequence homologues (Fig. 1.21, Chapter 3,
sequence alignment in Appendix C) NfMI was experimentally confirmed to be a
maleate isomerase. It is only the fourth sequenced enzyme with this associated
activity.
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The pH optimum of 7.5 is lower than any described MI and is at the lower end in the
superfamily. The pH range for activity is similar than in other described enzymes in the
superfamily with a slight shift in activity towards lower pH. The KM of 10 μM is the
lowest of any superfamily member with their respective substrates described in the
literature to date, whereas the kcat of 6 s-1 is lower than for the two maleate isomerases
described but in the middle compared to the rest of the superfamily.
The temperature analysis is more complex as the optimum temperature for a reaction
also depends on the speed of protein inactivation at high temperatures. Likewise, the
oxidation of the enzyme further reduces its activity. In assays without reducing agents
the temperature optimum for a 20 min assay was determined to be between 35 and 40
°C but the enzyme was only stable for 1 h up to 30 °C.
P. fluorescens MI was described to be dependent on thiols for activity (100). Like all
other described MI activities NfMI does not need this activation. Conversely thiols do
stabilise the enzyme and protect it from inactivation at increased temperatures and
prolong its long term stability at low temperature. In the literature, the exact role of
thiols in the activation or stabilisation has never been established clearly (100,103).
The analysis of these factors is complicated by the fact that thiols are able to isomerise
maleate chemically. This chemical background activity is still detectable at 5 mM DTT
in the enzyme assays.
Combining the work presented here and previously published data, it is reasonable to
assume that the cysteines are highly susceptible to oxidation which inactivates the
enzyme. This process is reversible through the addition of thiols, capable of specifically
reducing the cysteines. The necessity for activation using thiols with P. fluorescens is
probably due to the oxidation of the enzyme by the extraction process. The inactivation
of NfMI after long term storage even in presence of DTT, can be explained by the
instability of DTT under the normal atmosphere especially at alkaline pH. This can be
tested by rescuing old enzyme preparation by adding fresh DTT, using more stable
TCEP instead of DTT or storing the enzyme under inert atmosphere to protect it from
oxidation. As TCEP is specific for cysteines, its use makes it possible to distinguish
whether enzyme inactivation is due to the oxidation of cysteine or methionine. It was
suggested that conserved Met197 makes it susceptible to oxidation in Alcaligenes
faecalis MI (103).
In addition to increased long term stability, DTT clearly improves the temperature
stability of NfMI. In preliminary data more than 60% of the activity was retained at 50 °C
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when preincubated with DTT for 1 h. There seem to be two separate effects of thermal
inactivation; that are oxidation dependent and oxidation independent. The oxidation
independent inactivation is most likely simple denaturation of the protein that cannot be
reversed by adding DTT. The protein starts to denature between 30 and 50 °C. The
oxidation dependent inactivation is most probably equal to the effect that inactivates
the enzyme during long term incubations at low temperature. The oxidation of
cysteines is accelerated by higher temperature between 4 and 30 °C. These results
have to be considered cautiously here, as the instability of DTT may be a major factor.
Quantifying the effect with the use of DTT and H2O2 would help to disentangle the roles
of oxidation and denaturation.
4.4.2 Mechanism
The reduced mutant activities of C76S, C194A and C193A/C194S compared to the
nearly full activity of C193A confirm that the sequence alignment with other known
superfamily members as well as the other maleate isomerases was correct. It identifies
Cys76 and Cys194 (not Cys193) as the catalytic cysteines. This is also in accordance
with reported cysteine to serine mutations in Bacillus stearothermophilus MI that lost
detectable activity. Unfortunately, the quantification limit reported is above the detection
limit of the HPLC assay used in this work. Therefore, possible residual activities in
these mutants cannot be compared with those reported here.
The thiol moieties of cysteines are observed to have different roles in enzymes. They
can act as acid/base catalysts, nucleophiles or weak hydrogen bonding partners. In
GluRs and AMDs the cysteines act as acid/base catalysts deprotonating and
protonating the Cα carbons (64,67,123).
Chemical isomerisation was reported to occur with three mechanisms involving a
rotation around a single bonded intermediate: radical, acid and thiol catalysis (105,108-
110). The radical mechanism can be excluded in this case. In both the acid and thiol
catalysis, a nucleophilic attack on a double bond carbon leads to a covalent adduct of
water or thiol to maleate to reach a single bonded intermediate. It is therefore possible
that one of the cysteine thiols acts as such a nucleophile.
Even after prolonged incubation the C76S mutant does not show any detectable
activity, which suggests that the thiol of Cys76 is crucial for activity and cannot be
replaced by an alcohol. This finding would be in accordance with Cys76, being a
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nucleophile, attacking the double bond carbon and producing an enediolate
intermediate observed in all the other Asp/Glu racemase superfamily members.
The analysis of the role of Cys194 is more complex. The complete inactivity of
C193A/C194S double mutant suggests that also the second cysteine’s thiol group is
equally indispensable for activity, yet the C193S/C194A mutant shows some activity,
though just detectable. The same residual activity is detectable in the C194A mutant. It
therefore seems that role of Cys194 can be partially assumed by a neighbouring serine
or cysteine. As C193A/C194S is not active at all and as two neighbouring amino acids
are not likely to point into the same direction, its complete inactivation is unlikely to be
through removal of the chemical group on the same amino acid but rather through a
structural rearrangement that shifts the chemical group from a more distant amino acid
away from the correct position. Tyr133 would be a good candidate as it is conserved
between MIs and AMDs and plays an important role as part of the dioxyanion hole (see
Chapter 5). Cys194 is therefore more likely to be an acid base catalyst or a crucial
hydrogen bonding partner than a nucleophile. This coincides with its role in AMDs.
The role of Cys194 and Tyr133 can be tested in several ways. A C194S mutant would
be expected to have some residual activity as Cys193 would remain unchanged and
keep Tyr133 in place. A Y133F mutant would lose the hydroxyl group in this position
and should have a reduced but still detectable activity, similar to C193A. Likewise the
same mutation in the background of C194A and C193S/C194A mutants should
completely abolish all remaining activity. Other ways, based on structural knowledge of
NfMI’s three dimensional structure, could be used to induce structural changes on
Tyr133 to confirm its role in the active site.
Confirming other reports on MIs from other organisms, NfMI is completely specific to
maleate as substrate. The only other reaction detected in a previous study (52) was the
reverse reaction that could not be confirmed here as fumarate was contaminated by
too high amounts of maleate and as Keq in the measured conditions was 517.
Bromomaleate, citraconate and maleamate are not accepted as substrates. These and
other substrates including cis- and trans-3-chloroacrylate, 2-chloromaleate and 2-
chlorofumarate, tiglate, trans-2-pentenoate and 2,3-dimethylmaleate have also been
tested with negative results in previous studies (98,100,101). In this study
dimethylcitraconate and citrate have also been shown not to be substrates.
The activity can be affected by different properties of the substrates. Firstly, the
thermodynamic equilibrium of the double bond isomers determines that only maleate
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reacts in sufficient amounts to be detected. This might explain the inactivity of some
substrates. Secondly, the two carboxyl groups are strongly electron withdrawing thus
rendering the double bond carbons more positively charged, which makes the
possibility of a nucleophilic attack of a cysteine a reasonable mechanism. Thirdly, the
substrate has to be able to bind to the active site. With other substrates, the binding
might be hindered sterically because of substituents on the double bond or larger
chemical groups at the ends. The substrate may also be prevented from binding simply
by the absence of hydrogen bonding possibilities with the active site.
For most of these substrates, steric hindrance would be the most straightforward
explanation of the inactivity. The methyl or halogen substituents on the double bond or
the methylesters all increase the size of the substrate. For maleamate and cis-3-
chloroacrylate this cannot be the explanation, especially for maleamate, which is
approximately isosteric. Although the hydrophilicity of the amide is similar to the
carboxyl, the hydrogen bonding and the missing negative charge may strongly reduce
the binding. In addition, the amide group is much less electron withdrawing than the
carboxyl group, which may also explain the inactivity. In the case of the chloroacrylates
the electron withdrawing capacity is maintained. In this case, the reduced binding must
be the reason for the inactivity as the chlorines are much smaller than the carboxylates.
The hypothesis of steric hindrance can be tested by using fluoromaleate being isosteric
to maleate. Testing the methylester of maleate would complete the picture of steric
hindrance although it is not expected to be converted by NfMI.
Despite the possibility of steric hindrance affecting substrate binding, it is surprising
that chloro- and bromomaleate are not substrates. Their size is still limited and if a
nucleophilic attack was to occur, the additional electron withdrawing capacity would
favour nucleophilic attack. It cannot be excluded that the loss of symmetry by the
addition of a substituent affects the mechanism as the molecule can bind in two ways,
one of which may disfavour the reaction. To test this hypothesis, disubstituted
compounds like difluoromaleate and dimethylmaleate could be assayed.
A large variety of compounds have been tested as inhibitors on MIs in previous reports
(98,100,101). All compounds identified this way were either heavy atoms or oxidative
inhibitors such as Hg2+ and iodoacetamide, inhibiting the catalytic cysteines. Various
other compounds containing mono-, di- and tricarboxylic acids and/or double bonds
have been tested including maleamate, cis-1,4-butenediol, diethyl- and
dimethylmaleate, citraconate, mesaconate, cyclopentenedione, L-malate, L-aspartate,
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L-glutamate and EDTA. Apart from L-aspartate and EDTA inhibiting at high
concentrations, no competitive inhibitor has been identified so far.
The only strong non-oxidative inhibitor identified was bromomaleate. Although more
data have to be collected for more accurate rate determinations, taking into account the
substrate inhibition, the data are consistent with the model of competitive inhibition.
Irreversible inactivation can be ruled out as the rate would have to drop proportionally
to the substrate concentration. Noncompetitive and uncompetitive inhibition would not
affect the KM that is clearly increasing with inhibitor concentration. Mixed inhibition
leading to an increase in KM with a simultaneous decrease in kcat cannot be ruled out
with complete certainty; however, the similarity of the structures of the inhibitor and the
substrate further support the competitive inhibition model over the mixed inhibition
model.
It is surprising that bromomaleate is not a substrate and it would be interesting to see
whether fluoromaleate would behave similarly to bromomaleate or whether it would
overcome the supposed steric hindrance and be a substrate. Also citraconate being
isosteric to bromomaleate is not an inhibitor, suggesting an electrostatic component in
the inhibition.
More information about the mechanism could be obtained from structural data showing
the binding mode of substrate and/or inhibitor. Also structural data of slightly active and
completely inactive mutants are likely to reveal more details about the binding mode
and the role of the catalytic residues.
To gain more insight into the role of the cysteines, their pKa should be determined. The
values of active site cysteines can be in a wide range depending on the
microenvironment. A plot of the pH versus the catalytic efficiency (kcat/KM) would show
two different inflection points corresponding to the pKa values of both cysteines as the
enzyme is most active when both cysteines are in the correct protonation state.
4.4.3 Industrial Usefulness
Due to the absolute substrate specificity observed for all MIs so far, the use of MI is
limited to the production of fumarate from maleate or, if the equilibrium is pushed, also
in the reverse direction. Depending on the reasons for the substrate restriction, there is
hope for the extension of the isomerisation activity through engineering of the active
site. Structural data are crucial for informed decisions on mutations.
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NfMI has the lowest pH optimum of all MIs described to date and a large pH range,
which could potentially make it more useful. It also has the lowest KM value with a
moderately high kcat. The latter would most probably need to be improved for industrial
application but the low KM provides an interesting addition to the enzymes available for
engineering. Also the substrate inhibition is an unwanted property for industrial
production that would have to be considered in more detail.
Fumarate, however, with its two distinct chemical functionalities is very versatile
chemical intermediate that is widely used for the production of unsaturated polyester
resins, paper sizing chemicals, lubricants and lacquers. Fumarate can be converted
into malate. Both are used as food and drink acidulants. Fumarate is also converted
into aspartate (105). Both L-malate and L-aspartate can easily be produced
stereospecifically using the enzymes fumarate hydratase (EC 4.2.1.2) and aspartate
ammonia lyase (EC 4.3.1.1) (4). Analogously, maleate hydratase (EC 4.2.1.31) could
be used to produce D-malate (Fig. 4.20) (4).
Figure 4.20. Possible biotransformations of maleate and fumarate.
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Currently fumarate as well as its precursor maleic anhydride, that is also widely used,
are produced from butane that is refined from fossil oil (105). The microbial production
of maleate from organic waste materials, originating from food industries and
agriculture, provides a possible alternative route in a chemical industry independent of
fossil oil. Fumarate could then be produced by the same microbes using maleate
isomerase or alternatively, the conversion to fumarate could be interrupted to allow the
extraction of maleate that can further be dehydrated to form maleic anhydride (Fig.
4.21.)
Figure 4.21. Production of fumarate and maleic anhydride. The current fossil
fuel based production (grey) and a possible bio based production (green).
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Chapter 5
Crystal Structure of NfMI
5.1 Introduction
The biochemical observations of NfMI in the previous chapter have confirmed many
characteristics known for other MIs such as the substrate specificity, the sensitivity to
oxidation and the presence of the catalytic cysteine dyad. In addition, bromomaleate
was found to be a competitive inhibitor of NfMI. Despite all this, characterisation of the
precise mechanism of the maleate isomerisation still remains elusive. Structural data
are key for a full understanding of an enzymatic mechanism; however, no experimental
three dimensional structure of a MI is described so far.
A series of maleate isomerisation activities has been described (see previous chapter)
but only three MI sequences have been annotated experimentally (52,103,104). With
NfMI a fourth sequence has been added to this collection. Until now, all structural
knowledge about MIs had to be inferred from sequence comparisons with known
structures in the Asp/Glu racemase superfamily. This has led to the identification of the
catalytic cysteines as confirmed by site directed mutations to serine in Alcaligenes
faecalis MI (104). In the same way Cys76 and Cys194 were found to be the catalytic
residues in NfMI (previous chapter).
Although the approach based on sequence comparisons has correctly predicted the
conservation of the protein fold in the superfamily, it clearly has its limitations in
predicting the function and mechanism. In Chapter 3 it was shown that the automatic
annotation of gene functions based on sequence motifs and grouping by similarity still
fails to recognise the activity of the homologues that have less than 40% sequence
identity. Only NfMI and Mesorhizobium sp. BNC1 AMD activities were successfully
predicted (48).
The Asp/Glu racemase superfamily is catalytically very flexible and harbours
industrially and pharmaceutically interesting activities such as racemisation and
decarboxylation. While it was possible to invert the enantiospecificity of the
decarboxylation by BbAMD by simply swapping the conserved glycine and cysteine
and to obtain racemisation by replacing the glycine with a second cysteine, only low
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activities could be obtained (79,93). Also attempts to increase the range of substrates
in BbAMD had rather limited success (48,67). This results in an apparent contradiction
that despite the large evolutionary flexibility of the superfamily, the individual activities
are very specific and cannot be changed by simple mutagenesis in substrate binding
residues.
These limitations in our knowledge about the structure function relationship in the
Asp/Glu racemase superfamily stress the need for a MI structure. Maleate cis-trans
isomerisation is substantially different in its mechanism from the other reactions in the
superfamily but recruits the same fold and the same catalytic residues. The mechanism
most probably has to go through an intermediate that allows free rotation around the
double bond. This is a completely new feature in the superfamily and the
understanding of the structural requirements will broaden the understanding of
catalysis in the whole superfamily and help facilitate the exploitation of the catalytic
potential by targeted engineering and the discovery of new activities.
In this chapter, the solution of the X-ray crystal structure of NfMI will be presented.
Based on the binding of a TRIS molecule in the active site the possible role of the
active site residues will be discussed and different models for substrate binding will be
presented. The role of flexibility in the enzyme will also be highlighted.
5.2 Methods
5.2.1 Cloning and Protein Purification of NfMI
See Chapter 2.
5.2.2 His-tag Cleavage
The pET-YSBLIC3C plasmid includes a HRV 3C protease cleavage site (LEVLFQ↓GP)
in front of the insert protein’s N-terminus allowing the cleavage of the His-tag. The
cleavage was performed on 1 mg mL-1 target protein incubated with 0.01 mg mL-1 of
the protease at 4 °C for 14 h in the protein storage buffer (20 mM TRIS, 150 mM NaCl,
pH 8.0). The cleavage of the His-tag was checked by SDS-PAGE analysis. The
cleaved protein was separated from the uncleaved protein, cleaved His-tag and the
protease (containing a His-tag itself) by an additional nickel-affinity column purification
step. The purified protein contained three remaining N-terminal amino acids (GPA) not
belonging to the native protein.
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5.2.3 Crystallisation
Protein samples at 3 - 17 mg mL-1 concentration were prepared freshly or taken from
snap frozen -80 °C stocks. Proteins were stored at pH 8 in TRIS or sodium phosphate
buffers containing 150 - 300 mM NaCl. Some samples contained additives: 5 mM DTT,
10 mM BME or 10 mM TCEP to prevent oxidation or 100 - 200 μM PMSF to inhibit
serine proteases.
Crystallisation trials were performed with the following screens: PACT Premier
(Molecular Dimension Ltd), Index (Hampton Research), CSS 1 and 2 (with MES pH 5.6
or 6.0 and TRIS pH 8.0 (124), and PEG Ion/Ion 2 (without buffers, Hampton Research).
The screens were prepared on 96-well sitting drop vapour diffusion plates (MRC
Wilden) with a reservoir volume of 60 μL. Drops of 150 nL protein solution and 150 or
300 nL reservoir solution respectively were dispensed using a Mosquito robot (TTP
Latech).
Positive hits were scaled up to 1 μL protein solution and 1 or 2 μL reservoir solution
and optimised using the hanging drop vapour diffusion technique on siliconised glass
cover slides over 24-well cell culture plates (Greiner) using 1 mL reservoir solutions.
Drops were incubated from 1 day to 2 weeks at 25 °C.
5.2.4 Data collection
Protein crystals were transferred from the drops into cryoprotectant solution using the
mother liquor including 10% 1,2,6-hexanetriol or 30% PEG 3350 and subsequently
snap frozen in liquid nitrogen. Diffraction was tested in-house using Micromax 007HF
rotating copper anode X-ray generator (Rigaku) and mar345 X-ray detector
(marresearch) at 120 K. Diffracting crystals were sent to the European Synchrotron
Radiation Facility (ESRF) in Grenoble (France), beamline ID23-1 with a Q315r CCD
detector (ADSC). Diffraction images were collected at a wavelength of 0.98 Å at 100 K
(Oxford Cryosystems Cryostream). For data collection statistics see Table 5.2.
5.2.5 Data Processing, Structure Solution and Refinement
The diffraction data obtained from the synchrotron were indexed and integrated with
imosflm (125) and the intensities were scaled and reduced with SCALA (126). The
Matthews coefficient of 2.4 Å3 Da-1 with a corresponding solvent content of 48%
indicated four molecules in the asymmetric unit with a probability of 66% (127). The
structure phases were solved by molecular replacement using the BbAMD coordinates
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(PDB: 3dg9) as a search model using Phaser (128). The phases were improved by
NCS averaging and solvent flattening using DM (129).
A model of the well defined regions was built in COOT (130) and refined with Phenix
(131) including simulated annealing to reduce the model bias. Several cycles of
building additional parts of the structure model and refinement were used to build the
remaining fragments. The final model was refined using Phenix introducing TLS
corrections taking each polypeptide chain as a group.
5.2.6 Structure Validation and Analysis
The model was validated with Molprobity (Table 5.1) (132) and the secondary structure
was assigned with DSSP (133). The areas of interfaces between molecules were
calculated with PISA via the EBI web interface (134).
Table 5.1. Structure validation statistics.
The identity of a metal atom present between molecules was analysed by refining with
each of the suspected identities. Subsequently, the σ-value of the corresponding peak
in the electron difference map, the resulting B-factor of the metal atom and the
distances to the coordinating atoms were determined. The σ-value and the B-factor
were compared between the different atoms and the coordination distances were
compared to known experimental values in the MESPEUS database (135). An
additional X-ray fluorescence scan was performed on another crystal. The presence of
a heavy metal was analysed by determining an anomalous difference map.
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Images were produced using CCP4mg (136). In the case of TRIS bound to NfMI the
angular restraints were relaxed to account for the flexibility of TRIS and the uncertainty
of the exact oxygen position.
5.2.7 Ligand Modelling and Docking
The surface and volume of the active site was determined with the CASTp server
(137), the surfaces and volumes of TRIS, maleate and fumarate were determined with
ChemBioOffice (CambridgeSoft). The volume necessary for a rotation of one carboxyl
group from the maleate conformation to the fumarate conformation was approximated
by calculating the volumes of the theoretical tori resulting from the rotation of the atoms
around the axis. In all cases the molecular surfaces and volume (Connolly’s surface
and volume) were used.
The observed density in the active sites after refinement that could not be explained by
modelling water molecules was attributed to TRIS. The TRIS coordinates were taken
from the REFMAC5 monomer library (138). The ligand was build in with COOT and
refined again as described above.
Based on the TRIS molecule, maleate and fumarate were modelled into the active site
of molecule A by manually overlaying the oxygen atoms of the ligands (also obtained
from the REFMAC5 monomer library) with the oxygen atoms of TRIS. Orientations of
the molecules that had atoms heavily clashing with the protein atoms were not
considered. Alternatively, maleate was docked to the active site of the protein model
using AutoDock (139).
5.3 Results
5.3.1 Crystallisation
The full sequence of NfMI was cloned using the LIC technique (see Chapter 2) and
expressed by IPTG induction in Escherichia coli cells. The protein was purified by its N-
terminal His-tag first by nickel-affinity and subsequently by gel filtration and was
concentrated to 12-15 mg mL-1. The concentrated sample was run on SDS-PAGE and
judged to be sufficiently pure for crystallisation (see Chapter 3). The monodispersity of
the protein sample was tested with DLS. With 14% polydispersity the sample was
considered monodisperse. The hydrodynamic radius was determined to be 3.2 nm
which is equivalent of an approximate molecular mass of 51 kDa corresponding
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assuming a spherical protein. This would correspond to a dimer of NfMI with a
molecular mass of 53 kDa.
Conditions for crystallisation of NfMI were found through screening of a large number
of conditions using commercially available sets of crystallisation solutions in a 96-well
format (PACT, Index, PEG Ion I&II, CSS I&II). Conditions found in this way were
optimised and upscaled in a larger 24-well format. The best crystals were grown in 300
mM calcium acetate, 100 mM TRIS pH 7.5, 16% PEG 3350, 5 mM maleate using
seeding of crushed low quality crystals grown in higher PEG concentrations. If the
protein was stored in a buffer containing 10 mM TCEP in addition to 20 mM TRIS pH
8.0, 150 mM NaCl the quality of the crystals increased greatly.
In all conditions containing bulky crystals the shape of the crystals was conserved.
They were elongated hexagonal prisms with a slanted end containing a defect in the
form of a cavity at the thicker end (Fig. 5.1 left). In an attempt to improve the diffraction
power, protein with 3C protease cleaved His-tag was produced. Crystals resulting from
these protein samples grew in different conditions (200 mM MgCl2, 100 mM TRIS pH
8.0, 20% PEG 3350) resulting in different crystal shapes (rhombohedral, Fig. 5.1 right).
No diffraction could be achieved in-house with these crystals.
Figure 5.1. Crystals of NfMI. Left: His-tagged protein. Right: Protein with cleaved
His-tag.
Co-crystallisation with 1-100 mM maleate (substrate) and fumarate (product), 1 mM
bromomaleate (inhibitor) and 1-20 mM of various other substrate analogues such as
malonate, succinate and D/L-malate were tried without an improvement of the crystal
shapes or diffraction. Co-crystallisations with bromomaleate only diffracted to
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approximately 5 Å in-house. A crystal from protein containing its His-tag, co-crystallised
with 5 mM maleate was finally used for data collection. It was snap frozen in liquid
nitrogen with a total of 30% PEG 3350 as cryoprotectant and diffracted to a maximum
of 2.7 Å resolution in-house.
5.3.2 Data Collection, Phasing, Model Building and Refinement
Data were collected at the synchrotron light source ESRF in Grenoble (France). The
crystals diffracted to a maximum resolution of 1.9 Å. However, the data were highly
anisotropic, which resulted in the final useful resolution limit of only 2.5 Å
corresponding to the resolution along the weakly diffracting axis. Crystals belonged to
the orthorhombic space group P212121 with a very long c axis (238 Å) containing four
molecules in the asymmetric unit.
The phases could be calculated using molecular replacement based on the Asp/Glu
enzyme superfamily homologue representing the highest sequence similarity available
in the protein structure database: BbAMD (PDB: 3dg9). The proteins only have a
sequence identity of 22%, yet the protein fold is highly conserved in all available
structures throughout the whole superfamily. Initial phases yielding an initial model
could be determined this way. Through the use of non-crystallographic symmetry
(NCS) averaging and density modification through solvent flattening, the map could be
improved considerably. This way, it was possible to determine the core of the protein
used for the manual extension of the model.
To overcome the model bias caused by the low sequence similarities, refinement with
simulated annealing was applied to the molecular replacement solution. This method
introduces molecular dynamics into the refinement process meaning that the atoms are
randomly assigned a certain velocity resulting in an overall temperature. The method
allows the structure to overcome local minima and converge towards the global
minimum while the temperature is decreased in each optimisation cycle (140). The
same method was used throughout the refinement process. In the end TLS refinement
was applied taking each protein molecule as one group. The resulting final R-values
were 0.21 (Rwork) and 0.29 (Rfree). For additional statistics see Table 5.2.
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Table 5.2. Data collection and refinement statistics.
5.3.3 Quaternary Structure and Overall Fold
The asymmetric unit is composed of four molecules. The two central molecules (A and
B) form a crystallographic dimer. The molecules other two molecules (C and D) each
form another dimer with the corresponding partner in the adjacent asymmetric unit. The
dimer contact interface in both AB and CD is formed by α-helices A and C and β-strand
2 on domain 1. The total interface area is 926 Å2 as determined with the PISA server.
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The two monomers are rotated by approximately 180 ° and orientated resulting in their
active sites facing the other monomer (Fig. 5.2).
The dimers are in contact via a smaller interface of 414 Å2 formed by the start of α-helix
E and the preceding loop as well as α-helix G and the following loop. Between the two
dimers is a metal ion participating in keeping the dimers together. Moreover, the dimers
are rotated in respect to each other by 180 ° forming a long chain of monomers in the
crystal linked by inter and intra dimer contacts (Fig. 5.2).
Figure 5.2. Asymmetric unit. Ribbon model of the four molecules. AB forms a
dimer with an approximate 180 ° symmetry axis parallel to the image plane and
CD’, C’D form equivalent dimers across the asymmetric unit boundaries. Dimers
are linked through Ca2+ ions (magenta). TRIS molecules (green) are bound in
molecule A and molecule D.
The metal ion is coordinated in octahedral fashion but its identity is not entirely clear.
The crystallisation conditions contained 300 mM Ca2+ and the protein buffer contained
150 mM Na+. An X-ray fluorescence scan of a crystal from the same conditions showed
a very small peak corresponding to zinc atoms. The metal ions Na+, Ca2+ and Zn2+
were all placed in this position and refined (Table 5.2). The picture resulting from these
data is not entirely clear. According to the difference map Zn2+ would fit best. The B-
factor for Na+ is the lowest but the distances between the coordinating oxygen atoms
and the metal are closest to the expected values for Ca2+. As Ca2+ has intermediate
values for both the difference map peak and B-factor, it is most likely to be the
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observed metal. In addition, no anomalous difference map peak could be observed as
would be expected for Zn2+ at a wavelength of 0.98 Å.
Table 5.2. Coordination of metal ion between molecules A and D.
NfMI consists of two similar Rossmann fold domains (βαβ, with parallel β-strands),
arranged in a pseudo 2-fold symmetry corresponding to a rotation of about 170 °,
forming the active site cleft between the domains. Each domain consists of a central β-
sheet formed of four parallel strands (1-4 and 6-8) alternated with one or two α-helices
(A-L). β-Strand number 8 and α-helix L are only weakly structured. The two catalytic
residues Cys76 and Cys194 are on equivalent positions on the loops between the third
β-strand and the following α-helix (3 and D as well as 7 and J respectively) on either
side of the active site in positions facing each other. The loops at both ends of the
active site cleft, following the second β-strand in each domain (2 and 6 respectively)
cover the active site (Fig. 5.3). This fold is shared with all the other known structures of
the Asp/Glu racemase superfamily (62,63,71,141-150). The fold is thought to have
evolved from by ancestral gene duplication (143).
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Figure 5.3. Three dimensional fold. Top: Stereoview of ribbon diagram in
rainbow colour following the Cα-trace. In the active site the catalytic cysteines
(grey) and the bound TRIS molecule (green) are shown as stick models. Bottom
left: Topology diagram showing domain 1 (blue) and domain 2 (red). β-Strands are
shown as triangles (1-8) and α-helices as circles (A-L) with their first and last
residue numbered. The two loops covering the active site are shown as thick lines.
Bottom right: Ribbon diagram showing temperature factors of 30 and below (blue),
䩃䩃䩃䩃䩃䩃䩃䩃䩃䩃䩃䩃䩃䩃䩃䩃䩃䩃䩃õ 䩃䩃䩃䩃䩃䩃䩃䩃䩃 䩃 䩃䩃䩃The quality of the
The quality of the electron density map is very heterogeneous over the asymmetric unit
resulting in high B-factors for low quality regions. The average B-factor for each
molecule increases from 48 in molecule A over 51 in B and 62 in C to 72 in molecule D.
The loops in molecule D and C at the furthest apart ends of the asymmetric unit have
the highest B-factors as the electron density maps are very poor to non-existent in this
area. Therefore the model in these regions (molecule D, helix J, helix I with loop as well
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as molecule C loop and helix B) is mostly based on the symmetry related parts of the
other molecules and has to be considered with caution.
There are also regions of higher B-factors than the rest of the molecule that are
repeated in all molecules: the active site covering loops on both domains (between
strand 2 and helix B and between strand 6 and helix G) and the solvent exposed
extremity of domain 2 (loop between helix I and strand 7, end of helix J, Fig. 5.3 bottom
right).
5.3.4 Active Site Conformation and Substrate Modelling
The active sites contain unexplained electron density that was modelled by adding a
TRIS molecule, present in the crystallisation conditions. The TRIS molecules refined
well in the active site of molecule A and D and very badly in the other two (very high B-
factors and low quality electron density maps). Therefore TRIS was only modelled into
these active sites and the active sites of molecule B and C were modelled with water
molecules. As molecule A contains a TRIS in the active site and has the lowest B-
factor and the best electron density map, only molecule A will be considered from now
onwards (Fig. 5.4).
Oxygen O1 of TRIS is in hydrogen bonding distance to the backbone nitrogen of
Val195 and to the hydroxyl oxygen of Tyr133. O1 is also close to sulphur of Cys194
(3.4 Å). Oxygen O2 is not in hydrogen bonding distance to any atom but relatively close
to the backbone nitrogen atoms of Leu77 (3.5 Å), Val78 (3.8 Å) and Ala79 (3.8 Å) and
could potentially establish transitional bonding given there is enough flexibility in the
binding. Oxygen O3 is in hydrogen bonding distance to the amide nitrogen atom of
Asn14. Here again the amide nitrogen and oxygen are close (3.6 and 3.8 Å). The
amide nitrogen in TRIS is in a completely hydrophobic environment mainly determined
by one γ- and the β-carbon atom of Val78 (3.1 and 3.6 Å) as well as the ε-carbon of
Met42 (4.0 Å, Fig. 5.4).
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Figure 5.4. Active site. Stereoview of stick model showing active site residues
(grey sticks) with the positive difference density map set to 3σ (green wire). The
fitted TRIS molecule (green sticks) is shown with hydrogen bonds to active site
residues (purple dashed lines).
The presence of the active site pocket was confirmed with the CASTp server that
identified it as the biggest pocket measuring 237 Å3 having a surface of 260 Å2. This
fits well with TRIS that has a volume of 111 Å3 and a surface of 197 Å2 (Fig. 5.5).
Figure 5.5. Active site pocket. Stereoview of TRIS (green sticks) bound to the
active site.
There are currently 29 structures of 16 Asp/Glu racemase superfamily members in the
protein structure database, 21 structures (12 sequences) of GluR, 4 structures (1
sequence) of AspR, 1 HydR structure, 5 AMD structures (1 sequence), 1 structure of
unknown function. Although the sequence identities within GluRs vary from 36% to
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68%, their protein fold is highly conserved. When aligned, the structures around the
active site vary more according to the bound ligand than according to their sequence
differences. In eleven GluR structures containing D-glutamate in the active site there
are only two different conformations of the ligand. The proteins are all well aligned.
The dioxyanion hole has been described as a conserved feature in AspRs, GluRs and
AMDs. The two negatively charged oxygen atoms of the enol intermediate (enediolate),
formed after deprotonation or decarboxylation, are stabilised by six hydrogen bonds.
Three hydrogen bonds are made with backbone amines; two with hydroxyls of
threonine and serine or asparagine and the last with water or hydroxyl of tyrosine.
These features are conserved in the sequence alignment of these activities. When MIs
are aligned, these features are only partially conserved as the hydrophilic side chains
of threonine and serine or asparagine are replaced by the hydrophobic side chains
Leu77 and Val78 in MI removing two out of six hydrogen bonding possibilities (for
alignment see Appendix C).
All the structures of different activities and containing different ligands could be
structurally aligned on three conserved atom positions of this dioxyanion hole lying on
domain 2. These are; the sulphur atom of Cys194, the nitrogen atom of Val195 and the
η-oxygen of Tyr133 (equivalent to the oxygen atom of water between threonine and the
ligand in racemases). Through the alignment, almost all ligands aligned at their
potential enediolate position.
The structure of NfMI was aligned with one representative of GluRs, AspRs and AMDs
containing a ligand. The chosen structures were Enterococcus faecalis GluR binding D-
glutamate (EfGluR, PDB: 2vvt, resolution = 1.7 Å, Rfree = 0.18) (151), Pyrococcus
horikoshii AspR binding citrate (PDB: 2dx7, resolution = 2.0 Å, Rfree = 0.22) (72) and
BbAMD binding PO4 (PDB: 3dg9, resolution = 1.5 Å, Rfree = 0.19) (48). Oxygen (O1) of
TRIS co-localises with the oxygen of the other ligands binding to nitrogen of Val195
and to the η-oxygen of Tyr133 (Fig. 5.6). As was already predicted from the sequence,
the dioxyanion hole is only partially conserved as the two hydrophobic side chains of
Leu77 and Val78 remove two possible hydrogen bonds in NfMI. In spite of this, the
general structure of this part of the active site remains unchanged.
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Figure 5.6. Overlay of dioxyanion holes and ligands. Stereoview of NfMI (grey)
containing TRIS (grey), EfGluR containing D-Glu (blue, PDB: 2vvt), PhAspR
(green, PDB 2dx7) containing citrate and BbAMD containing PO4 (purple, PDB
3dg9) are superposed onto Tyr133 η-oxygen, Water molecules of GluR and AspR
aligning with Tyr133 η-oxygen are shown as small spheres. Cys194 sulphur and
Val195 backbone nitrogen. Hydrogen bonds involved in ligand binding are shown
for NfMI (green broken line) and for GluR (blue broken line).
As expected, the two cysteines conserved in racemases are also structurally
conserved in NfMI. The Cys194 is located on the more stable domain 2, the side of the
active site that is structurally strongly conserved, whereas Cys76 is embedded in the
more flexible domain 1, which changes according to the bound ligand in GluRs and
contains the glycine in AMDs. Furthermore, the position of Cys76 differs considerably
from the equivalent positions in the other enzymes. The backbone is about 1.3 Å
further away from the Cys194 side, and the side chain is turned approximately 120 °
away from the active site compared to the situation in EfGluR pointing into the protein
core. It is bound in a small, largely hydrophobic pocket formed by Val9, Pro11, Met40,
Met53 and Tyr74. This results in a large distance of 4.3 Å between the positions of the
equivalent sulphur of NfMI and EfGluR.
Based on the conservation of the dioxyanion binding site and the bound TRIS
molecule, maleate and fumarate molecules were modelled into the active site.
Fumarate and maleate both have a similar molecular volume (80 Å3) and surface (265
and 271 Å2) to TRIS and should therefore fit into the cavity as observed in the structure
(Fig. 5.5). TRIS has three oxygen positions of which one is bound to the remnant of the
dioxyanion whole (O1), one is close to Cys76 (O2) and one is bound to Asn14 in the
back of the active site (O3). Moreover, the distance between two oxygen atoms of
TRIS approximately corresponds to the distance between an inner (OA) and an outer
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oxygen (OB) of each carboxyl group in maleate. Putting one oxygen atom of maleate
into the conserved “dioxyanion” position and aligning it with the TRIS oxygen atoms,
four possible positions for maleate remain. However, only two of the four positions do
not result in major clashes. One position exposes the double bond carbon (C3) to
Cys76 whereas the other exposes the second carboxyl group to Cys76. In both
orientations the corresponding fumarate resulting from a simple superposition of the O1
oxygen atoms and the double bond slightly clashes with Met42. This does not take into
account other binding possibilities of fumarate or active site rearrangements as there is
in principle enough space in the active site and flexibility in the methionine side chain
(Fig. 5.7).
As a second substrate modelling approach, docking using the software AutoDock was
run. In this approach, no bias from the binding of TRIS is introduced as the substrate is
fitted into a space grid defining the active site as probabilities of the presence of certain
atom types. The 100 most likely positions of maleate all corresponded within a very low
deviation to the orientation having the carboxyl group exposed to Cys76 (Fig. 5.7 top).
According to AutoDock, the chance of the orientation having the double bond carbon
C3 exposed to Cys76 (Fig. 5.7 bottom) is there for less than 1% (Data not shown). This
result has to be considered with care as the flexibility of the protein was not taken into
account.
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Figure 5.7. Scenarios of ligand binding. Maleate oxygens are superposed onto
the TRIS oxygens in two orientations conserving the dioxyanion binding site and
minimising clashes between atoms. Subsequently, fumarate molecules (light
colours) are superposed onto the maleate molecules (dark colours). The relative
position of EfGluR Cys74 is shown in blue. Top: Stereoview of orientation exposing
the carboxyl group to Cys76. Bottom: Stereoview of orientation exposing the
maleate double bond to Cys76.
5.3.5 Oxidation Resistance Involving Met197
By mutating a conserved methionine close to the active site to cysteine in Serratia
marcescens MI (SmMI, Met197 in NfMI) it was reported that the enzyme became more
resistant to oxidation by H2O2 whilst being only slightly less active (103). However, the
authors did not give a mechanistic explanation for this. Despite the Val195 and Gln196
between Met197 and the active site Cys194, they are structurally adjacent to each
other. Yet, the sulphur atoms are not in contact as Pro132 is intruding the space
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between them. These are all residues that are conserved between the different
sequences (see Appendix C). The sulphur atom of a cysteine in the same place could
be in contact with Cys194 as it would pass below Pro132. Additionally Met197 is also in
close proximity of the residues Ile169 between α-helix H and I and Val174 on helix I
being close adjacent to the active site covering loop in domain 2 (data not shown).
5.4 Discussion
Despite the low sequence identity to AMDs and racemases, the structure of NfMI
clearly shows that the enzyme is part of the Asp/Glu racemase superfamily. It contains
its characteristic features like the pseudo dyad of two Rossmann fold domains. Also the
two catalytic cysteines are situated at the same positions in small conserved stretches
of the protein backbone (48,62,71). Like the other superfamily members, NfMI accepts
a small carboxylic acid as substrate (dicarboxylic acid in all cases except for
hydantoins). The bound substrate is completely buried under covering loops following
the second β-strands on each domain, which shield the reaction from bulk water. In
contrast to GluRs, AspRs and AMDs the dioxyanion hole is less pronounced and offers
less stabilisation of the intermediate as in the former enzymes. MIs seem to share this
loss of dioxyanion hole strength with HydR that even lack the Tyr as in BbAMD or
Thr/water as in GluR and AspR for dienolate binding.
The contact area between two monomers is large enough to expect a stable dimer in
solution. The crystal structure therefore confirms the dimeric state of NfMI observed by
DLS. The interaction between the dimers is most probably an artefact from the
crystallisation process that is helped by Ca2+. To confirm more conclusively that this
multimeric state is really present in solution, a calibration using gel filtration would be
needed. If possible this would have to be done at low concentration more similar to
physiological concentrations where the enzymes could still be present as monomers.
The structure allows speculation about the reason for the reduction of oxidation
sensitivity resulting from the mutation of conserved Met197 to cysteine. One possibility
would be the increase in size of oxidised Met197 interfering with the activity through
displacement of the neighbouring catalytic Cys194 or Tyr133 involved in substrate
binding. The proximity of Met197 to the covering loop on domain 2 could also mean
that it does not properly close anymore. By reducing the size of the amino acid in this
position these effects would not occur anymore. Alternatively, the thiol of cysteine
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would be able to contact Cys194 below Pro132 allowing it to reduce the catalytically
active form if it is inactivated by oxidation.
The high B-factor and poor electron density suggest a high flexibility in various parts of
the protein, including the covering loops, the stretch containing Cys76 as well as the
whole domain 1. This flexibility might be an explanation for the anisotropy of the crystal
and thus the relatively low resolution of the X-ray diffraction. Although this could also
simply be due to the elongated shape of the asymmetric unit, the flexibility can also be
observed in other superfamily members. In one structure of BbAMD (PDB 2vlb) the
four molecules in the asymmetric unit show significant conformational differences (88).
The different glutamate racemase adopt different structures according to the binding of
different ligands. Also in these enzymes the flexibility is especially pronounced in
domain 1. The flexibility could therefore be an inherent property of the whole
superfamily.
The proposed mechanisms of the decarboxylase and racemases do not largely depend
on flexibility. Only the access of the substrate to the active site requires the covering
loops to move. For NfMI, however, the conformation of maleate and fumarate differ
substantially requiring a large space when converted, which involves a flip or rotation of
4.6 Å of oxygen OA around the double bond axis. The rotation of the carboxyl group
around carbon C2-C3 bond would require an additional volume of 120 Å3, more than
doubling the space requirement for the active site. For this movement to be possible,
there must either be large space available or the enzyme has to be very flexible.
Although the active site volume of 237 Å3 is numerically enough it does not account for
shape. The observed flexibility is, therefore, probably crucial for the isomerisation
activity. The inherent flexibility of the superfamily may have allowed the evolution of the
new activities. Unfortunately, it is very difficult to observe the flexibility in an enzyme in
action. Molecular dynamics simulation would be a way of showing possible movements
in loops and in the active site.
Mutational studies have shown that the mechanism of isomerisation involves both
cysteines (see Chapter 4) (104). This is also underpinned by the fact that the cysteines
in the other superfamily members are also the catalytic residues. However, in both
models for the possible orientation of maleate in the active site the substrate lacks
direct contact with Cys76. Given the apparent flexibility of domain one and Cys76 with
its surroundings it is reasonable to imagine that a reorientation occurs upon binding of
the correct substrate. In this case, Cys76 would take a position more similar to that in
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its homologues. As Cys76 is bound into a small hydrophobic pocket only little energy is
necessary for breaking the interaction.
Considering the apparent flexibility of the protein, the models of the substrate binding
are only speculative. However, the conservation of the dioxyanion hole conformation
with Leu77, Cys194 and Val195 suggests that this binding site is conserved. For the
decision on the orientation of maleate and fumarate, clearly more data are needed. The
orientation found by the docking experiment strengthens the case for the orientation
exposing the carboxyl group to Cy76. Crystals with bromomaleate inhibitor bound or
crystals of active site mutants with the substrate bound should give more insight on the
mode of substrate binding.
The implications of the structural data of the present chapter and biochemical data of
the previous chapter for the reaction mechanism will be discussed in the general
discussion (Chapter 6). Different scenarios for the reaction mechanism will be
discussed.
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Chapter 6
General Discussion
6.1 Evolution of the Asp/Glu Racemase
Superfamily
Taken together, the sequence similarity, the conservation of the protein fold and the
similarity of the mechanism reconfirm that the HydR, AMDs and MI are part of the
Asp/Glu racemase superfamily. Superfamily is the appropriate term as clearly the
homology is present, the reaction intermediate seems to be conserved but the activities
are various (46).
It therefore becomes interesting to speculate about the evolution of the superfamily,
even though this is not the main scope of this study. The phylogenetic tree shows clear
grouping of the activities, which allowed the prediction the NfMI function (Fig. 1.21).
From the failure of predicting the activity of the other homologues it can be concluded
that the assignment of group activities is more detailed than previously thought. As
there was no outgroup defined, the tree is not rooted. On the other hand GluRs are, at
least in some organisms, essential for cell wall synthesis and had to be present for a
long time in evolutionary terms. HydR, MI and AMD activities seem to be involved in
the catabolism of special nutrients and are not absolutely required for survival. It is
therefore reasonable to set the evolutionary origin of the superfamily at GluRs. This
would explain the large sequence variation within GluRs compared to the other
activities like in AMDs.
Starting from GluRs, only minor arrangements in the active site would have to be made
to evolve into AspR. The catalysis is conserved completely and the substrate binding
only changes by a little. To evolve HydR, the deprotonation and reprotonation
mechanism would still be conserved but the stabilisation of the intermediate needs
adjustments and the formation of the enzyme-substrate complex needs a much larger
binding pocket. This change could have allowed the evolution of a very different
mechanism involving rotation around a carbon-carbon bond such as with the MI. The
resulting increased flexibility of the active site could have lead to the possibility of a
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second carboxyl group to binding and the increased space could have allowed an aryl
group to bind; the requirements for AMDs. The cysteine on domain 1 would then have
lost its function and the mutated glycine allowing for more space. It has to be added
that the natural substrate of AMDs is not known at present.
Given the pseudo 2-fold symmetry in the protein structures it has been hypothesised
that these arise from an ancient gene duplication (143). No mention has been made of
the original gene’s function.
The tested homologues in Chapter 3 are not AMDs and Pfe seems not to be a MI. This
corresponds well to the details in phylogenetic tree where the homologues form three
distinct groups corresponding to the observation of their genomic context. The group of
Sme and Mle are both from rhizobial species and embedded into possible amino acid
degradation operons. The group with RseD, SceD and Sae containing an aspartate
residue at the catalytic position on domain 2 are adjacent to their paralogue with a
double cysteine (RseC, SceC and the paralogue of Sae that was not tested). Ste, Pfe,
RseC, SceC make the last group. Three more different activities can thus be expected
to be present in the Asp/Glu racemase superfamily.
6.2 Decarboxylation of Malonates
Of all the enzymes tested in the present work, only BbAMD was active against
arylmalonates. Starting from the sequence annotations in the databases and the
conserved active site residues for the active site, this was at first surprising. The fact
that it was possible to confer racemase activity to BbAMD by simply mutating Gly74 to
cysteine and subsequently change the product enantiospecificity of BbAMD by further
replacing Cys188 to serine instigated initial confidence of being able to transform any
superfamily activity into another superfamily activity (79).
Reconsidering the case, it appears much less surprising that the homologues lacked
AMD activity and that Pfe does not catalyse other reactions (Fig. 6.1). The groups of
the phylogenetic tree cluster well (Fig. 1.21). The sequence identities of below 30% are
generally considered too low for predictions. The homologues have differences in the
amino acids crucial to BbAMD activity. Given the completely different structural
requirements of MIs and AMDs that are so close in the phylogenetic tree the failure of
transforming RseC into a decarboxylase by one or two mutations is not surprising.
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The superfamily enzyme structures seem to be very flexible over a long term
evolutionary time scale but the enzymes have no apparent promiscuous activities and
cannot be transformed to different catalytic activities by simple point mutations. The
binding of the substrate to the active site results in a complete covering of the substrate
by the covering loops requiring theses loops to be very flexible. This was observed in
crystals structures of superfamily members that were present in open and closed
forms, had changed loop conformations in different molecules of the asymmetric unit
and high B-factors of the loops. The requirements for these loops are difficult to
rationalise in terms of point mutations. The superfamily would therefore probably lend
itself more to directed evolution approaches than to rational engineering. However, an
efficient selection process would be needed that allows for reliable colony screening
and/or screening of multi-well plates. A better understanding of the colorimetric
decarboxylation assay, not applied in this study, would be useful for high throughput
approaches.
Alkylmalonates are neither converted by BbAMD nor by any of the homologues or
mutants of RseC and BbAMD. This is surprising in the sense that there is a great
variety of sequences and activities in the Asp/Glu racemase superfamily. Thus, one
would have expected that there are at least residual activities towards these
compounds. On the other hand, the chemistry of decarboxylation in general requires
enzymatic mechanisms that involve activation by oxidation or binding to cofactors such
as coenzyme A, phosphopantetheine, thiamine diphosphate, pyridoxal phosphate or
biotin. Retrospectively it is therefore reasonable to expect some restriction in the range
of substrates accepted.
Decarboxylation results in the transfer of one electron to the α-carbon, which has to be
stabilised. In AMDs the dioxyanion hole together with the hydrophobic pocket for the
carboxylate are responsible for the destabilisation of the cleaved carboxylate as well as
the stabilisation of the decarboxylated intermediate. However, the additional electron
withdrawing capacity of the aryl- or alkenyl group is required. The electron donating
effect of alkyl groups would be expected to destabilise the intermediate and therefore
to deactivate the leaving carboxyl group making it more difficult to decarboxylate.
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Table 6.1. Summary of tested alternative activities.
These reasons taken together seem to suggest that the only viable routes to the
production of chiral alkylalkanoates are substrate engineering or utilisation of a
cofactor-dependent enzyme. Substrate engineering would involve the introduction of an
electron withdrawing group as substituent. Alkenyl groups seem to be very suitable but
a range of other groups could be considered introducing other functions that would
need to be converted to aliphatic chains if required (67). The use of cofactor-dependent
enzymes is unattractive because of the cost of cofactors; however, the use of whole
cell systems using altered metabolic routes in the original host or engineered pathways
in heterologuous hosts could represent a feasible alternative. The fact that the
substrate has no problem entering the cell is, in principle, encouraging in this respect.
Whether engineering the whole metabolism is possible depends on the nature of the
enzyme system. Factors such as the solubility of the enzymes, requirements for
subcellular location and inhibition will play a role.
In another alternative approach to mining known genomes, the microbial diversity of
the soil was mined using selective enrichment cultures (Appendix D). This shows that
there are indeed organisms capable of growing on alkylmalonates. Because of time
constraints, the isolates could not be characterised further to determine the responsible
biocatalysts or to determine whether decarboxylation is indeed the first step in the
degradation. It was shown that there exist phosphopantetheine-dependent
decarboxylase pathways for the decarboxylation of malonate in soil bacteria
(30,31,152). It is therefore possible that the identified soil isolates are using the same
or a similar pathway. The results show in addition that there are microorganisms
capable of growing on these substrates making it more likely to find a microorganism
suitable for engineering.
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6.3 Reaction Mechanism of NfMI
The cis-trans isomerisation of maleate to fumarate must involve a free rotation of one
carboxyl group around the bond between carbon C2 and C3. It will therefore involve a
reversible saturation of the double bond during the course of the reaction. Cys76 and
Cys194 are conserved catalytic residues in the Asp/Glu racemase superfamily and
were shown to be indispensable for the activity of NfMI. They can therefore be
assumed to be the catalytic residues. At the pH range where the enzyme is active
maleate and fumarate are deprotonated.
The racemisation and decarboxylation reaction mechanisms of the superfamily share a
common enediolate intermediate that is stabilised by the conserved dioxyanion hole of
the active site. A possibility to achieve the formation of an enediolate from maleate
through the action of a cysteine would be a nucleophilic attack by the thiolate on one of
the double bond carbons. The enediolate intermediate could then be stabilised by four
hydrogen bonds of the remnant dioxyanion hole and by the other cysteine (Fig. 6.2 A).
As replacing Cys76 with serine leads to complete loss of activity whereas replacing
Cys194 with alanine results in a low residual activity, it is more likely in this case that
Cys76 would be performing the nucleophilic attack. The flexibility of Cys76 and that
side of the active site would be necessary for the movements involved in rotating the
free carboxyl group around the carbon C2 and C3 bond. The result of docking the
substrate into the active site led to the preference of the carboxyl group exposed to
Cys76 rather than the double bond, which seems to speak against this mechanism.
Then again, Cys76 would have to undergo less movement during the rotation by
attacking C3 from re-face that is exposed in this orientation than by attacking from the
si-face.
Succinylations of cysteines have been reported as posttranslational modification of
proteins (153). It could therefore be imagined that a nucleophilic attack on C3 of
maleate could lead to a succinyl intermediate without the need for stabilisation. In this
case the carboxyl at the dioxyanion hole would be free to rotate instead of Cys76
turning around with the rest of the molecule. The thiol of Cys194 could be responsible
too for the protonation of the intermediate after the nucleophilic attack. The protonation
would be favoured as the dioxyanion hole is less electron withdrawing than in
decarboxylases and racemases leaving more negative charge at C2 (Fig. 6.2 B).
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The fact that maleamide and citraconate are not substrates for NfMI could be explained
by the hypothesis of a nucleophilic attack as both methyls and amides are either
electron donating or less electron withdrawing than hydrogen and carboxylate. On the
other hand, bromomaleate would not be expected to be a competitive inhibitor with this
mechanism as bromine is an electron withdrawing group, exposing C3 more to
nucleophilic attack than in the case of maleate. This would either result in an improved
substrate or an irreversible inhibitor rather than a competitive inhibitor. There is also no
evidence by MS for a covalent adduct of the substrate to NfMI during incubation at
alkaline pH.
As cysteine is generally protonated at physiological pH a mechanism for deprotonation
of the attacking thiol has to be provided. In cofactor-independent racemases this is not
fully understood either. It has been proposed that a neighbouring aspartate or the N-
terminal dipoles adjacent α-helices would stabilise the deprotonated state (63). There
are no adjacent acids to Cys76 but α-helices D and F do point to its position. In
addition, Cys76 is bound in a hydrophobic pocket that could provide an environment to
lower its pKa. Similar destabilisation of an active site lysine was observed in
acetoacetate decarboxylase (36).
Other than by thiol addition, chemical catalysis can also be achieved through radicals
or with acids. Although not related to MIs, the enzymes isopropylmalate isomerase
(able to dehydrate malate and hydrate maleate) and fumarate hydratase are catalysing
this reaction (154-156). The cysteines of NfMI could therefore also act as general acid
and base, activating water, which then performs a nucleophilic attack on the double
bond. The other cysteine could then stabilise the negative charge or fully protonate the
intermediate (Fig. 6.2 C). The fact that TRIS binds to the active site with three alcohols
might indicate the binding of water besides the substrate. In spite of this, there is no
evidence for a stable intermediate during the reaction as all maleate was
stoichiometrically converted into fumarate without the appearance of other HPLC peaks
during the reaction.
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Figure 6.2. Three possible reaction mechanisms. (A) Mechanism conserving
the role of the dioxyanion hole, initiated by a nucleophilic attack on a double bond
carbon. (B) The same as (A) but with a succinyl intermediate independent of
dioxyanion stabilisation. (C) General acid/base mechanism involving the activation
of a water molecule.
The behaviour of bromomaleate is surprising in that it is not a substrate and is an
inhibitor. It cannot be determined at the moment whether this is because of a steric
effect rather than an electrostatic one. The size of bromine could restrict the access of
the cysteine to the carbon or simply interfere with substrate binding. A simple steric
effect is unlikely as citraconate is not an inhibitor but it could be a combined effect.
Fluoromaleate would be a good candidate to test this as it is isosteric with maleate and
isoelectric with bromomaleate. If it is an inhibitor similar to bromomaleate then the
electrostatics is everything. If it is a substrate then electrostatics has to be combined
with size. Solving the structure of the complex of NfMI bound to bromomaleate could
also disentangle the two effects. Some weakly diffracting crystals have already been
obtained.
6.4 Outlook
The main target of the work with NfMI is the elucidation of the mechanism as this would
improve the understanding of the whole Asp/Glu racemase superfamily. Knowledge of
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the mode of ligand binding is crucial to this understanding. It has to be determined
whether the ligand binds covalently to the protein and if it binds to the cysteine. The
range of possible functions of the cysteines could be narrowed down by determining
their pKa by plotting the pH versus the kcat/KM. The role of the cysteine could also be
narrowed down by complementing an inactive mutant with a soluble thiol. If a thiol
complemented a lacking active site cysteine this would show that the thiol acts in a
general way not requiring the precise microenvironment and positioning, rather than
stabilising an intermediate with precisely orientated hydrogen bonds. The determination
of the ligand binding mode by crystallography would also allow differentiating between
different attacking points of the active site cysteines with the whole protein
environment, including the flexible loops and Cys76. Assisting residues can more
easily be identified in substrate/enzyme or inhibitor/enzyme complex, which would
further illuminate the mode of action. Most importantly the transition state of the
reaction and the mode of stabilisation by the enzyme have to be determined. It is not
clear what part of the substrate is rotating and how it is allowed. Molecular dynamics
simulations could show more precisely how flexible the covering loops are and what
portion of the active site allows the carboxyl to rotate.
Once the mechanism is better understood, it would be possible to focus on an
extension of the substrate specificity. Substrates used unsuccessfully in this work, such
as citraconate or mesaconate would lend themselves as potential new substrates. An
enzyme with an extended substrate range would be highly interesting for industrial
applications as it has the potential capacity of changing the specificities of
transformations. This could be applied in enzymatic resolution biotransformations.
Maleate and fumarate are both symmetrical molecules and in this respect less
interesting for industry. Both citraconate and mesaconate are small variations of
maleate and fumarate making them asymmetrical. Substituting the double bond could
then be performed in an asymmetric manner. An enzyme with a broader substrate
range also has the advantage of being suitable for directed evolution approaches as
these require residual activities to start with.
Enzymes from the Asp/Glu racemase superfamily are potentially ideal tools for industry
as they are small bacterial proteins, easy to produce and independent of cofactors.
GluRs and AMDs have already met broad interest. Elucidating the activity of the
BbAMD homologues represents an opportunity to find more activities in a group of
proteins that are easy to handle. Unfortunately it is a difficult task to test for unknown
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activities. Therfore, this highlights the importance of understanding the mechanism of
MIs as unusual members of the superfamily.
The common characteristics of all reactions could be taken as starting point for the
discovery of new activities. All substrates are small molecules (<200 Da) with a
carboxylate at one end, HydR being the exception. All reactions proceed through a
stabilised enediolate intermediate that is protonated during the reaction, MIs may be
different. If a reaction fulfilling these properties is required, it is worth testing the
substrates on the cloned homologues. Other approaches could include screening for
ligands by NMR or computationally model ligands into the active site. The
computational approach could be supported by restricting the possibilities using the
conditions mentioned above. It has been shown that it is possible to engineer
completely new activities on suitable protein scaffolds combining the power of
computational protein modelling with directed evolution approaches if the appropriate
chemical reaction partners and stabilising residues for the reaction are given (157).
Reaction partners for maleate isomerisation have been identified for a long time
already (108-110) and a nearly perfect protein scaffold is known for NfMI now. It should
therefore be possible to perform the reverse process and identify the role of the
catalytic residues computationally. Using similar mechanisms, it should also become
possible to assign functions to unknown enzymes in the Asp/Glu racemase
superfamily.
If the decarboxylation of alkylmalonates rather than harnessing the superfamily is the
primary goal, an analysis of the isolates growing on these substrates, described in the
Appendix D, would be necessary. An analysis of the pathway could involve feeding of
intermediates to test whether they are accepted as substrates or analysing a mutant
library able to grow or not on the substrate or intermediates. Against the evidence
shown in Appendix D, the activity could still be due to a single soluble enzyme. If this is
the case, it could be possible to isolate the activity by targeted purification of the
catalyst and sequencing of the protein to design degenerate primers able to amplify the
gene from genomic DNA.
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Appendix A
BbAMD Gene Sequence
720 bp codon-optimised gene without stop codon.
1 60
ATGCAGCAGGCGAGCACCCCGACCATTGGCATGATTGTGCCGCCGGCAGCGGGTCTGGTT
CCGGCGGATGGCGCGCGTCTGTATCCGGATCTGCCGTTTATTGCGAGCGGCCTGGGCCTG
GGTAGCGTTACCCCGGAAGGCTATGATGCGGTGATTGAAAGCGTGGTGGATCATGCGCGT
CGTCTGCAGAAACAGGGTGCGGCGGTGGTGAGCCTGATGGGCACCAGCCTGAGCTTTTAT
CGTGGTGCGGCGTTTAACGCGGCGCTGACCGTGGCGATGCGTGAAGCGACCGGTCTGCCG
TGCACCACCATGTCTACCGCGGTGCTGAATGGTCTGCGTGCGCTGGGTGTGCGTCGTGTT
GCGCTGGCCACCGCGTATATCGATGATGTGAACGAACGTCTGGCCGCGTTTCTGGCCGAA
GAAAGCCTGGTGCCGACCGGTTGTCGTAGCCTGGGCATTACCGGCGTGGAAGCGATGGCG
CGTGTGGATACCGCGACCCTGGTGGATCTGTGCGTGCGTGCGTTTGAAGCGGCACCGGAT
AGCGATGGCATTCTGCTGTCTTGCGGCGGTCTGCTGACCCTGGATGCGATTCCGGAAGTG
GAACGTCGTCTGGGCGTGCCGGTGGTTAGCAGCAGCCCGGCAGGCTTTTGGGATGCGGTG
CGTCTGGCCGGTGGTGGTGCGAAAGCGCGTCCGGGCTATGGCCGTCTGTTTGATGAAAGC
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Appendix B
Sequence of pET-YSBLIC3C Plasmid
5399 bp sequence based on pET-28a(+) with altered multiple cloning site. The BseRI
binding site is underlined. Two nucleotides are replaced by the insert during LIC
(between | and |). The added N-terminal His-tag sequence is shown in single letter
code including The HRV-3C protease binding site (><).
1 60
CTGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGC
GCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTT
CCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAG
GGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTT
CACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGT
TCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATT
CTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTT
AACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTCAGGTGGCACTT
TTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGT
ATCCGCTCATGAATTAATTCTTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTA
TTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAA
AACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACT
CGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAG
AAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGTTTATGCATTTCTTTC
CAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAA
CCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGA
CAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATA
TTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCA
GTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGC
ATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTA
CCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATT
GTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCC
ATGTTGGAATTTAATCGCGGCCTAGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACA
CCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGACCAAAATCCCTTA
ACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTG
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AGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGC
GGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAG
CAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAA
GAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGC
CAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGC
GCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTA
CACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAG
AAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCT
TCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGA
GCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGC
GGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTT
ATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCG
CAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCG
GTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATATGGTGCACTCTCAGT
ACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATACACTCCGCTATCGCTACGTGACT
GGGTCATGGCTGCGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTC
TGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGA
GGTTTTCACCGTCATCACCGAAACGCGCGAGGCAGCTGCGGTAAAGCTCATCAGCGTGGT
CGTGAAGCGATTCACAGATGTCTGCCTGTTCATCCGCGTCCAGCTCGTTGAGTTTCTCCA
GAAGCGTTAATGTCTGGCTTCTGATAAAGCGGGCCATGTTAAGGGCGGTTTTTTCCTGTT
TGGTCACTGATGCCTCCGTGTAAGGGGGATTTCTGTTCATGGGGGTAATGATACCGATGA
AACGAGAGAGGATGCTCACGATACGGGTTACTGATGATGAACATGCCCGGTTACTGGAAC
GTTGTGAGGGTAAACAACTGGCGGTATGGATGCGGCGGGACCAGAGAAAAATCACTCAGG
GTCAATGCCAGCGCTTCGTTAATACAGATGTAGGTGTTCCACAGGGTAGCCAGCAGCATC
CTGCGATGCAGATCCGGAACATAATGGTGCAGGGCGCTGACTTCCGCGTTTCCAGACTTT
ACGAAACACGGAAACCGAAGACCATTCATGTTGTTGCTCAGGTCGCAGACGTTTTGCAGC
AGCAGTCGCTTCACGTTCGCTCGCGTATCGGTGATTCATTCTGCTAACCAGTAAGGCAAC
CCCGCCAGCCTAGCCGGGTCCTCAACGACAGGAGCACGATCATGCGCACCCGTGGGGCCG
CCATGCCGGCGATAATGGCCTGCTTCTCGCCGAAACGTTTGGTGGCGGGACCAGTGACGA
AGGCTTGAGCGAGGGCGTGCAAGATTCCGAATACCGCAAGCGACAGGCCGATCATCGTCG
CGCTCCAGCGAAAGCGGTCCTCGCCGAAAATGACCCAGAGCGCTGCCGGCACCTGTCCTA
CGAGTTGCATGATAAAGAAGACAGTCATAAGTGCGGCGACGATAGTCATGCCCCGCGCCC
ACCGGAAGGAGCTGACTGGGTTGAAGGCTCTCAAGGGCATCGGTCGAGATCCCGGTGCCT
AATGAGTGAGCTAACTTACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAA
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ACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTA
TTGGGCGCCAGGGTGGTTTTTCTTTTCACCAGTGAGACGGGCAACAGCTGATTGCCCTTC
ACCGCCTGGCCCTGAGAGAGTTGCAGCAAGCGGTCCACGCTGGTTTGCCCCAGCAGGCGA
AAATCCTGTTTGATGGTGGTTAACGGCGGGATATAACATGAGCTGTCTTCGGTATCGTCG
TATCCCACTACCGAGATATCCGCACCAACGCGCAGCCCGGACTCGGTAATGGCGCGCATT
GCGCCCAGCGCCATCTGATCGTTGGCAACCAGCATCGCAGTGGGAACGATGCCCTCATTC
AGCATTTGCATGGTTTGTTGAAAACCGGACATGGCACTCCAGTCGCCTTCCCGTTCCGCT
ATCGGCTGAATTTGATTGCGAGTGAGATATTTATGCCAGCCAGCCAGACGCAGACGCGCC
GAGACAGAACTTAATGGGCCCGCTAACAGCGCGATTTGCTGGTGACCCAATGCGACCAGA
TGCTCCACGCCCAGTCGCGTACCGTCTTCATGGGAGAAAATAATACTGTTGATGGGTGTC
TGGTCAGAGACATCAAGAAATAACGCCGGAACATTAGTGCAGGCAGCTTCCACAGCAATG
GCATCCTGGTCATCCAGCGGATAGTTAATGATCAGCCCACTGACGCGTTGCGCGAGAAGA
TTGTGCACCGCCGCTTTACAGGCTTCGACGCCGCTTCGTTCTACCATCGACACCACCACG
CTGGCACCCAGTTGATCGGCGCGAGATTTAATCGCCGCGACAATTTGCGACGGCGCGTGC
AGGGCCAGACTGGAGGTGGCAACGCCAATCAGCAACGACTGTTTGCCCGCCAGTTGTTGT
GCCACGCGGTTGGGAATGTAATTCAGCTCCGCCATCGCCGCTTCCACTTTTTCCCGCGTT
TTCGCAGAAACGTGGCTGGCCTGGTTCACCACGCGGGAAACGGTCTGATAAGAGACACCG
GCATACTCTGCGACATCGTATAACGTTACTGGTTTCACATTCACCACCCTGAATTGACTC
TCTTCCGGGCGCTATCATGCCATACCGCGAAAGGTTTTGCGCCATTCGATGGTGTCCGGG
ATCTCGACGCTCTCCCTTATGCGACTCCTGCATTAGGAAGCAGCCCAGTAGTAGGTTGAG
GCCGTTGAGCACCGCCGCCGCAAGGAATGGTGCATGCAAGGAGATGGCGCCCAACAGTCC
CCCGGCCACGGGGCCTGCCACCATACCCACGCCGAAACAAGCGCTCATGAGCCCGAAGTG
GCGAGCCCGATCTTCCCCATCGGTGATGTCGGCGATATAGGCGCCAGCAACCGCACCTGT
GGCGCCGGTGATGCCGGCCACGATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCG
AAATTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATA
ATTTTGTTTAACTTTAAGAAGGAGATATACCATGGGCAGCAGCCATCATCATCATCATCA
M G S S H H H H H H
CAGCAGCGGCCTGGAAGTTCTGTTCCAGGGACCAGCAA|GG|CGCGCCTTCTCCTCACAT
S S G L E V L F Q><G P A
ATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGCGGATCCGAATTCGAGCTCCGTCGA
CAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAA
AGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCT
TGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGAT
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Appendix C
Alignment of Asp/Glu Racemase
Superfamily Members
Sequences of all selected homologues (see Chapter 3, Table 3.1), all experimentally
confirmed activities and all known structures were aligned using ClustalW2. The highly
conserved stretches from the active site used to build the ClustalW2 guide tree (Fig.
1.21) are marked with a line on top of the alignment (for details see Chapter 2).
The positions of the conserved catalytic cysteines are marked with # on top of the
alignment. The active site residues of BbAMD are marked in underlined bold face.
UniProt accession codes are followed by the name and X if structure coordinates are
available. Sequences discussed in results chapters are underlined.
Abbreviations used are: AfMI, Alcaligenes faecalis; PhAspR, Pyrococcus horikoshii;
ApGluR, Aquifex pyrophilus; AsAMD, Achromobacter sp. KU 1311; BaGluR, Bacillus
anthracis; BaGluR, Bacillus anthracis; BbAMD, Bordetella bronchiseptica; BpGluR,
Bacillus pumilus; BsGluR, Bacillus subtilis; BsMI, Bacillus stearothermophilus; EcAMD,
Enterobacter cloacae; EcGluR, Escherichia coli; EfAspR, Enterococcus faecium;
EfGluR, Enterococcus faecium; EfGluR, Enterococcus faecalis; HpGluR, Helicobacter
pylori; LbGluR, Lactobacillus brevis; LcAspR, Lactobacillus casei; LdAspR,
Lactobacillus delbrueckii; LfGluR, Lactobacillus fermentum; LmGluR, Listeria
monocytogenes; LpGluR, Lactobacillus plantarum; Mle, Mesorhizobium loti; MsAMD,
Mesorhizobium sp. BNC1; NfMI, Nocardia farcinica; Pfe, Pyrococcus furiosus; PhAspR,
Pyrococcus horikoshii; PhHydR, Pyrococcus horikoshii; PpGluR, Pediococcus
pentosaceus; PsHydR, Pseudomonas sp. NS671; RseC, Rhodococcus sp. RHA1;
RseD, Rhodococcus sp. RHA1; Sae, Streptomyces avermitilis; SaGluR,
Staphylococcus aureus; SceC, Streptomyces coelicolor; SceD, Streptomyces
coelicolor; ShGluR, Staphylococcus haemolyticus; Sme, Sinorhizobium meliloti;
SmHydR, Sinorhizobium meliloti; SmMI, Serratia marcescens; SpGluR, Streptococcus
pneumoniae; SpGluR, Streptococcus pyogenes; Ste, Sulfolobus tokodaii.
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Q8Y7N7 LmGluR X ----------------------MKQAIGFIDSGVGGLTVVREVLKQLPHEQVYYLGDTAR-------------CPYGPRDKEEVAKFTWEMTNFLVDRG-
Q6GHT5 SaGluR X ----------------------MNKPIGVIDSGVGGLTVAKEIMRQLPNETIYYLGDIGR-------------CPYGPRPGEQVKQYTVEIARKLMEFD-
P52974 ShGluR ----------------------MNKPIGVIDSGVGGLTVAKEIMRQLPNETIYYLGDIAR-------------CPYGPRPGDEVKQFTTQLANKLMQFD-
Q81LA8 BaGluR X --------------------MKLNRAIGVIDSGVGGLTVAKELIRQLPKERIIYLGDTAR-------------CPYGPRSREEVRQFTWEMTEHLLDLN-
Q3XZW8 EfGluR X -------------MKKRMIRLTDNRPIGFIDSGVGGLTVVKEALKQLPNENILFVGDTAR-------------CPYGPRPAEQVIQYTWEMTDYLVEQG-
Q81UL8 BaGluR X -----------------MSVCHKHSVIGVLDSGVGGLTVASEIIRQLPKESICYIGDNER-------------CPYGPRSVEEVQSFVFEMVEFLKQFP-
P94556 BsGluR X ---------------------MLEQPIGVIDSGVGGLTVAKEIMRQLPKENIIYVGDTKR-------------CPYGPRPEEEVLQYTWELTNYLLENHH
Q7M0V6 BpGluR ---------------------MLDQPIGVIDSGVGGLTVAKEIMRQLPKEKIIYVGDTKR-------------CPYGPRKEEEVLHYTWEMAHYLLKHHH
Q836J0 EfGluR X --------------------MSNQEAIGLIDSGVGGLTVLKEALKQLPNERLIYLGDTAR-------------CPYGPRPAEQVVQFTWEMADFLLKKR-
Q88V19 LpGluR --------------------MANEHAIGFMDSGVGGLTVVKQALKQLPRETVYFIGDQAR-------------LPYGPRPAEQVRTFSFQMADFLMAKQ-
P63640 SpGluR ---------------------MDNRPIGFLDSGVGGLTVVRELMRQLPHEEIVYIGDSAR-------------APYGPRPAEQIREYTWQLVNFLLTKD-
Q9A1B7 SpGluR X ---------------------MDTRPIGFLDSGVGGLTVVCELIRQLPHEKIVYIGDSAR-------------APYGPRPKKQIKEYTWELVNFLLTQN-
Q03469 LfGluR ---------------------MDNRPIGVMDSGLGGLSVVRVIQQKLPNEEVIFVGDQGH-------------FPYGTKDQAEVRQLALSIGAFLLKHD-
P48797 LbGluR ---------------------MQNDPIGLMDSGVGGLTVLKEVQRLLPTENTVFLGDQAR-------------LPYGPRSVAEVTMFTKQIAQFLRQQAR
Q08783 PpGluR ---------------------MDNRPIGFMDSGVGGLTVVKTAQKLLPNEEIIFIGDEAR-------------MPYGPRPTAEVVEFSRQMASFLMTKN-
P56868 ApGluR X ------------------------MKIGIFDSGVGGLTVLKAIRNRYRKVDIVYLGDTAR-------------VPYGIRSKDTIIRYSLECAGFLKDKG-
Q9ZLT0 HpGluR X ------------------------MKIGVFDSGVGGFSVLKSLLKARLFDEIIYYGDSAR-------------VPYGTKDPTTIKQFGLEALDFFKPHE-
P22634 EcGluR X ---MATKLQDGNTPCLAATPSEPRPTVLVFDSGVGGLSVYDEIRHLLPDLHYIYAFDNVA-------------FPYGEKSEAFIVERVVAIVTAVQERYP
O59384 PhAspR X ------------------------MKKIGIIGGTTPESTLYYYKKYIEISREKFEKYFYPELIIYSINFK--EFFQNPEGWEGRKKILINAAKALERAG-
O58403 PhAspR X ------------------------MKTIGILGGMGPLATAELFRRI-VIKTPAKRDQEHPKVIIFNNPQIPDRTAYILGKGEDPRPQLIWTAKRLEECG-
P29079 EfAspR -----------------------MENFFSILGGMG--TMATESFVRLINHRTKATKDQEY-------------LNYVLFNHATVPDRTAYILDRSEENPM
B3W8K5 LcAspR -----------------------MRQFFTVIGGMG--TPATESYVRLLNQRTHAHSDQEY-------------LNYILVNDATVPDRTDYILDHSKPSFY
Q1G8B6 LdAspR -----------------------MKHFFSIIGGMG--TIATESYVRLINHRVKISKDQDY-------------LNYILVNDAQVPDRTAYIKDHSQPNFF
O58781 PhHydR X ---------------------MYRMDKYTIGLIRVITLEDKEILNLHGRIIESAFPELKVVSRCIE---DQPKGIYNEETEREAEPKIIRLAKEFEREG-
Q00924 PsHydR ------------------------MKIKVINPNTTLAMTKG----IEHAAKSAARSDTQIVAVSPK---MGPASIESYYDEYLSIPGVIEEIKKGEEEG-
Q92ML1 RmHydR ------------------------MHIHLINPNSTASMTAQ----ALESALLVKHAHTHVSASNPT---DTPASIEGGADEAMSVPGMLAEIRQGEAQG-
Q5YXQ1 NfMI ---------------------MGIRRIGLVVPSSNVTVETEMPALLSR----HPGAEFSF------HSTRMRMHTVSPEGLAAMNAQRERCVLEIADAA-
Q9KWI0 SmMI --------------------MSNHYRIGQIVPSSNTTMETEIPAMLGARQLIRPE-RFTF------HSSRMRMKHVNKEELAAMDAESDRCALELSDAR-
O24766 AfMI ---------------------MKTYRIGQIVPSSNTTMETEIPAMLQARYAEFPEERFTF------HSSRMRMMHVNPEELKAMDIASDRCAVELSDAR-
Q9WX57 BsMI --------------------MAKHFRIGMIVPSSNTTMETEIPAMLQSRMKEIPEETFTF------HSSRMRMMHVTKEELKKMDEESDRCAIELSDAR-
Q987A4 Mle MKPLPEIKVYPKRPSLDDRPLDKRVGLIILATDHTSEPDFRRMVASERIGVHVARIP-------------YANPTTPENLRKMQPALTAGAALILPDEK-
Q92WC5 Sme MRTAVALSLAARRPRLDDRPLDKRIGLVILATDHTTEVDFQRMVASDRIGVYVTRIP-------------YANPVTPENLRAMQPSLTEAAALILPDET-
Q974K3 Ste X -------------------MPGGRGRIGVILPANNAGMEYDLWKMAPEGVSIHSTRM--------------KPTKGCEPENVEEFEKELKYSYSLLAEV-
Q8U183 Pfe -------------------MFGWRGRIGLLVPSSNTTMEMELHSYLPEGVSLHTSRI--------------PLKKVNEEELTKMVGYSIEGAKLLADAG-
Q0S7X3 RseC --------MLELNIPEFEGPIAQRG-IGIIAPFDLALERELWRWAPLEVSLHLARTP---------------YEPVPVSLEMAELVSERRHLMAATRDVL
Q93J74 SceC -----------MDISFLGGPAPQRG-VGVVAPFDFALDRELWRWVPDDVSLHMTRTP---------------FVPVEVSLDLARMVSEHETLGEAVRTLN
Q0S7X2 RseD ------------------MTSTPTPTVGFIYPDHAAEDDYPFAAEMLGVDLPVVHIY------------GTDLHAVPELLDLGSPEKLAGGAALLAEEK-
Q93J75 SceD ------------------MT-----ALGFLYPGHSGEDDYPRIEQLLGSDIRVDLVH---------TDIGEDAHRVDALLEMGSPRRLEAGVAELRLAG-
Q82CV3 Sae ------------------MT-----ALGFLYPGHSAEDDYPRIEQLLGSDIRLPLVH---------TDIGEDAHRVDALLEMGSAARLAAGVEELRLSG-
Q11DV3 MsAMD -------------------MSAEDPVIGLIVPPAAGLVPPEAVAMYPEVTFHASGLG---------------LKEMTPCGYAGVIDLVGDHAERHAQAG-
AsAMD ------------------MQQSSTPTIGMIVPPAAGLVPADGARLYPDLPFIASGLG---------------LGSVTPQGYDAVIESVVDHARRLREQG-
Q05115 BbAMD X ------------------MQQASTPTIGMIVPPAAGLVPADGARLYPDLPFIASGLG---------------LGSVTPEGYDAVIESVVDHARRLQKQG-
EcAMD ------------------MQQTSTPVIGMIVPPAAGLVPADGARLYPGLPFIASGLG---------------LGSVTPEGYDAVIESVVDHARRLKEQG-
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Q8Y7N7 LmGluR X --------------IKMLVIACNTATAAALYDIREKLDIPVIGVIQPG--SRAALKAT--RNNKIGVLGTLGTVESMAYPTALKGLNRRVEVDS-LACPK
Q6GHT5 SaGluR X --------------IKMLVIACNTATAVALEYLQKTLSIPVIGVIEPG--ARTAIMTT--RNQNVLVLGTEGTIKSEAYRTHIKRINPHVEVHG-VACPG
P52974 ShGluR --------------IKMLVIACNTATAVALEHLQQMLPIPVIGVIEPG--SRTAIMTT--KNQNVLILGTEGTIKSEAYRHHIKHINPNVHVLW-CGLPG
Q81LA8 BaGluR X --------------IKMLVIACNTATAVVLEEMQKQLPIPVVGVIHPG--SRTALKVT--NTYHVGIIGTIGTVKSGAYEEALKSINNRVMVES-LACPP
Q3XZW8 EfGluR X --------------IKMLVIACNTATAVALEEIKAALSIPVIGVILPG--TRAAVKKT--QNKQVGIIGTIGTVKSQAYEKALKEKVPELTVTS-LACPK
Q81UL8 BaGluR X --------------LKALVVACNTAAAATLAALQEALSIPVIGVIHPG--ARAAIKVT--KKGKIGVIGTVGTIQSNMYEKALHELDTYLKVHS-HACPT
P94556 BsGluR X --------------IKMLVIACNTATAIALDDIQRSVGIPVVGVIQPG--ARAAIKVT--DNQHIGVIGTENTIKSNAYEEALLALNPDLKVEN-LACPL
Q7M0V6 BpGluR --------------IKMLVIACNTATAIALDEIKATLDIPVIGVIQPG--ARTAIKVT--NNQHIGVIGTINTIKSEAYKEALLSLKAGLTVQS-LACPL
Q836J0 EfGluR X --------------IKMLVIACNTATAVALEEIKAALPIPVVGVILPG--ARAAVKVT--KNNKIGVIGTLGTIKSASYEIAIKSKAPTIEVTS-LDCPK
Q88V19 LpGluR --------------IKMLVIACNTATAAALPALRQQLSIPVIGVIAPG--SRAALKAS--HRNRIGVIATEGTIRSNAYRDAILTKDPTATVVS-QACPK
P63640 SpGluR --------------VKMIVIACNTATAVVWEEIKAQLDIPVLGVILPG--ASAAIKSS--QGGKIGVIGTPMTVQSDIYRQKIHDLDPDLQVES-LACPK
Q9A1B7 SpGluR X --------------VKMIVFACNTATAVAWEEVKAALDIPVLGVVLPG--ASAAIKST--TKGQVGVIGTPMTVASDIYRKKIQLLAPSIQVRS-LACPK
Q03469 LfGluR --------------VKMMVVACNTATAAALPALQAALPIPVIGVIEPG--ARAALAQD--KKGPIGVIATTATTTAGAYPATIERLAPGTPVIA-KATQP
P48797 LbGluR --------------IKALVIACNTATAAALTTMQQTLPIPVIGVIAPG--AQAAVQTT--RNHRIGVIATAGTVKSDQYRRDILAAAPNSQIFS-VACPE
Q08783 PpGluR --------------IKALVIACNTATNAALAVLQAELPIPVIGVILPG--AIAANRQT--KNQKIGVIATLGTIKSEAYPKALAEINTKLRAYP-VACQE
P56868 ApGluR X --------------VDIIVVACNTASAYALERLKKEINVPVFGVIEPG--VKEALKKS--RNKKIGVIGTPATVKSGAYQRKLEE--GGADVFA-KACPL
Q9ZLT0 HpGluR X --------------IELLIVACNTASALALEEMQKYSKIPIVGVIEPS--ILAIKRQVEDKNAPILVLGTKATIQSNAYDNALKQQ-GYLNISH-LATSL
P22634 EcGluR X --------------LALAVVACNTASTVSLPALREKFDFPVVGVVP-----AIKPAARLTANGIVGLLATRGTVKR-SYTHELIARFANECQIEMLGSAE
O59384 PhAspR X --------------AELIAFAANTP-HLVFDDVQREVNVPMVSIID-----AVAEEILKRGVRKVLLLGTKTTMTADFYIKTLEEKGLEVVVPN-DEEKE
O58403 PhAspR X --------------ADFIIMPCNTA-HAFVEDIRKAIKIPIISMIEET-----AKKVKELGFKKAGLLATTGTIVSGVYEKEFSKYGVEIMTPTEDEQKD
P29079 EfAspR PFLLDDIEKQNLLRPNFIVLTCNTA-HYFFEELQAATDIPILHMPREA--ANELVRQH-TTG-RVAILGTEGSMKAGIYEREVKNLGFETVIPD-TALQE
B3W8K5 LcAspR PDLLEDIQDQSLLNPEFMVIVCNTA-HYFYDQLAAATPIPLLHMPHLA--ISDMCERF-PDEKRVGLIATQGTIQDGIYSHEIETSGREVVLGD-QALQD
Q1G8B6 LdAspR NALKEDVLGQAKLGPDFMVMPCNTA-HYFYDDLAALTDIPFLHMMRIA--VHQYVDQF-PNSPKIGLIATEGSIYDHLYEDEIHRVGREVEFGG-PEIQP
O58781 PhHydR X --------------VDAIIISCAADP--AVEKVRKLLSIPVIGAGS---------------SVSALALAYGRRVGVLNLTEETPKVIRSILGNN-LIAED
Q00924 PsHydR --------------VDAFVIACWGDP--GLHAAREVTDKPVVGIAE-----------SSVYLASMLAARFSVVTVLPRIKTMLEDLVDSYGMQKRVLNIR
Q92ML1 RmHydR --------------VDAYVIACFDDP--GLHAAREVAKGPVIGICQ-----------AAVQVAMTISRRFSVITTLPRSVPIIEDLVSDYGAERHCRKVR
Q5YXQ1 NfMI --------------PEVILYACLVAVMVGGPGEHHRVESAVAEQLATGGSQALVRSSAGALVEGLRALDAQRVALVTPYMRPLAEKVVAYLEAEGFTISD
Q9KWI0 SmMI --------------VDVLGYACLVAIMAMGLGYHRESQARLAQVTKDNQAAAPVISSAGALVNGLKVIGAKRIALVAPYMKPLTQLVVDYIQHEGIEVKV
O24766 AfMI --------------MSVMAYACLVAIMAQGDGYHRVSQARLQNTVKENGVEIPVLSSAGALVDTLKEFGYKKVSIITPYMKPLTKRVADYIEAEGIEVQD
Q9WX57 BsMI --------------CDVLAYACLVAIMCQGPGYHEKSEARLASLTAQNGGAAPVISSAGALIDGIRTLGAKKIALIAPYMKPLTNQVIEYITASGIEVTD
Q987A4 Mle --------------LDAICYSCTSASVVIG--DAEIETAIQAAKPG-----VPVVTPPMAGVRGLNAFGVRRISILTPYTVETSRPMAAYFAARGFEIAS
Q92WC5 Sme --------------LDVVMYSCTSASVVIG--DREVAAAIKAAKPE-----AAVVTPTAASVQGLRALSANRISVLTPYTIETSRPMADYFAERGFAIDR
Q974K3 Ste X --------------SDIIIYGRTYG---------THKHAHVIKRVI-----KDVVIPEESVYELLKKLNVRKLWIGTPYIKERTLEEVEWWRNKGFEIVG
Q8U183 Pfe --------------VEVIAFGCTSGSFIGGKDFEKELEMKIEEEVK-----IETFTTSTAVLEALNVLDIQSLVVVTPYIDEINQREKEFLEENGFTVLD
Q0S7X3 RseC HVE-----------PEVVAYLCTSGSFIKGLEYERTLCDAICEAGA-----QHAITTSGALVEAIEHLELSRLSVITPYDAPLTERLHAFLHEAGTEVVR
Q93J74 SceC AIA-----------PEVVAYACTSGSFVGGIAGERAMCEAMTWAGA-----VPSVTTSGALLDALAELGVRRVALVTPYTVSVTRALEAYVAEAGVTVTG
Q0S7X2 RseD --------------PDAVVWACTSGSFVYGPDGAKQQAETLAAATG-----VPTSSTSFAFVHALHALGITRVAVAASYPEDVAKLFVEFLAAAGIEVLS
Q93J75 SceD --------------ADAVVWACTSGSFVHGWDGAHAQVRALAQAAG-----LPASSTSFAFVHAAKELGVRRVSIGATYPDDVARLFGDFLGAAGIEVAD
Q82CV3 Sae --------------AEAVVWACTSGSFVYGWQGAHDQVRSLARTAG-----LPASSTSFAFAHAARELGVRRVAIGATYPDDVAALFAAFLKDAGVEVVA
Q11DV3 MsAMD --------------AQAVALMGTSLSFFRGAAFNAELITHMSNRSG-----LPATTMSQAVVDELKSHGARRIAVVTAYRQDVNNLLAAFLNEHGIEARS
AsAMD --------------AAVVSLMGTSLSFYRGAAFNAALTEAMREATG-----LPCTTMSTAVLNGLRALGVQRVALATAYIDDVNERLAAFLAEEGLVPAG
Q05115 BbAMD X --------------AAVVSLMGTSLSFYRGAAFNAALTVAMREATG-----LPCTTMSTAVLNGLRALGVRRVALATAYIDDVNERLAAFLAEESLVPTG
EcAMD --------------AAVVSLMGTSLSFYRGAAFNTALTEAMRESTG-----LPCTTMSTAVLKGLRALGVRRVALATAYIDDVNERLAAFLAEEGLAPAG
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Q8Y7N7 LmGluR X FVSVVESGEYKS-AIAKKVVAESLLP--LKSTKIDTVILGCTHYPLLKPIIENFMGDGVAVINS--GEETASEVSALLDYHNLLDATD-EEIEHRFFTTG
Q6GHT5 SaGluR X FVPLVEQMRYSDPTITSIVIHQTLKR--WRNSESDTVILGCTHYPLLYKPIYDYFGGKKTVISS--GLETAREVSALLTFSNEHASYT-EHPDHRFFATG
P52974 ShGluR FVPLVEQMRYDDPTITSIVIHQTLKQ--WRNTDADTIILGCTHYPLLYKPINDYFGGEKKVISS--GLETAREVSALLTFSNEHASYT-QHPEHRFFATG
Q81LA8 BaGluR X FVELVESGNFES-EMAYEVVRETLQP--LKNTDIDTLILGCTHYPILGPVIKQVMGDKVQLISS--GDETAREVSTILYHSKMLNEGE-EQSDHLFLTTG
Q3XZW8 EfGluR X FVSVVESNEYHS-SVAKKIVAETLAP--LTTKKIDTLILGCTHYPLLRPIIQNVMGENVQLIDS--GAETVGEVSMLLDYFNLSNSPQNGRTLCQFYTTG
Q81UL8 BaGluR X LATVVENRLEDT-AYVTQQVKQALLP--LTKEDIDTLILGCTHYPLLESYIKKELGEDVTIISS--AEETAIELSTILQHKGILADNL--NPKHRFFTTG
P94556 BsGluR X LVPFVESGKFLD-KTADEIVKTSLYP--LKDTSIDSLILGCTHYPILKEAIQRYMGEHVNIISS--GDETAREVSTILSYKGLLNQSP-IAPDHQFLTTG
Q7M0V6 BpGluR LVPFVESGTFLD-QTAEAVVKDSLEP--MKETGIDTLILGCTHYPILKEPIQRFMGSDVSIISS--GDETAREASTILSYKGLLNTSK-ETPVHTFYTTG
Q836J0 EfGluR X FVPIVESNQYRS-SVAKKIVAETLQA--LQLKGLDTLILGCTHYPLLRPVIQNVMGSHVTLIDS--GAETVGEVSMLLDYFDIAHTPEAPTQPHEFYTTG
Q88V19 LpGluR FVPLVESNEYQS-TVAKRVVAETLKQ--LKKQDVDTLVLGCTHYPLLRPLIQNVMGPGVTLIDS--GAETVNDVSAVLDYLDIANDRSTKRYPDEYYTTG
P63640 SpGluR FAPLVESGALST-SVTKKVVYETLRP--LVG-KVDSLILGCTHYPLLRPIIQNVMGPKVQLIDS--GAECVRDISVLLNYFEINRGRDAGPLHHRFYTTA
Q9A1B7 SpGluR X FVPIVESNEMCS-SIAKKIVYDSLAP--LVG-KIDTLVLGCTHYPLLRPIIQNVMGPSVKLIDS--GAECVRDISVLLNYFDINGNYHQKAVEHRFFTTA
Q03469 LfGluR MVEIVEHGQTGT-AKAQEVVSEQLMT--FKEHPVKTLIMGCTHFPFLAPEISKAVGPTVALVDP--AKETVATAKSWLEQHQAMGNHA--HPNYHLYSTG
P48797 LbGluR MVTLAEQNDLTT-THAQSVVAANLAS--LMDKKIDTLVMGCTHFPLLRSAIQHAVGSQVTLVDP--GLATAEQTVAILKTRGLLNSAT-TRGTAQFFTTG
Q08783 PpGluR FVEIAEKNELHT-TAAQKVMNEKLAE--FRQDQIDTLILGCTHFPLLEEGIQAAVGPDVTLVDP--GVETVHQLIEILTKQALQHAEG-PKAQDQYYSTG
P56868 ApGluR X FVPLAEEGLLEG--EITRKVVEHYLK--EFKGKIDTLILGCTHYPLLKKEIKKFLGDVEVVDSSEALSLSLHNFIKDDGSSSLELFFTDLSPNLQFLIK-
Q9ZLT0 HpGluR X FVPLIEESILEG--ELLETCMHYYFT--PLEILPEVIILGCTHFPLIAQKIEGYFMGHFALPTPPLLIHSGDAIVEYLQQKYALKNNACTFPKVEFHASG
P22634 EcGluR X MVELAEAK-LHGEDVSLDALKRILRPWLRMKEPPDTVVLGCTHFPLLQEELLQVLPEGTRLVDS--GAAIARRTAWLLEHEAPDAKSADANIAFCMAMTP
O59384 PhAspR X ELNRIIFEELAFGNLKNKEWIVRLIEKYRESEGIEGVILGCTELPLAIKQ----GDVSVEVFDS-------AEIHMRKLIELASE---------------
O58403 PhAspR X VMR-GIYEGVKAGNLKLGRELLLKTAKILEERGAECIIAGCTEVSVVLKQ----DDLKVPLIDP---MDVIAEVAVKVALEK------------------
P29079 EfAspR KINYLIYHEIKESDHLNQELYYEILEEAVERLNCEKVILGCTELSLMNEFAEDN---HYPVIDA---QSILADRTIERALAERN-EALDTVSEK------
B3W8K5 LcAspR MVTELIYKYVKEKGEVNAALYHRILQRMHDDFNVNVIVLGCTELSFAQEKAGDH---PYHVIDA---QSIIVDKTIALGKAFRQSEAAGKALLNQMMAR-
Q1G8B6 LdAspR MVTELIYRDIKEKGIVDKELYHEILRKMHDEYGCDVILLGCTELSLAQEQAPDH---PYQVIDP---QSIIADVSIELALAIRNGQDPRQACQKYLYD--
O58781 PhHydR X HPSGVSNTLDLLTDWGRREVINAAKR--LKEKGVEVIALGCTGMSTIGIAPVLEEEVGIPVIDP--VIASGAVALHALKRREVKRFEGR-----------
Q00924 PsHydR TTPMGVLDFERDPEAGIEMLRQEGKRAVEED-NAEAILLGCAGMAEF--ADSLEKELGVPVIDG--VVAGVKFAETIVDLGKKTSKLKTYKYPEKKEYVG
Q92ML1 RmHydR AIDLPVLALEEDPQRAERLLLKEIEIAKAED-GAEAIVLGCAGMSSL--CDRLQKATGVPVIDG--VTAAVKMAEALLGAGYATSKVNTYAYPRIKAAAG
Q5YXQ1 NfMI WRALEVADNTEVGCIPGEQVMAAARSLDLSE-VDALVISCCVQMPSLPLVETAEREFGIPVLSA--ATAGAYSILRSLDLPVAVPGAGRLLRQDSAVTAS
Q9KWI0 SmMI WRALEIPDNLDVGRHDPARLPGIVAEMDLRE-VDAIVLSACVQMPSLPAVPTVEAQTGKPVITA--AIATTYAMLTALELEPIVPGAGALLSGAY-----
O24766 AfMI SISLEVSDNLEVGLLNPENLLEHVKRLNHDG-VDAVILSACVQMPSLPAIQRAQDQIGKPVLSA--AVWTVYQMLKNLGLETRVPNAGHILSGVKPQA--
Q9WX57 BsMI SISLEIPDNLEVGRQDPMRLIEIVKNLDVSN-ADAVVLSACVQMPSLPAIQKVQDQLGLPVLSA--ATSTVYKILKSLNLKTYVPNAGSLLSGKY-----
Q987A4 Mle FTCLGFEDDREMARIPPAALVDLARQVTDPQ--ADALFVSCTALRGALAVTGMEQAIGRPVVTS--NQATAWNCLRLCGDETP--RPEFGQLMTLPLPRD
Q92WC5 Sme FTCLGLTDDREMARISPKEIVAFAKEAAAPA--SDALFISCTAVRAAGVIAEIEQAIGKPVVSS--NYATAWACLRLCGDREA--RPQLGRLMELPLEEE
Q974K3 Ste X YDGLGKIRGIDISNTPIFTIYRLVKRHLNEVLKADAVYIACTALSTYEAVQYLHEDLDMPVVSE--NAAAMWEALNKLKIKAKLPGF-------------
Q8U183 Pfe IRGLGIEDNLEIGRLSPYIPYMLAKSMF--MEEADGVFISCTNLRTFEIIEKLERDLGIPVVTS--NQATLWYALREIDVRES-LPLGKLLREF------
Q0S7X3 RseC SDHLGLGG--GIWKVNYRTIAERIIAADDPR--SEAIFVSCTNLPTYDVIAPLEQELGKPVLTA--NQLTIWACLGRMKLPMTGPGKWLRNVF-------
Q93J74 SceC CAFMGLTR--HIWKVPYRDVADMARQAVPAPGAADALFISCTNLPTYDVIPQLEAELRIPVISA--NQVTMWAALRRLGTPAVGPYQALTDPAARLGPAA
Q0S7X2 RseD MSSAGIDTAAEVGLLSPESVVELAVENDHPD--AEALLIPDTAMRTLGALSTLEQRLGKPVLTA--NQVTIWEGLRLAGHTAV--HPSLGTLFEKGHSHG
Q93J75 SceD VVSSGIITAAEVGTWTEAEVLALARAADRPD--VEAVLLPDTALHTAAHIPALEKELGKPVLTA--NQVTIWEGLRLADRRVN--APELGALFTREPVVQ
Q82CV3 Sae VRGSGIITAAEVATWDEEQVLALARAADHPE--AEAVLLPDTALHTASHIQALEAALGKPVLTA--NQVTVWEALRLADRRVN--APRLGTLFTKEPLVQ
Q11DV3 MsAMD LKSLGITSVADVAGTPAKRLLQLCKEAVHDAGPVDAVLISCGGLHTLDVIVDVEISTGLPVVTS--ATAGVRGAVGLLKRSAETAEHATSKFLTGRA---
AsAMD CRSLGITGVEAMGRVDTDTLVDLCVRAFEAAPDSDGILLSCGGLLTLDAIPEVERRLGVPVVSS--SPAGFWDAVRLAGGGGK-ARPGYGRLFDES----
Q05115 BbAMD X CRSLGITGVEAMARVDTATLVDLCVRAFEAAPDSDGILLSCGGLLTLDAIPEVERRLGVPVVSS--SPAGFWDAVRLAGGGAK-ARPGYGRLFDES----
EcAMD CRSLGITGVDAMARVDTDTLVDLCVRAAEAAPDSDGILLSCGGLLTLDAIPEVERRLGMPVVSS--SPAGFWDAVRLAGCEVQ-AAPGYGRLSGVH----
301 347
Q8Y7N7 LmGluR X STQIFKDIAKDWLNMPDMTVEHIKLGK--------------------
Q6GHT5 SaGluR X DTTHITNIIKEWLNL-SVNVERISVND--------------------
P52974 ShGluR DTVHIKNIILQWLKL-DVEVERISVDE--------------------
Q81LA8 BaGluR X KIGLFKEIASKWFGQPIENVKHIHLEKE-------------------
Q3XZW8 EfGluR X SAKLFEEIAEDWLGIGHLNVEHIELGGK-------------------
Q81UL8 BaGluR X SVSSFEHIAERWLGY-QISVDCVDLPVKNARICN-------------
P94556 BsGluR X ARDQFAKIADDWFGHEVGHVECISLQEPIKR----------------
Q7M0V6 BpGluR QQQNFQNIARDWFGYLPGKVETVSLEHIYQQ----------------
Q836J0 EfGluR X SAKMFEEIASSWLGIENLKAQQIHLGGNEND----------------
Q88V19 LpGluR AADQFEAIARNWLGQPDFHAQHIDLGSEAND----------------
P63640 SpGluR SSQSFAQIGEEWLEK-EIHVEHVEL----------------------
Q9A1B7 SpGluR X NPEIFQEIASIWLKQ-KINVEHVTL----------------------
Q03469 LfGluR NLPDLRAGVNKWLLSGHFDLGTAQIEEGD------------------
P48797 LbGluR ETDQFDTLASQWLDQQPTPAKHVAIAQLTTPMEVN------------
Q08783 PpGluR NIKNFEEIARTFLNQDLR-VEEVKID---------------------
P56868 ApGluR X LILGRDYPVKLAEGVFTH-----------------------------
Q9ZLT0 HpGluR X DVIWLERQAKEWLKL--------------------------------
P22634 EcGluR X GAEQLLPVLQRYGFETLEKLAVLG-----------------------
O59384 PhAspR X -----------------------------------------------
O58403 PhAspR X -----------------------------------------------
P29079 EfAspR -----------------------------------------------
B3W8K5 LcAspR -----------------------------------------------
Q1G8B6 LdAspR -----------------------------------------------
O58781 PhHydR X -----------------------------------------------
Q00924 PsHydR ALENFGRNQTTTK----------------------------------
Q92ML1 RmHydR HKVCA------------------------------------------
Q5YXQ1 NfMI -----------------------------------------------
Q9KWI0 SmMI -----------------------------------------------
O24766 AfMI -----------------------------------------------
Q9WX57 BsMI -----------------------------------------------
Q987A4 Mle -----------------------------------------------
Q92WC5 Sme RP---------------------------------------------
Q974K3 Ste X -----------------------------------------------
Q8U183 Pfe -----------------------------------------------
Q0S7X3 RseC -----------------------------------------------
Q93J74 SceC TGAVGPAVVGPPGPVDPAVAGPVGPAAVDMPGVGDVPDTEQQQEGWT
Q0S7X2 RseD SD---------------------------------------------
Q93J75 SceD A----------------------------------------------
Q82CV3 Sae VH---------------------------------------------
Q11DV3 MsAMD -----------------------------------------------
AsAMD -----------------------------------------------
Q05115 BbAMD X -----------------------------------------------
EcAMD -----------------------------------------------
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Appendix D
Isolation of Alkylmalonates
Decarboxylating Bacteria
D.1 Introduction
The mining of known microbial gene sequences from the Asp/Glu racemase
superfamily has proven less effective than assumed as no enzyme active against
arylmalonate could be identified (see Chapter 3). In addition, altering the substrate
specificity to alkylmalonates through rational engineering of BbAMD proved to be
limited. One reason for the limitation lies in the substrate itself. Additional electron
withdrawing capability is needed on the malonates, provided by the aryl or alkenyl
substituent, allowing the stabilisation of the decarboxylated doubly negatively charged
intermediate. Another reason is the fold of the enzyme. The size of the small substrate
binding pocket of BbAMD could not be increased to accept substituents larger than
methyl. Site saturation mutagenesis of residues in this pocket only yielded inactive
enzyme and therefore proved to be more complex than previously assumed (personal
communication by Dr. Krzysztof Okrasa) (48,67).
To overcome this apparently intrinsic limitation of AMDs given by their fold and
mechanism the search of target enzymes has to be broadened. As no other aryl- or
alkylmalonate decarboxylating enzymes are described in literature, mining of the
microbial diversity to find an organism that decarboxylates alkylmalonates provides a
promising alternative approach. This approach opens the scope for new enzyme
families. Only a very small part of the enormous microbial biodiversity has been studied
(generally estimated to around 1%), which offers a large pool of potential biocatalysts.
Most of the vast number of natural compounds can be degraded by microorganisms.
BbAMD was found in Bordetella bronchiseptica isolated through enrichment from soil
samples for arylmalonate decarboxylating bacteria by providing arylmalonates as the
sole carbon source (76). A different system using an acyl carrier protein to produce
acetate by decarboxylating malonate was described Klebsiella peumoniae and
Malonomonas rubra (30,31,152). Given this diversity of organisms and mechanisms it
174
is reasonable to assume that there exists a microorganism in nature that contains an
enzyme capable of transforming alkylmalonates.
Screening directly for alkylmalonate decarboxylation instead of converting an
arylmalonate decarboxylating enzyme also shortcuts the complex process of
engineering of the active site to change the enzyme’s substrate specificity. It offers the
possibility of finding a completely unanticipated mechanism and is not restricted to the
architecture of one single active site.
Nonetheless, this approach also has the disadvantage that the number of organisms to
screen is practically limited. In order to increase the chances, samples would need to
be taken at sites where the substrate is present in high concentrations. Unfortunately,
alkylmalonates are not natural compounds and no site polluted by these chemicals is
known. The only remaining option is therefore to screen organisms from soil samples
taken from random sites.
BASF is interested in the decarboxylation of MPrM and EBM, having slightly longer
chains than MEM tested on microorganisms in their own laboratories. In this chapter
the isolation of several strains capable of growing on alkylmalonates as their sole
carbon source will be presented together with results from preliminary analysis of
activity by whole cells.
D.2 Methods
D.2.1 Collection of Soil Samples
Soil samples were collected from various locations around the campus of the University
of York (UK) and from a Ministry of Defence demolition site in Longtown (Cumbria,
UK). The samples were collected under dense vegetation cover. All soil samples were
stored at 4 °C.
D.2.2 Preparation of Minimal Medium
In 971 mL water, 0.1 g NaCl, 1 g (NH4)2SO4, 0.2 g MgSO4•7H2O, 0.02 g CaCl2•2H2O,
15 g agarose and optionally 0.05 g yeast extract were dissolved and autoclaved. The
medium was buffered by adding 20 mL of filter sterilised 10% (w/v) KH2PO4 pH 7. The
medium was supplemented with 4 mL of filter sterilised 250x trace elements solution
produced by dissolving 10 g MgSO4, 2 g CaCO3, 5.5 g FeSO4•7H2O, 1.44 g
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ZnSO4•7H2O, 1.11 g MnSO4•4H2O, 0.25 CuSO4•5H2O, 0.28 g CoSO4•7H2O, 0.062 g
H3BO3 in 50 mL concentrated HCl and water to a total of 1000 mL. The medium was
further supplemented with 2 mL of 1000x vitamins solution produced by dissolving
5 mL of 100 mg mL-1 nicotinic acid in 70% (v/v) ethanol, 50 mg myo-inositol calcium
pantothenate, 50 mg riboflavin (B2), 50 mg ascorbic acid (C), 50 mg folic acid, 50 mg
D-biotin in a total of 50 mL water. An optional 4 mL of filter sterilised 50% (w/v) glucose
solution was added together with 20 mL of filter sterilised 25% (w/v) solution of MPrM
or EBM adjusted to pH 7.
D.2.3 Liquid Culture Enrichment
Selective enrichments in liquid cultures were performed as described previously (76). A
soil sample of 0.5 g was added to 10 mL of minimal medium containing 5 g L-1 of MPrM
or EBM, supplemented with yeast extract and glucose. The cultures were incubated in
conical flasks at 30 °C shaking for 4 d. Then the cultures were filtered with Whatman 0
filter paper (GE Healthcare) and 200 μL filtrate was subcultured in 10 mL fresh medium
supplemented with yeast extract but not glucose. The cultures were incubated for
another 4 d before 100 μL samples from both sets of culture were serially diluted from
10-1 to 10-5 and grown on minimal medium agarose plates containing 5 g L-1 MPrM and
EBM with and without the supplementation of glucose and yeast extract. Colonies were
visible after incubation for 4 d at 30 °C.
D.2.4 In-Soil Enrichment
Selective enrichments in wet soil were performed according to the method used by
BASF for MEM (personal communication by Dr. Nina Baudendistel). Samples of 5 g
soil were soaked with minimal medium containing 5 g L-1 of MPrM or EBM,
supplemented with yeast extract and glucose. The soil samples were kept wet in open
50 mL centrifuge tubes at 30 °C for 11 d (a total of approximately 5 mL medium was
added per sample) before another 5 mL minimal medium was applied, the tubes closed
and incubated shaking for another 4 d. Then the cultures were filtered with Whatman 0
filter paper (GE Healthcare) and 100 μL of each culture were serially diluted from 10-1
to 10-5 and grown on minimal medium agarose plates containing 5 g L-1 MPrM and
EBM, without yeast extract, with and without the supplementation of glucose. Colonies
were visible after incubation for 4 d at 30 °C.
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D.2.5 Purification of Agar Plates and Liquid Culture
Single colonies obtained from enrichment cultures were purified spreading on fresh
minimal medium agar plates containing 5 g L-1 MPrM or EBM containing no yeast
extract or glucose. This was repeated 2 - 3 times. To exclude the cultures growing on
agarose, 12 large colonies for each substrate were picked and 5 mL minimal medium
containing 5 g L-1 substrate containing no glucose or yeast extract were inoculated and
incubated at 30 °C shaking for 4 d before serial dilutions from 10-1 to 10-5 were grown
on minimal medium agar plates. From the same cultures, 250 μL were taken to test the
disappearance of the substrate by reverse phase HPLC. Another 800 μL of growing
cultures were mixed with 400 μL of 60% glycerol, snap frozen in liquid nitrogen to store
at -80 °C.
D.2.6 HPLC Analysis
Samples originating from bacterial isolates cultures containing alkylmalonates (5 g L-1)
as their sole carbon source were centrifuged at 18,000 × g for 5 min and 50 μL were
directly injected into Onyx Monolithic C18 100 x 4.8 mm reverse phase HPLC column
(Phenomenex). The compounds were run at 45 °C at 2 mL min-1 flow rate with a
programme using a 20 mM KH2PO4 pH 2.5 buffer solution (A) and methanol (B). The
programme sequence was 0.0-5.5 min 50% B, 6.0-7.0 min 70% B and 7.5-10.0 min
50% B. The 2695 Separations Module and the 2996 Photodiode Array Detector
(Waters) were used and compounds were detected at 205 nm. Expected retention
times were MPrM 1.1 min, MP 1.6 min, EBM 1.3 min, EH 3.9 min.
D.2.7 16S Sequencing
Taxonomic characterisation was performed by sequencing of ribosomal 16S subunit
RNA as described earlier (158). A large colony was suspended in 50 μL pure water.
The cells were lysed by heating the suspension to 95 °C for 300 s then five cycles of
heating to 95 °C for 30 s and cooling to 15 °C for 30 s and finally freezing the cells at
-20 °C. The 16S sequences were amplified using 0.625 U GoTaq DNA Polymerase
and 1x PCR buffer (Promega), 1.5 mM MgCl2, 0.25 mM of each dNTP, 0.4 μM of each
primer fD1 and rP2 (Table 2.1, Sigma Genosys), 1 μL cell extract and completed to 25
μL total volume with water. The temperature cycles were one initial melting step at 95
°C for 300 s then 30 times melting at 95 °C for 30 s, annealing at 55 °C for 30 s and
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elongation at 72 °C for 90 s followed by one final elongation at 72 °C for 300 s
performed on a Px2 Thermal Cycler (Thermo Scientific).
D.3 Results
D.3.1 Enrichment of Soil Cultures
There is no known natural source of alkylmalonates. Equally, there are no
contaminated sites of alkylmalonates as these compounds were not produced in large
quantities by industry. Therefore no known site exists where microorganisms have
been exposed to alkylmalonates and have met such selective pressure to evolve
enzyme activities that are able to specifically degrade the compounds. The University
campus was therefore chosen to take soil samples for its easy accessibility.
Samples were collected from different types of soil under dense vegetation cover in
order to maximise the diversity of microorganisms. As an additional source, a
microorganism rich soil sample from an explosives contaminated soil on a military
training ground previously collected by our laboratory was chosen.
Two methods were used to enrich the soil cultures in alkylmalonate degrading
microorganisms. Firstly a soil suspension culture was produced as described
previously (76), which involved adding 0.5 g of soil to 10 mL of minimal mineral
medium containing no other carbon source than either of MPrM or EBM (Fig. D.1). The
cultures were incubated and subcultured for twice 4 d.
Secondly, a different wet soil culture method was applied using a protocol provided by
BASF (personal communication with Dr. Nina Baudendistel). In this method 5 g of soil
were immersed with the same minimal medium containing either of the two substrates
and incubated for 11 d keeping the soil wet all the time. In the end the soil samples
were washed with the medium and the liquid collected.
Culture samples from both methods were spread on agarose plates containing the
same minimal medium and substrates. Growing colonies were picked and spread on
fresh plates to obtain pure cultures. In this process two cultures were growing to thick
cultures in the soil suspension containing MPrM. On plates, colonies from these (FIso1
and FIso2) were growing fast if the medium contained substrate but not if the medium
contained no substrate (Fig. D.1)
178
Figure D.1. Selection of isolates on media with MPrM as sole carbon source.
Erlenmeyer flasks containing medium with cultures growing (right, FIso1) and not
growing (left). Petri dishes with two isolates growing on MPrM (top) and not
growing without carbon source (bottom).
Many colonies showed slow growth on the plates and were also observed to grow non-
specifically on plates without substrate. To exclude the possibility of them growing on
agarose or impurities of the latter, an additional isolate purification step was introduced.
This was again performed in liquid medium not containing any agarose. After 4 to 17 d
the cultures were checked for signs of microbial growth (turbidity or aggregated cells in
flakes). The growing cultures were again spread on selective media.
In total nine isolates were selected in this manner (Fig. D.2). Surprisingly FIso2,
selected earlier, did not show repeated growth in the purification procedure. Only
isolates growing on MPrM showed significant growth (FIso1, 2-6) whereas colonies
growing on EBM (FIso6-9) showed only residual growth that was not significantly more
pronounced than on the control plates not containing substrate.
FIso1 and 3 were large reddish colonies whereas FIso4 and 5 were of the same size
and aspect but with a more yellowish tint. FIso2 from the previous isolation step
showed similar growth to FIso4 and 5. In contrast the colonies of FIso6 were smaller
and white-transparent having a very distinct aspect (Fig. D.2).
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Figure D.2. Isolates on media containing alkylmalonates as sole carbon
source. FIso1-6 on MPrM, FIso7-9 on EBM. FIso2 missing.
Colonies of FIso1, 3-6, 9 were analysed by 16S ribosomal subunit sequencing to
determine their relationship to known bacterial species. As this was a preliminary
experiment, the PCR conditions were not optimised, the sequences were only analysed
with one forward primer. As a result PCR products could only be obtained for FIso4-6.
The quality of chromatograms was good allowing to read approximately 700 bp for
FIso4 and 5 and 500 bp for FIso6. No contamination could be observed in the
sequencing chromatograms. A BLAST search using the obtained sequences
suggested that FIso4 and 6 related to those from Acinetobacter species and in the
case FIso5 to those from Rhodococcus species.
D.3.2 Screening for Activity of the Isolates
To test whether the bacterial growth on the substrates is the result of the conversion of
the alkylmalonates (MPrM and EBM) into alkylalkanoates (MP and EH) the isolates
were regrown in liquid cultures with minimal medium with one of each substrate not
containing yeast or glucose. After 5 days of growth at 30 °C the media were analysed
on HPLC detecting carboxyl groups at 205 nm for removal of substrate and
appearance of product.
During the incubation time FIso1 and 3 were using up almost all MPrM, producing a
small amount of MP and another compound with a shorter elution time than MP,
compound X. In addition there was a small amount of another compound with an even
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shorter elution time, compound Y. FIso4 and 5 showed a similar behaviour using up
less MPrM and converting in much smaller amounts of the compound X and only very
small traces of MP if at all. FIso2 and 6 do not show any degradation of MPrM when
compared to the no bacteria control (Fig. D.3). These results confirm previously
recorded results with the only exception that at that time FIso6 was a contaminant of
FIso5 that was only separated later (data not shown).
Figure D.3. HPLC analysis of isolates cultures growing on MPrM for 4 d. Full
view on top, enlargement on bottom. 50 μL of supernatant from cultures grown on
5 g L-1 substrate were injected. RTs are 1.1 min for MPrM, 1.6 min for MP.
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In the case of EBM none of the isolates (FIso7-9) degraded any significant amount of
the substrate. The peak corresponding to the product EH observed for FIso7 and 8
exactly matches the size of the substrate contamination in the no bacteria control.
There are few insignificant peaks not present in the standards but present in the no
bacteria control that most probably correspond to chemicals in the medium. FIso9,
however, is the only sample where the EH peak completely disappeared (Fig. D.4).
These results confirmed previous results with the exception that FIso8 behaved like
FIso9 in that experiment (data not shown).
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Figure D.4. HPLC analysis of isolates cultures growing on EBM for 4 d. Full
view on top, enlargement on bottom. 50 μL of supernatant from cultures grown on
5 g L-1 substrate were injected. RTs are 1.3 min for EBM, 3.9 min for EH.
D.4 Discussion
It was previously reported that many bacteria are able to degrade malonate using
either of two different acyl carrier protein systems to decarboxylate malonate and
produce acetate and carbon dioxide (30,31,152). The enzyme systems are located in
the cytoplasm and need transport of the substrate into the cytoplasm. It is likely that
these systems are also capable of degrading substituted alkylmalonates.
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The present results show that there are bacteria capable of growing on MPrM and
degrading it whereas no degraders for EBM were found. Taking the physical aspect of
the colonies together with the activity results, one could reasonably conclude that there
three strains are able to degrade MPrM. FIso1 and 3 can be considered as the same
reddish strain being the most active on MPrM, converting most of it into compound X.
FIso4 and 5 can be considered as another yellowish strain being less active on MPrM
and consequently producing less compound X. FIso9 seems to be able to degrade EH.
All other strains are not active on their respective substrates. For simplification, only
FIso1, FIso4 and FIso9 will be discussed further.
MPrM is thus degraded by at least two different bacterial strains; however, it is not
clear through what chemical pathway this happens and whether the first step of this
pathway really is decarboxylation. Yet, the presence of a small amount of MP in some
cultures indicates that decarboxylation is a probable first step in the degradation. Other
mechanisms could equally be involved such as a reduction of the carboxylic acid to an
aldehyde and subsequent decarbonylation (159,160).
Due to time constraints, the identity of compound X and Y could not be determined. In
addition, the optical detection at 205 nm entails the danger of overestimating the
amount of compounds as the optical sensitivity depends on the types of bonds
contained in the molecules. The introduction of a double bond for example, would
greatly increase the response of the detector. To avoid this risk of overestimation, an
absorbance independent approach such as GC-FID could be an easy way to
circumvent that problem as it results in peak heights proportional to the number of
carbon atoms in the compound. Currently, it can only be said that compound X and Y
are both more hydrophobic than MPrM but less hydrophobic than MP.
Experiments conducted at BASF by the group of Dr. Nina Baudendistel using the
shorter chain length MEM showed very similar results to the experiments with MPrM.
MEM was used and converted resulting in a peak appearing just before MB. Efforts to
analyse this peak at BASF did unfortunately not result in the identification of the
compound corresponding to that peak. This could be an indication of insufficient
amount of a double bonded compound giving a disproportionally large signal.
When the cells were lysed at BASF all activity was lost. There could be several
explanations for this: the system could be membrane associated, cofactor-dependent
or sensitive to the conditions such as the redox potential or pH of the buffer. A multi-
subunit acyl carrier protein system as described above would be expected to lose the
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activity after cell lysis. It is therefore reasonable to assume that the isolates used in this
work and at BASF are indeed acyl carrier protein systems. Still, the lysis has not yet
been performed with the isolates in the present work.
Even though FIso9 is probably able to degrade EH no EBM was degraded. The chain
length of the malonates therefore is important. This could simply be a membrane
transport issue or a limitation by the size of the active site. On the other hand the
degraded MEM and MPrM both have a relatively small methyl group as a second
substituent on carbon C2 of malonate and EH has an even smaller hydrogen atom at
the same position. EBM has an ethyl group which could be specifically excluded by the
enzyme. The importance of the size difference between methyl and ethyl groups is
evident with BbAMD that accepts MPM but not 2-ethyl-2-phenylmalonate as substrate
(67,76).
For any further conclusion the pathway and the enzymes would have to be identified.
To analyse the pathway, cell extract could be analysed and the relevant metabolites
determined by GC-MS. Feeding the decarboxylated intermediates to the cell cultures
would indicate whether these are indeed the intermediates in the degradation pathway.
The presence of the known acyl carrier protein degradation system could be confirmed
by PCR using degenerate primers.
If the described multi subunit enzyme system was identified as the responsible catalytic
system it would make it more complex to use for industrial applications. A possible
solution to that problem could be to knock out the downstream processing enzymes in
the selected strains and use whole cell transformations instead of engineered enzyme
in a cell free system. As the strains can feed on the substrates, the process would lend
itself to directed evolution approaches for the engineering of the whole metabolism.
Finally, 16S sequencing showed that there are at least two different strains
(Acinetobacter sp. and Rhodococcus sp.) from two different phyla (Proteobacteria and
Actinobacteria). There is supposedly a large diversity of bacteria capable of degrading
alkylmalonates and the trait seems to be rather common as they were found in soils not
known for containing any special bacteria. More bacteria can therefore be expected to
be found using this procedure.
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